The Principles and Practice of Vitamin B12 Therapy with Reference to the Treatment of Patients with Pernicious Anaemia and Other Vitamin B12 Deficiency States by Adams,
THE
PRINCIPLES AND PRACTICE 
OP
VITAMIN B12 THERAPY 
With reference to the treatment of patients 
with pernicious anaemia and other vitamin B^2 
deficiency states.
A Thesis submitted for the Degree of Doctor of 
Medicine. University of Glasgow.
by
J. E. ADAMS
V.R.D., M.B., Ch.B., P.R.P.P.S., Glas., M.R.C.P., Ed., 
B«Obst, R.C.O.G..
1962
ProQuest Number: 13850791
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13850791
Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
"Would you tell me, please, which way I ought 
to go from here?"
"That depends a good deal on where you want to 
get to," said the Cat.
"I don't much care where - so long as I get 
somewhere," Alice added as an explanation.
"Oh, you're sure to do that," said the Cat,
"if you only walk long enough."
Alice's Adventures in Wonderland,
Chapter 6 .
(1)
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PREFACE
The investigations reported in this thesis 
had their basis in some apparently simple 
problems posed by the introduction of vitamin B ^  
in the treatment of patients suffering from 
Addisonian pernicious anaemia and other vitamin 
Bp2 deficiency states. It might be thought that 
with the experience gained from the wide use of 
vitamin B ^  in the last decade few, if any, 
problems remained about the treatment of such 
patients. That there are problems however, is 
clearly apparent if only from the widely varying 
recommendations about vitamin B-^ therapy to be 
found in textbooks, monographs and articles.
The onus of solving these problems lies with 
the clinician who must bear the ultimate 
responsibility for the treatment of patients and 
this thesis is a record of studies carried out 
by a clinician with the object of clarifying 
some aspects of the principles and practice of 
vitamin B-^ therapy in patients with pernicious 
anaemia and other vitamin B-^ deficiency states.
INTRODUCTION
It seemed likely that one outstanding 
clinical problem arising in the treatment of 
patients suffering from pernicious anaemia with 
vitamin namely that of defining adequate
maintenance therapy, could be solved by meeting 
two requirements and applying them to the study 
of patients with this disease. The first 
requirement was a method of determining the loss 
of injected vitamin accurately: with such a 
method the site and extent of the loss could be 
located and measured and an estimate made of the 
amount remaining in the body. The second 
requirement was a method of establishing the time 
for a known amount of vitamin B ^  in 'the body 
to be utilised. During investigations into 
these requirements various other problems 
relevant to the use of vitamin B-^ in therapeutic 
practice, were encountered and studied and some 
of these investigations are also recorded in this 
thesis.
It has been found convenient to present the 
material in such a manner that each chapter 
appears to be a report of an isolated investigation.
(4)
/It will be obvious however, that each apparently 
limited inquiry forms an integral part of one study. 
Plan of the thesis
The thesis is in two volumes. Volume 1 
contains the text with relevant figures and tables 
in eight chapters and, a note of acknowledgments. 
Volume 2 is an appendix containing tables, 
details of technical methods, details of some 
of the patients studied and a bibliography. The 
pages of each volume are numbered consecutively. 
Title pages are coloured for easy reference.
Tables and figures in the text are each 
numbered consecutively and are placed as near to 
relevant points in the text as possible.
Detailed results, which are presented in summary 
or figures in the text are given in full in the 
tables in the Appendix; these tables are numbered 
consecutively with the prefix A; thus Table 21 is 
in the text and Table A.21 in the Appendix.
Technical methods are mentioned briefly in the 
text and full details are given in appropriate 
sections in the Appendix.
References cited in the text or elsewhere are 
given in full in conventional sequence and form
(5)
/in a bibliography in the Appendix. Included
therein are titles of several communications
presented to the Second European Symposium on
Vitamin and Intrinsic Factor held at Hamburg
in August 1961. Publication of these communications
originally scheduled for 1 9 6 1, has been delayed
and rather than await publication, and thus delay
submitting this thesis for at least six months,
it has been decided to refer to relevant
communications by the title of the abstract or
of the manuscript. The proceedings should be
published by the time this thesis is submitted.
Terminology
Certain conventions have been followed and
a few disregarded. The term vitamin
hallowed by clinical usage is preferred to the more
scientific term cyanocobalamin. The term Co
vitamin is used to indicate vitamin B ^
with radioactive cobalt incorporated in the
molecule: where a particular radioactive isotope
is incorporated the appropriate prefix is 
58employed e.g. Co vitamin The term serum
vitamin B^^ level is used, as by most other
(6)
/authors, in preference to serum vitamin 
concentration although, the term concentration is 
used in preference to level in other contexts.
The terms dose and injection are often used, as 
in pharmacological practice, in preference to the 
term mass. The phenomenon of equilibration is 
occasionally referred to as mixing. The mass, 
dose or concentration of vitamin or Go vitamin
is expressed as micro grammes (ug) or 
micromicrogrammes (uug) and the terms milli- 
microgrammes or milligrammes have been avoided.
The term control has not necessarily been used 
to indicate a normal subject: the meaning will 
be clear from the context in which it is used.
Both case initials and case numbers are used.
The former, e.g. Case J.B.A.,for patients, 
particularly those with vitamin B ^  deficiency 
states who were often the subject of more than 
one investigation: details of these patients, 
and some others of particular interest are given 
in a section in the Appendix. Case numbers are 
used for patients, most believed not to have 
any upset of vitamin B ^  metabolism, who were
(7)
/usually the subject of one investigation only. 
Details of these patients are given in Tables 
in the text and it will be obvious from these 
that Case 6 , say, of an investigation reported 
in Chapter 1 is not the same person as Case 6 
of an investigation reported in Chapter 7*
(8)
CHAPTER I
THE URINARY EXCRETION OP ASSAYABLE VITAMIN B12 
AND OP RADIOACTIVITY AFTER PARENTERAL 5 Co 
VITAMIN B12 IN MAN.
The Concept, Development, Proof and Implications 
of a Technical Method.
(9)
The measurement of the vitamin B ^  
excreted in urine, bile and faeces after 
parenteral administration presents difficulties,. 
Colorimetric and spectroscopic methods are 
obviously valueless. Chemical methods are 
uncertainly specific, complicated and clumsy. 
Microbiological assay methods are not specific, 
subject to a considerable variation and are 
more suitable for measuring low concentrations 
of vitamin than the high concentrations 
which may be found in urine after parenteral 
vitamin Isotope dilution and reversed
isotope dilution techniques are theoretically 
ideal but are time consuming and technically 
difficult demanding rigorous purification 
techniques. In addition, the measurement of 
injected vitamin B e x c r e t e d  in faeces is 
complicated by the fact that faeces normally 
contain large amounts of vitamin an<*
measurement of vitamin B ^  in bile is 
complicated by the fact that bile inhibits the 
growth of at least one microbiological assay 
organism.
(10)
Because of these difficulties, 
consideration was given to the feasibility of 
using Co vitamin to measure the loss in
urine directly after parenteral administration.
THEORETICAL CONSIDERATIONS
It is generally believed that vitamin
whether absorbed from the intestine or given
by injection, functions in the body as an active
substance and does not undergo chemical change.
It follows therefore, that if a patient who
had no vitamin B ^  in his body and who was not
excreting any radioactive substance in his
58urine were given an injection of Co vitamin 
^1 2’ ^  v,ou-^(^ ^e a reasonahle assumption that 
the amount of radioactivity excreted in the
urine would be a true indication of the amount 
58of  ^ Co vitamin B12 excreted. Por example,
if this hypothetical patient were given
1000 ug *^Co vitamin B ^  parenterally and
205& of the radioactivity were excreted then
58that 20/o would represent 200 ug ' Co vitamin 
B-^ 2 * Patients with vitamin B-^ deficiency 
presenting in haematological relapse are the
(11)
/clinical equivalents of this hypothetical
patient and it seemed likely that this
assumption would also apply to them. Proof
that this were so would he agreement between
the values for radioactivity excreted and
assayable vitamin B ^  excreted in the urine
58after an injection of Co vitamin
It was obviously essential that the
normal subject should be studied also.
Because of the large body stores of vitamin B-^
in normal subjects however, it could not be
assumed that the excretion of radioactivity
58after parenteral Co vitamin B ^  would be a
true indication of the amount of vitamin B ^
excreted. The possibility had to be
considered that injected Cu vitamin B-^
might equilibrate, or mix, with the body stores.
Under these circumstances the amount of
radioactivity appearing in the urine after an 
58
injection of Co vitamin W 0U1<1 no  ^ a 
true indication of the mass of vitamin B ^  
excreted but would represent only a fraction 
of it. For example, if a patient with 3000 ug
(12)
/non radioactive vitamin B12 in his body were
58
given 1000 ug Co vitamin B-^ parenterally 
and 20% of the dose of radioactivity were 
excreted in the urine, then that 20% would 
represent 20% of (1000 a proportion of 3000) ug 
vitamin B ^  depending on the extent of equilibration.
Preliminary investigations showed that the 
normal subject excreted about 60% of the dose 
of radioactivity after a parenteral injection of
581000 ug Co vitamin B-^ and it was obvious
that complete equilibration could not have taken
place otherwise this would have represented
2400 ug if the body stores were 3000 ug - an
absurd situation. It was clearly important to
determine whether any significant degree of
equilibration did, in fact, occur and again the
58method of giving parenteral Co vitamin B-^ 
and comparing the urinary excretion of 
radioactivity and of assayable vitamin B-^ 
seemed to be suitable. If there was good agreement 
between the results obtained by the two methods 
this would indicate that equilibration had not 
taken place whereas if a significant degree
(13)
/of equilibration did occur the amount of
assayable vitamin B ^  in the urine would be in
excess of the amount indicated by radioactivity
present. For example, if a subject were given 
581000 ug Co vitamin B p a r e n t e r a l l y  and 50$
of the radioactivity were excreted and a
total of 500 ug of vitamin B ^  were found by
assay then this would be evidence against
equilibration of significant degree: if however,
50$ of the radioactivity were excreted and
750 ug of vitamin B^^ were found by assay this
58would suggest that the 1000 ug Co vitamin
had equilibrated with 500 ug of the body stores
of non radioactive vitamin B-^.
Comparison of the radioactivity excreted
and the assayable vitamin B ^  excreted after 
58parenteral Co vitamin B^^ in normal subjects 
to determine if there was any significant 
degree of equilibration appeared to be an 
acceptable procedure provided that the assay 
results were accurate. In the example already 
given where 50$ of the radioactivity were 
excreted and the assayable vitamin was
(14)
/750 ug it is obvious that this could happen 
not only as a result of equilibration but also 
as a result of erroneously high assay readings 
when there was no equilibration. The problem 
raised by the possibility of such a constant 
error in the assay causing misleading results 
could obviously be solved by duplicating the 
experiment in patients with little or no
vitamin B i n  the body. For example, if a
58normal subject were given 1000 ug Go
vitamin and 50?© of the radioactivity were
excreted in the urine and 600 ug of vitamin B ^
were found by assay this would suggest either
that there had been some equilibration or that
the assay result was too high. If the same
result was obtained in a patient with little or
no body stores of vitamin B-^ then it would be
clear evidence that the assay reading were high.
58Repeated injections of Co vitamin B-^ 
could be given to vitamin B ^  deficient subjects 
without prejudicing the value of the results as,
even if equilibration did occur, the injected 
58Co vitamin B-^ would equilibrate with 
*^Co vitamin B-^ remaining in the body from the
(15)
/previous injection. Por example, if a control
58patient were given 1000 ug Co vitamin
and 50% were excreted lie would retain in his 
58body 500 ug Co vitamin B-^ with 50% of the
dose of radioactivity given. If a second 
58
injection of Co vitamin B-^ 1000 ug
radioactivity 100% were given and 60% of the
dose of radioactivity were then found in the
urine this would still represent 600 ug since
the total of the body stores plus the second
injection would equal 1500 ug radioactivity
150% for practical purposes.
The use of vitamin B-^ deficient subjects
as controls would not only serve to reveal a
constant error in the assay, if such were present,
but would also give some indication of the
degree of equilibration, if any, which took
place when normal subjects were given 
58parenteral  ^ Co vitamin B ^ .
With these theoretical conditions in
mind an experiment was planned to throw light
58on the possibility of using Co vitamin B_^ 
to estimate urinary losses after injection in
(16)
/vitamin B_p deficient and normal subjects
and to investigate the extent, if any, of
58equilibration of injected Go vitamin B-^ 
with the body stores of vitamin B-^ in 
normal subjects.
PLAN Off EXPERIMENT
The object of the experiment was to
compare the values of radioactivity and of
assayable vitamin B-^ excreted in the urine
58after parenteral injections of Co vitamin 
B ^  in normal subjects, control subjects who 
were suffering from vitamin B^^ deficiency and 
subjects who had been treated for vitamin B ^  
deficiency and whose body stores of vitamin B 
would probably lie between those of the normal 
and control group.
PATIENTS, MATERIALS ABB METHODS
The control patients were ward inpatients 
suffering from vitamin B ^  deficiency as shown 
by a macrocytic anaemia, megaloblastic 
erythropoiesis seen on bone marrow biopsy smears, 
a low serum vitamin B^ 2 level and reticulocyte
(17)
/response and rise in peripheral blood values
55on treatment with parentoral Co vitamin B-^. 
Details of these patients are given in the 
Case Reports in the Appendix.
These patients were given injections of
55Co vitamin B d a i l y ,  or on alternate days, 
until a suitable number of results was obtained.
On general principles any other drug therapy 
was avoided during the investigation but in some 
cases drugs were given deliberately as part of 
studies reported elsewhere in this thesis.
In every case it was established that the presence 
of drugs or their end products in urine did not 
affect the assay result and it was also 
established that they did not affect the 
amounts of radioactivity excreted.
The ’normal1 patients were ward inpatients 
with a variety of diseases in which depletion 
of body vitamin stores or upset of vitamin 
®12 me'tabo^ism 1S no"t a ^nown feature. All 
had a normal serum vitamin level. These
patients were given a single intramuscular 
. . 58injection of Co vitamin Some of these
(18)
/patients were receiving treatment at the time
of the experiment and it was established that
this did not affect the assay result. Details
of these patients are given in Tables A.5,
A. 12 & 13, A. 16, A.20 & A.24 in the Appendix.,
The borderline1 patients were regular
attenders at an outpatient clinic and all had
been diagnosed as having a vitamin deficiency
state when first seen. At the time of the 
58injection of Co vitamin B ^  they were known 
to have serum vitamin B ^  levels at the lower 
limit of normal suggesting that their body 
stores of vitamin B-^ lay between these of the 
control and normal groups. Details of these 
patients are given in the Case Reports in the 
Appendix.
The nature and objects of the experiments 
were explained to the patients, all of whom
cooperated willingly.
58The doses of Co vitamin B ^  used were 
50 ug 0 .3  uc, 54 ug 0.3 uc, 100 ug 0.2 uc,
1000 ug 0.2 uc and 1140 ug 0.2 uc. In 
experiments using doses of 5 4, 540 and 1140 ug
(19)
58/the same hatch of Co vitamin B ^  was used 
for all patients in each dose group (*matchedf 
series) and in experiments with doses of 100
and 1000 ug which were conducted over a longer
58period of time, different hatches of Co
vitamin B ^  were used (‘miscellaneous* series).
Urine collections were made for 24 hours
prior to, and subsequent to, the injection of 
58Co vitamin B ^  m  the normal subjects. In
the case of the control patients a 24 hour
collection was made prior to the first 
58injection of Co vitamin B-^ and 24 hour
collections were made thereafter until the 
experiment was terminated. None of the
borderline patients had been given any
radioactive isotope and urine was collected
from these patients for the 24 hours after
injection only. There was no reason to believe
that the collections were other than complete.
58The methods of preparing the Co vitamin 
solutions for injections and the methods 
of collecting urine are described in the Appendix. 
The amount of microbiologically active material
(20)
/in each urine collection was measured by the 
Euglena gracilis assay in at least two different 
assay batches and the mean results expressed 
as ug of total assayable vitamin B-^^• T*16 amount 
of radioactivity was measured and the value 
expressed as radioactivity excreted as a 
percentage of the amount in a dose. Details 
of the assay and isotope techniques used are 
given in the Appendix.
The regression equations relating the 
isotope values (y) to the assay values (x) 
for each group of patients in each dose group 
were calculated and the coefficient of correlation 
was also calculated. The regression coefficients 
in each dose group were compared to each other. 
Details of the statistical methods used are 
given in the Appendix.
RESULTS
The urine collections obtained prior to 
injections of ^^Go vitamin B-^ were not found 
to contain detectable amounts of radioactivity 
and the amounts of assayable vitamin B ^  
in these collections were trivial.
(21)
58/ Deterioration of the Co vitamin 
solutions in vitro did not occur as judged by- 
serial microbiological assays during the time 
each batch was in use.
The disposition of patients into experimental 
groups is shown in Table A.l and full details 
of individual results are given in Tables A.2-24 
in the Appendix.
The results are summarised in Figs.1-5 
and the essential statistical results shown 
in Tables 1 & 2. In each group of patients in
each dose group there was a linear correlation 
between the amounts of radioactivity excreted 
and the amounts of assayable vitamin B ^  
excreted, the coefficients of correlation 
differing significantly from zero. In each dose 
group the regression coefficients were not 
found to differ significantly from each other 
(t = <2.0, P *>0.05). Minor differences in the 
results presented in Table 1 and those submitted 
by Adams (1961a) are due to the fact that the 
calculations were done by different workers* 
those in Table 1 being done by the author;
(22)
/a difference in the regression equations in 
the 1140 ug series was due to accidental 
transposition of results; those given in Table 1 
are correct.
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Discussion
Review of the literature
Apart from a report giving results from 
a smaller series of cases investigated by the 
same techniques (Adams 1961a) no comparable 
investigation appears to have been carried out 
in man.
The appearance of radioactivity in the 
urine following injections of Co vitamin 
to rats and to man had been noted by Barbee 
& Johnson (1951) Horrigan & Heinle (1952)
Mollin et al (1956) and others (vide infra) 
as an incidental observation prior to the present 
investigation. There was also evidence from 
extraction, chromatographic and isotope dilution 
studies that the urinary radioactivity was due 
to intact Co vitamin B ^  molecules and not to 
free Co. (Chow et al 1951; Smith 1952, 1953; 
McLean & Bloch 1954). Acceptable quantitative 
evidence however, that the radioactivity 
excreted after parenteral Co vitamin B-^ is a 
true measure of the assayable vitamin B-^ 
excreted, such as is reported here, had not been
/produced.
After the present investigations had been 
completed it was found that the conclusion that 
the radioactivity excreted in urine following 
parenteral Co vitamin was a measure of the 
vitamin B ^  excreted had in fact been reached
by several workers. The significance of these 
reports is difficult to assess as details of 
work justifying this conclusion were not given 
by Rosenblum et al (1952), Smith et al (1952),
Smith (1953)> Harte et al (1953) or Lang et al 
(1 9 5 3)> while the evidence presented by 
Yamamoto et al (1951) from a few experiments 
on rats certainly does not justify that conclusion. 
It appears that these conclusions were not 
acceptable as the isotope method of measuring 
urinary loss of injected Co vitamin B-^ has 
not become a standard technique and the implication
of the finding in relation to the question of 
equilibration of injected Co vitamin B ^  with the 
body stores has never been raised.
Discussion of techniques
A possible criticism of the results is that
(32)
/the assay technique used did not give accurate
results within the limitations of the method.
When comparing results obtained from normal,
borderline and control groups this is not
important as the groups were studied in the
same period of time and any error would be
constant; it is however, relevant when
considering whether the isotope method gives a
58true indication of the amount of Co vitamin 
B^2 excreted by vitamin B-^ deficient subjects.
A significant degree of inaccuracy is unlikely. 
Falsely high results, such as occur with the 
presence of pseudovitamin B ^  (Baker et al 
1956a) are virtually excluded by the low values 
obtained from the preinjection collections of 
urine and by the fact that the injected 
vitamin B ^  was pure. Falsely low results, due 
to the presence of inhibitors to the growth of 
Euglena gracilis, such as drugs and their 
breakdown products, were excluded by the results 
of recovery experiments on the urines of patients 
taking drugs and a few patients not taking 
drugs. In view of these facts it can be taken
/that the assay did measure urinary vitamin B-^ 
accurately and that the results are valid.
The value for assayable vitamin B ^  present in
the 24 hour preinjection urine collection was
not subtracted from the value for the post
injection 24 hour urine collection; it might
have seemed logical to do this on the assumption
that the value for the preinjection collection
represented a basal output of vitamin B ^  in
urine but it is obvious that such a refinement
would not have made any difference to the results.
Ideally the results for the control group
should have been obtained only from the first 
58injection of Go vitamin B-^ given to a large
number of untreated vitamin B ^  deficient
patients. The method used is apparently open
to criticism on the grounds that after the first 
58injection of Go vitamin B-^ no patient was 
then vitamin B ^  deficient. Strictly speaking 
this is so but consideration of the facts 
presented in the introduction shows that, for 
the purpose of the experiment, it is perfectly 
permissible to include all the results obtained
/from these patients.
The investigation was deliberately limited 
to a period of 24 hours after an injection of 
Co vitamin Tile amounts of radioactivity
and of assayable vitamin B.^ excreted after 
this period are very small in the majority of 
cases (see Tables A.2-4, A.6-10, A.14 & 15, 
A.17-19* A.21 & 22) and there did not seem 
to be any good reason for extending the 
investigation to include this period.
As already noted the effect of some drugs 
and differing routes of administration was 
studied concurrently in some of the vitamin B.^ 
deficient patients to find out if these affected 
the amounts of radioactivity excreted. It 
was established by recovery experiments that the 
presence of the drugs, or their end products, 
in urine did not affect the assay result and 
it was therefore legitimate to include the results 
in this investigation as the object was to 
compare the amounts of radioactivity excreted 
and assayable vitamin B-^ excreted. In fact, as 
will be shown later none of these measures
/affected the amounts of radioactivity excreted.
Similarly it is of no importance in this context
that the cause of the vitamin B-^ deficiency
state in the control patients differed from
case to case: the fact that they were vitamin B ^
deficient is all that matters.
Significance of results
Two facts emerge clearly from the results.
The first, which is of practical value, is that
58when man is given Co vitamin B ^  parenterally, 
in the dose range 54 - 1140 ug, the amount of 
radioactivity excreted in the urine in the 
subsequent 24 hours is a true indication of the 
amount of assayable vitamin B ^  excreted: this 
is established whether the body stores of 
vitamin B ^  are normal, grossly depleted or 
at a value between these two extremes. This 
is an important observation because it means 
that this direct isotope method of estimating 
urinary excretion of injected vitamin B-^ 
can be used with complete confidence instead of 
measuring the amount excreted by microbiological 
assay. This method, which makes use of a very
(36)
/small dose of radioactivity, has considerable 
advantages over the assay method. As a technical 
method it is inherently more accurate than the 
assay method, the isotope counting technique used
having an accuracy of 1 - 2f« as opposed to the 
accepted error of jt 20 >^ with the assay technique 
used (Ross et al 1957, Killander 1957a, 1958d, 
Shinton 1959, G-irdwood 1960a). In addition 
any errors in the assay method may be magnified 
by the necessary use of urine dilutions of from 
1 .1 0 to 1 .1 0 0 0 depending on the original 
concentration although this potential source 
of error may possibly be offset by the greater 
recovery which occurs, at least with sera, 
when high dilutions are used (Girdwood 1960a). 
With the direct isotope method results may be 
obtained quickly and with but little expenditure 
of time and labour whereas the assay method 
requires a considerable amount of work and time 
before an acceptable result is obtained. A 
result may be obtained by the direct isotope 
method within a few minutes of the specimen 
being collected. Even when urine dilutions are
/assayed in only two different assay batches, 
and many samples were assayed in at least three 
different batches to ensure accuracy in this 
study, the final result is rarely available within 
two weeks of receipt of the sample. This interval 
could be reduced by using one of the more rapid 
assay methods (Girdwood 1954, Spray 19559 
Tiffin & Williamson 1958) but even so the 
gain in time with the direct isotope method 
would still be considerable. The saving in 
labour with the direct isotope method can only 
be fully appreciated by those who have a working 
knowledge of microbiological assays. In brief 
a technical method of some precision has been
shown to be superior on all counts to a laborious 
and relatively inaccurate method. It is also 
clear that the direct isotope method is more 
convenient, rapid and easy to use than chemical, 
isotope dilution or reversed isotope dilution 
methods and it is unlikely that it is less 
accurate than these methods.
The second fact which emerges from the 
results, and with equal clarity, is of more
/academic interest at present. It is that 
58Co vitamin B^, given parenterally in the
doses used, does not equilibrate with the body
stores of vitamin B ^  at least in the 24 hours
after injection.
For the purposes of experimental design
it was assumed that vitamin B ^  deficient
patients in haematological relapse had no
vitamin B ^  in their tissues, although it was
appreciated that this was not the case. The
amount of assayable vitamin B ^  in the liver
of a patient with pernicious anaemia in
haematological relapse is small (see Chapter 7)
but it cannot be assumed that it is negligible
when considering the question of equilibration
58particularly with injections of Co vitamin B ^  
of the order of 54 ug. The striking lack of
difference between the results for the vitamin Bn^
12
deficient and normal subjects in the 54 ug series 
in particular implies that if equilibration did 
occur at all it did so to no greater extent when 
the body stores were normal than when they were 
grossly depleted. This seems very unlikely and
/it can be taken for practical purposes that 
the lack of equilibration is complete in the dose 
range of 54 to 1140 ug. furthermore, in the 
54 ug series it is permissible for the regression 
lines and standard deviation curves to be extended 
to meet the abscissa and ordinate. The regression 
line for the normal group meets the ordinate 
at the point abscissa 0 , ordinate 2 .8223 and the 
regression line for the control group meets the 
ordinate at the point abscissa 0 , ordinate 
4.2155. The lower standard deviation curve for 
the normal group meets the ordinate at the point 
abscissa 0 , ordinate -7.29 and the lower standard 
deviation curve for the control group meets the 
ordinate at the point abscissa 0 , ordinate - 6 .0 3. 
As it was not assumed that either regression 
line would pass through the point abscissa 0 , 
ordinate 0 , these findings are good evidence that 
the lack of equilibration occurs in the entire 
dosage range up to 1140 ug.
An obvious explanation for the findings
is that the urinary excretion of injected 
58Co vitamin is so rapid that there is
(kO)
/insufficient time for equilibration, particularly
if the body stores of vitamin B ^  are in
‘compartments' or 'subpools'. Observations
on the excretion of injected vitamin show
that it is a rapid process (Chow et al 1950,
Chesterman et al 1951, Krevans et al 1951*
Sokoloff et al 1952) and observations on the
58excretion of parenteral Co vitamin
reported in Chapter 4, have confirmed and
elaborated these findings. As a rule, about
5850$ of the total Co vitamin B ^  excreted in
the urine after a parenteral injection is
eliminated within three hours of injection.
Equilibration however, is an extremely rapid
process and to attribute the lack of equilibration
solely to rapid excretion implies that the 
58injected Co vitamin B ^  does not enter the 
'subpools' in the body for an appreciable time. 
That this is not the case is apparent from the 
results reported by several workers from studies 
on the plasma clearance of injected Co vitamin 
B ^ *  Glass et al (1955), Estren et al (1958), 
Glass (1959) and Brody et al (i960) all report
(41)
/that the hepatic uptake of radioactivity is
very rapid while Mollin et al (1956), Miller
et al (1957), Estren et al (1958) and Hall (I960)
all report very rapid clearance of injected 
58Co vitamin B-^ from the blood stream. These
58results show that injected Co vitamin B ^  
enters the tissues rapidly. Thus the argument 
that injected Co vitamin does not equilibrate 
with the body stores because there is 
insufficient time for this to occur before it 
is excreted cannot be sustained.
Another explanation, which is also obvious, 
is that equilibration does not occur because 
vitamin B-^ does not exist as such in the body. 
This, in turn, implies that injected vitamin B^ 2 
retained in the body is converted to an analogue 
or active form. This concept entails a radical 
departure from the current notions of vitamin
Bj^ metabolism (Estren et al 1958) but it 
cannot be avoided. Furthermore, there is already 
evidence that this may be the case. A recently 
isolated enzyme, 5 :6 dimethyl benzimidazole 
cobamide coenzyme, (Weissbach et al 1959»
Barker et al 1960a) has been identified in
(42 )
/rabbit liver in a concentration which, allowing 
for losses in isolation, corresponds to about 
80% of the reported vitamin content of beef 
liver (Weissbach et al 1959). This finding has 
led to the suggestion that this enzyme, or 
similar enzyme (Barker et al 1958, Barker et al 
1960ab) may be the main form of vitamin B-^ or 
B^2“di^e compounds which are catalytically 
active in the enzymatic reactions of living
cells (Weissbach et al 1959)» & suggestion 
recently strengthened by the isolation of 
5 :6 dimethyl benzimidazole cobamide coenzyme from 
human liver (Barker 1961). It has also been 
reported that 5 :6 dimethyl benzimidazole cobamide 
coenzyme competes with vitamin B i n  a 
1 :1 ratio for attachment to intrinsic factor or 
liver homogenate receptors and that it exerts 
a haemopoietic effect equivalent to that of 
vitamin when given intramuscularly in doses 
of 1 ug to patients with pernicious anaemia 
(Wasserman et al I960). This enzyme, and others 
isolated by Barker et al (1958, 1960b) have 
distinctive absorption spectra but have not
U3)
/previously been detected in tissues reported 
to contain cobalamins. Weissbach et al (1959) 
suggest that the reason for this is that the 
enzymes are rapidly converted to vitamin 
by procedures invariably used to extract cobalamins 
from tissues, such as exposure to light, heat 
or cyanide ions. It should be noted that the 
isolation of the enzymes is very difficult, 
all procedures being carried out in the dark 
or in a very dim light and nearly always at 
temperatures of 0 - 4°0. (Barker et al 1960a).
In addition there is also evidence that 
hydroxocobalamin (vitamin B-^a or ®x2b ^  W^ C L^ 
forms the bulk of the total cobalamins in some 
animal proteins (Tarr 1952), may be the 
metabolically active form of vitamin B^ 2 
(Smith 1961). This view has recently been 
strengthened by the finding that the bulk of the 
radioactivity in the livers of dogs given oral 
or parenteral Go vitamin B-^ was present as 
Go hydroxocobalamin implying conversion of the 
retained Go vitamin B ^  to Go hydroxocobalamin 
in the body (Rosenblum 1 9 6 1).
/ The belief that, in man, vitamin B^ 2 
whether absorbed from the intestine or given 
by injection, functions in the body as an active 
substance is based essentially on five points:
(1 ) the clinical and haematological benefit 
obtained by the exhibition of pure vitamin B-^
to patients with pernicious anaemia.
(2) the results of recovery experiments 
in which vitamin B^ 2 added to tissues and
the effect measured by microbiological assay; 
an increase in microbiological activity, low 
in the tissues and body fluids of patients 
with pernicious anaemia, being obtained 
corresponding to the amount of vitamin B -^ 2 
added (Ross et al 1957i Killander 1957a,
Shinton 1959).
(3) on the results of microbiological 
assays of tissues with Ochromonas malhamensis 
which is the most specific assay organism for 
vitamin B -^ 2 (Ford 1953) as well as with Euglena 
gracilis (Ross & Mollin 1957).
(4) on the findings that the distribution 
of radioactivity in the body after an injection
US)
/of Co vitamin B-j~ differs from that resulting 
from an injection of Co chloride (Meyer et al 
1956).
(5) on the finding that the hepatic
radioactivity, present post mortem in subjects
who had received Co vitamin B ^  before death,
had the solubility and chromatographic
60characteristics of Co vitamin B a n d  that
there was no evidence of any mierobiologically
60active material containing Co other than 
^ C o  vitamin B-^  ^ (Glass & Mersheimer 1958, 
Schloesser et al 1958).
It is now clear that none of these 
findings is evidence against the concept that 
vitamin B-^ does not exist in the body or exists 
in the body to only an insignificant degree 
and that injected vitamin B ^  is converted to 
an active form in the body. The fact that a 
chemically pure substance induces relief from 
signs and symptoms does not necessarily imply 
that the cause of the signs and symptoms was 
deficiency of that substance - at least five 
analogues of vitamin B-^ appear to be as
(V6)
/haemopoietically active as vitamin 3 ^  
itself (Blackburn et al 1957). The fact that
the distribution of radioactivity in the body
60following an injection of Co vitamin B-^
differs, from that following an injection of 
60Co chloride can only be taken as evidence 
that the metabolic pathways of these substances 
or their derivatives differs. The procedures 
involved in microbiological assay and 
chromatographic techniques may alter the chemical 
structure of the active principle: even with such 
a refined technique as the reverse isotope 
dilution method it is salutory to note that the 
radioactivity in the liver of dogs given 
Co vitamin B-^ is largely in the form of Co 
vitamin B ^  if nitrous acid is used in the 
preparation of tissues and largely in the form 
of Co hydroxocobalamin if the tissues are 
prepared with papain or trypsin (Bosenblum et al 
I960, Bosenblum 1961), The extreme instability 
of the coenzymes particularly when exposed to 
visible light, cyanide ions or mild acid 
hydrolysis (Weissbach et al 1959) must be
(47)
/remembered in this context. It may be that the 
problem lies not in the techniques but in the 
preparation of tissues for analysis but this
does not affect the issue. Nearly all the 
mierobiologically active material - 'assayable 
vitamin B.^* — in the tissues is in the bound 
form. Binding implies at least a physical change 
since the assayable vitamin B-^ in liver is 
mierobiologically active but not dialysable 
(Pitney et al 1955, Boss & Mollin 1957). It 
is possible that the process of binding also 
involves chemical changes in the structure of 
injected vitamin B.^. This speculation, 
however tempting as an explanation for some 
of the facts must remain a speculation only at 
present.
Por present purposes it is enough to know
that the amount of radioactivity excreted
in the urine in the 24 hours after an injection 
58
of Co vitamin B^, at least in the dose range
5b0 - 1140 ug, is a true measure of the Co 
vitamin B^^ excreted as judged by microbiological 
assay whether the body stores of vitamin B-^
US)
/or its active principle are normal or depleted. 
Investigations using this direct isotope method 
of measuring the urinary loss after parenteral 
Uo vitamin will he reported in subsequent 
chapters, lor convenience much current terminology 
will be retained although with the full 
appreciation that it is inaccurate: for example 
the term fbody stores of vitamin ^2* 
used rather than the more precise term ‘body 
stores of the metabolically active form of 
vitamin an(^  the term ‘vitamin B ^  deficiency
state* will be. retained in preference to the 
clumsy but more accurate term ‘deficiency state 
relieved by vitamin the deficiency being
of an as yet unidentified active principle 
probably an analogue of vitamin ^•*
s u m m a r y
The difficulties in measuring the amount 
of vitamin excreted, especially in urine, 
after injections of vitamin B^^ a**e described 
briefly.
Theoretical considerations affecting the 
58use of Co vitamin B ^  m  measuring the urinary
loss directly are discussed, particular attention
being paid to the possibility of equilibration 
58of injected Co vitamin B^^ with the body stores.
An experiment, planned to examine the
58feasibility of using Co vitamin B ^  to measure
urinary loss after injection in normal, vitamin
3^ 12 deficient and ‘borderline* subjects is
described.
The results show that there is linear
correlation with a coefficient of correlation
differing very significantly from zero between
the. vitamin B12 excreted as judged by
microbiological assay using Euglena gracilis
and the radioactivity excreted after 
58injections of Co vitamin B ^  in doses of 
54 - 1140 ug in all groups of patients. The
(50)
/regression coefficients for normal, vitamin
I$12 deficient and ‘borderline* subjects do not
differ significantly from each other in each
dose group.
The literature on the subject is reviewed
and the validity of the techniques discussed. 
The significance of the results is discussed 
and it is concluded that the amount of
radioactivity present in the urine in the 24
58hours after an injection of Co vitamin
in the dose range 0 - 1140 ug is a true
measure of the amount of assayable vitamin B-^
excreted. The ease, simplicity and accuracy
of this method - the direct isotope method -
are stressed. It is also concluded that the
results demonstrate lack of equilibration of 
58injected Co vitamin B^^ with the body stores. 
The nature of this phenomenon is discussed and 
the likeliest explanation is considered to be 
that vitamin B.^ does not exist as such in the 
body but in an active form. The nature of this 
active form is discussed in the light of recent 
work.
(51)
CHAPTER II
OBSERVATIONS ON THE URINARY EXCRETION OF 
INJECTED 5 CO VITAMIN B., BY NORMAL AND 
VITAMIN B12 DEFICIENT SUBJECTS AND ON THE 
EXCRETION OF 5 CO VITAMIN B12 BY VITAMIN 
B12 DEFICIENT SUBJECTS GIVEN REPEATED 
INJECTIONS OF 5 CO VITAMIN B1 .
(§2)
One might expect that a vitamin 
deficient subject would retain in his or her 
tissues a greater proportion of an injection of 
vitamin B-^ than a normal subject. One might
also expect, particularly in the case of the 
vitamin B d e f i c i e n t  subject, that with repeated 
injections of vitamin B.^, the amount excreted
would increase, pari-passu with the increase 
in tissue stores, possibly reaching a stage 
at which the tissues were saturated when virtually 
all the injected vitamin B ^  would be excreted.
Reference to the literature showed that 
there was general agreement that the vitamin 
deficient subject excreted the same amount 
of vitamin B ^  after an injection as did the
i
normal subject; there was also general agreement \ -) 
that the amount excreted increased as the body 
stores were augmented by repeated injections.
Critical appraisal of these reports however, 
left room for doubt about the conclusions and 
as the urinary excretion of parenteral vitamin
B12 can be measured directly with ease and
58accuracy by using Co vitamin it was
(55)
/decided to reinvestigate these points. 
PLAN OF EXPERIMENTS. PATIENTS & METHODS
Two separate experiments were undertaken.
The first experiment was designed to find out
if vitamin deficient subjects excreted
significantly different amounts of injected 
58Co vitamin B ^  in the urine than normal 
subjects. For this purpose the amounts
excreted by nine previously untreated vitamin
Bi^ deficient subjects after an intramuscular
58injection of 100 ug 0.2 uc Co vitamin B ^
were compared to the amounts excreted by thirty
one normal subjects each given a single
intramuscular injection of 100 ug 0.2 uc 
58Co vitamin B ^  and to the amounts excreted
by eight chronically anaemic patients who
had normal serum vitamin B^^ levels and were
also given a single intramuscular injection of 
58
100 ug 0.2 uc Co vitamin ^ 2 *  Similarly 
the amounts excreted by twelve previously 
untreated vitamin B-^ deficient subjects after 
an intramuscular injection of 1000 ug 0.2 uc 
^ C o  vitamin B ^  were compared to the amounts
(54)
/excreted by fifteen normal subjects given a
single intramuscular injection of 100 ug 0*2 uc 
58Co vitamin and to the amounts excreted
by nine chronically anaemic subjects who had
normal serum vitamin levels and were also
given a single intramuscular injection of
581000 ug 0.2 uc Co vitamin B ^.
All the vitamin B ^  deficient subjects had 
a macrocytic anaemia, megaloblastic erythropoiesis
seen on marrow biopsy smears and a low serum 
vitamin B ^  level and all responded to 
58parenteral Co vitamin These patients are
listed in Tables A.25 and A.27 and full details 
of each case are given in the Case Reports in 
the Appendix* The normal subjects were those 
studied in the investigation reported in 
Chapter 1 and details of these patients are given 
in Tables A.12, A.13 and A.20. Details of the 
chronically anaemic subjects who had normal 
serum vitamin B-^ levels are given in Tables
A.26 and A.28 in the Appendix.,
Urine was collected from all subjects 
for 24 hours prior to, and subsequent to the
(55)
58/injection of Go vitamin Solutions of
58Co vitamin B-^ for injection were prepared
as described in the Appendix. Several different 
58batches of Co vitamin were used and each 
batch was assayed microbiologically each week 
it was in use to detect deterioration. ‘The 
isotope counting method used is described in 
the Appendix. The values obtained from the 
three groups of subjects in each dose group 
were compared by an analysis of variance.
The second experiment was designed to find out
58if the proportion of injected Co vitamin B ^
which was excreted altered as the body stores
of vitamin B ^  or its active form, were
replenished. This was done by measuring the
radioactivity excreted by vitamin B
deficient subjects given repeated injections of
58the same dose of Co vitamin The doses
used ranged from 54 ug 0.3 uc to 3 0 ,00 0 ug 
0.1 uc and thirty subjects were studied. All 
presented with a macrocytic anaemia, 
megaloblastic erythropoiesis seen on marrow 
biopsy smears and a low serum vitamin B ^
(56)
/level and all responded to treatment with 
58
parenteral Co vitamin B^2* addition five
other patients (Cases F.A., J.MeF., I.E., A.S.
& R.T.) who had presented with evidence of
vitamin deficiency and who had previously
received parenteral vitamin and were in
full haematological remission were studied by
the same method. The investigation in Cases
B.A. and I.E. was interrupted and during this
period they were given 1000 ug vitamin B ^
intramuscularly each month. In some patients
the effect of drugs or different routes of
58administration on the excretion of Co 
vitamin B-^ was studied concurrently. As 
will be shown later, in Chapter 3, these were 
without effect and it is therefore legitimate 
to include the results obtained from these 
patients in this investigation. Details of the 
patients are given in the Case Reports in the 
Appendix.
Urine was collected for 24 hours prior to
58the first injection of Co vitamin B-^ and 
for 24 hours after the injections of vitamin B12-
(57)
/In some cases where injections were given
frequently 24 hour collections were made
uninterruptedly for the period of the
58investigation. Solutions of Go vitamin B
for injection were made up as described in the
58Appendix. Several batches of Co vitamin 
were used and each was assayed microbiologically 
each week it was in use to detect deterioration. 
The isotope counting method used is described 
in the Appendix.
In both experiments all patients were aware 
of the nature and objects of the experiment and 
all cooperated willingly.
RESULTS
No radioactivity was detected in any urine 
collected prior to the first injection of 
^ C o  vitamin B ^ .  Deterioration of the 
“^ Co vitamin B ^  solution in vitro was not 
observed.
First experiment
The amounts of radioactivity excreted by 
the vitamin B -^  ^deficient subjects are given in
(5$)
/Tablis A.25 & 27, by normal subjects in Tables 
A. 12, A. 13 & A.20 and by the chronically anaemic 
subjects with normal serum vitamin levels 
in Tables A.26 & 2b in the Appendix. These 
results are summarised in Bigs. 6 & 7 and the 
essential statistical results in Table 3.
The mean values in each dose group do not 
differ significantly from each other: in the 
100 ug series 3? = 0.76, P = >0.05 and the 
standard error of a single measure is 1 2.0 1: 
in the 1000 ug series P = 0.16, P =>0.05 
and the standard error of a single measure is 
15.44.
(59)
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Fig, 6s Showing amounts of radioactivity excreted by
anaemic vitamin deficient patients, normal
subjects and chronically anaemic patients with normal
58serum vitamin B■ ^  levels given 100 ug Co vitamin 
B^^ intramuscularly.
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Fig. 7s Showing amounts of radioactivity excreted
by anaemic vitamin deficient patients, normal
subjects and chronically anaemic patients with normal
58
serum vitamin B 2 levels given 1000 ug Co vitamin 
intramuscularly.
(6l)
BOSE PATIENTS NUMBER
OF
RESULTS
MEAN VALUE 
EXCRETED
$ dose
100 ug
/
^12 (^e:^ L^C^ Len  ^
. Anaemic
9 31.9222
Normals
I—1 32.9903
\ Anaemic
( Non B ^  deficient 8 27.1000
1000 ug f B-^2 deficient 
I Anaemic
12 58.7166
Normals 15 5 4 * 7 6 6 6
( Anaemic
( Non B ^  deficient 9
56.98OO
Table 3s showing mean values excreted by anaemic vitamin
deficient patients, normal subjects and patients
with chronic anaemia and normal serum vitamin
levels, given injections of 100 ug and 1000 ug 
58
Co vitamin ^ 2 *  mean values ©a-ck dose
group do not differ significantly from each other.
(62)
RESULTS (cont.)
Second experiment
The amounts of radioactivity excreted by
patients given repeated injections of 
58Co vitamin B ^  in the dose range 54 - 30,000 ug
are shown in Pigs. 8 - 4 2 .  The amount of 
58Co vitamin retained by each patient,
obtained by subtracting the amount excreted
from the amount injected, is shown in Table 4.
Pull details of individual results are given
in Tables A.2 - 4, A . 6 - 10, A.14 & 15,
A.17 - 19, A.21 & 22, A.29 - 48. As there was
obviously no constant trend to an increase
58in the amounts of Co vitamin B12 excreted 
during the observation periods, the results 
were not subjected to detailed statistical 
analysis.
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54  /jg 5e CoB|2 injection
|
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nJTn-fl
0  I 2 3  4  3 8 7 8 9 10 II 12 13 14
days
Fig. 8
5 4  /ig ^®CoB(2 injection
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n
0 I 2 3  4  5 6 7 8 9 10 II 12 13
Pig. 9
5 4  /ug 5 s CoB|2 injection
Case J.M cM
100 pg SSCo B12 injection C aSe J C '
0  | 2 3 4  5 6 7 8 9 10 II 12 13 14 15 16
Fig. 10
100 fjg 5eCoB|2 injection
1 1 1  I I I  i l l  I I
Fig. 11
lOO/jgSSco B|2 injectio
Fig. 12 Fig. 13
Figs. 8-13: Showing amounts of radioactivity excreted by 
patients given repeated injections of 54 ug or 
100 ug "^Co vitamin (see Tables A.2-4> 6-8).
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100 /jg 5BCo B|2 Injectio
11
100 /jg ^8CoB|2 injection
I i i  I I 1 1 I I
C ast J . f tC I
a r Q n B
0  I 2 3 4 3 8 7 8 9 10 11 12 13 14 13 16 17 18 19 20 21
days
0  I 2 3  4  5 6 7 0 9 10 II 12 13 14
days
Fig. 14
100 jugSSCo B |2 Injection Cast K. M cD .
1 1 1 1 1 1 1 1 1 1 1 1 1 1
Fig. 15
5 4 0  /jg  58coB|2 injection
0 | 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16
days
Fig. 16 Fig. 17
540jUg 5eCoB|2 injection
1 1 1 1  I I I  1 1 1 1 1 1 1  I I I  I
O | 2 3 4  5 6 7 8 9 10 II 12 13 14 15 16 17 18
days_________________________________
Fig. 18
Figs. 14-18s Showing amounts of radioactivity excreted by 
patients given repeated injections of 100 ug or 
540 ug ^ C o  vitamin (see Tables A *9, 10, 14>
15 & 29).
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SSCoBia Inj
Pig. 19
1.000 ug 3 8 CoB|2 Injection C as*  J A -
Fig. 20
I,OCX) ^ug SSCoBjg in jection 
!
1,000 ,ug58 Co B12 injection
Pig. 21
!,0O0 >ug ^^CoBig injection
1 11
Fig. 22
Case S .J .
I i
O J 2 3  4  5 6 7  8 9 10 II 12 13 14 15 16 17 18
days
Pig. 23
► 19-23: Showing amounts of radioactivity excreted by 
patients given repeated injections of 1000 ug 
^ C o  vitamin B ( s e e  Tables A.17 & 18, A.30-32).
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1,000 >ug 3®CoB|2 Injectio
0 I 2 3 4  3 6 7  8 9 10 II 12 13 14 15 16 17 18
1,000 >ug 58 CoB|2 Injection
•Fig. 24
Case M.P.
100—j
|
** 80  H
Fig. 26
1.000 Jjg 58CoB|2 injection 
1 1 1 1 11
s
J> 4<H
10 II 12 13 U  13 16 17 18
Fig. 25
5 8 C oB |2 *nj 5 8 CoB |2  ini
| 5 |0  20  3 0  4 0  5 0  6 0  7 0  8 0
Fig. 27
1,000 Aig 58 CoB|2 injection
0 I 2 3 4  5 6 7 8 9 10 II 12 13 14 15 16 17
Fig. 28
Figs. 24-28; Showing amounts of radioactivity excreted hy 
patients given repeated injections of 1000 ug 
■^Co vitamin B ^  (see Tables A.33-37)*
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1,000 H9 58C o B |2 In jection
1,000 /jg 50CoB|2 injection
lil I I 1 I 1 1 1 I I
Fig. 29 Fig. 30
1,000 pg 5 8 CoB|2 Injection
1,140 pg 50CoB|2 injection
O | 2 3 4  5 6 7 8 9 10 II 12 13 14 15 16 I'
Fig. 31
0 I 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 20 21
Fig. 32
1,140 pg  5 8 CoB|2 injection
Fig. 33
Figs. 29-33! Showing amounts of radioactivity excreted by 
patients given repeated injections of 1000 ug or 
1140 ug ^Co vitamin (see Tables A.19, 21, 22,
38 & 39)-
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38 C o B |2 Inj
0 1  2 3 4 5 6 7  8 9  10 II
Fig. 34
Case J.H.
50 0 0  /jg 38co B|2 injection
IOO
80
60
40
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0
0 I 2 3 4 5 6 7 8 9 10 II 12 13
Fig. 35
5p00 /jg 56Co B|2 Injection
I I l t ) I 11 11
Case J-O-Cn.
5 0 0 0  /jg 3800 812 injection
J 1 I 1 I I J I i I 1 I
Pig. 36 Fig. 37
Pigs. 34-37: Showing amounts of radioactivity excreted by 
patients given repeated injections of 5000 ug 
"^ Co vitamin (see Tables A*40—43) •
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10,000 fig 5 8 CoB|2 Injectlo
m in i
0  I 2 3 4 3 6 7 8 9 10 II 12 13 14 15 16 17 18 19 2<
Fig* 38
10,000 fig 58Co B|2 tnjectioi
bUdilD
Fig. 39
10.000 j^g 38 Co B|2 Injection
j i j i 11 j i m u
Fig. 40
3 0 ,0 0 0  fig  5 8 C o B |2 injectit
i i 1
20,000 pg50Co B|2 injection
2 4  6 0 10 12 14 16 18 20 22 24 26 2830 32 34 36 38 40 42 44 46 48 50
days
Fig. 41
I 2 3  4  5 6 7  8  9  10 II 12 13 14 15 16 17
Fig. 42
Figs. 38-42: Showing amounts of radioactivity excreted by 
patients given repeated injections of 10,000 ug, 
20,000 ug or 30,000 ug ^ C o  vitamin B^  (see fables
A •44-48)•
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CASE ®8Co VITAMIN B p 
INJECTIONS 1
ug
cQTOTAL
ug
CALCULATED 
Co B 
RETAILS
ug
A.H. 10 x 54 540 466
H.McG. 10 X 54 540 401
J.McM. 10 x 54 540 494
J.C. 17 x 100 1700 1185
M.C • 18 x 100 1800 1042
J.F. 9 x 100 900 451
H.F. 16 x 100 1600 726
J .A.M. 8 x 100 800 585
K.McD. 17 x 100 1700 790
G.G. 18 x 540 9720 2731
J.J. 15 x 540 8100 2292
F.A. * 12 x 1000 12000 4195
J.A. 12 x 1000 12000 4104
i.e. 16 x 1000 16000 4044
J.D. 12 x 1000 12000 3132
S.J. 8 x 1000 8000 2272
E.McB. 12 x 1000 12000 5760
J.McF. * 12 x 1000 12000 4469
M.P. 12 x 1000 12000 4116
I.E. * 18 x 1000 18000 6229
A.S. * 12 x 1000 12000 5271
J.S. 18 x 1000 18000 5598
S.S. 14 x 1000 14000 4718
S.T. * 12 x 1000 12000 5007
C.D. 16 x 1140 18240 5727
H.K. 14 x 1140 12960 5681
A.E. 10 x 5000 50000 7125
CASE 58 ^Co VITAMIN B ? 
INJECTION'S
ug
-qTOTAL 
Co B. p
GIVEN
ug
^gALCULATED
retaiJSd
ug
J.G.G. 10 x 5000 50,000 9500
J.H. 6 x 5000 30.000 5760
J.O.M. 12 x 5000 60,000 8460
D .McC . 18 x 10000 180,000 6480
H.McD. 15 x 10000 150,000 43500
C.McI. 14 x 10000 140.000 50820
s.s. 17 x 20000 340,000 83300
C.B. 6 x 30000 180,000 41760
58Table 4: showing amounts of  ^Co vitamin B^2 given and 
amounts retained calculated by subtracting the amounts 
excreted in urine from amounts injected in the cases 
from which the results in figs. 8 - 42 were obtained.
The cases are listed in alphabetical order in each dose 
group. Cases marked with an asterisk all received 
vitamin B^2 either before or during the observation period.
(72)
DISCUSSION
First experiment
Although, there is general agreement in the 
literature that normal and vitamin
deficient subjects do not excrete significantly 
different amounts of injected vitamin B ^  this 
conclusion, either stated or implied, is based 
on flimsy evidence in most publications. The 
reports by Chow et al (1950), Conley et al 
(1950) and Krevans et al (1951) are based on 
results obtained from the same patients, three 
of whom were vitamin B  ^ deficient and two of 
whom were normal; those by Conley et al (1951) 
and Unglaub et al (1954) from results from two 
vitamin B ^  deficient and two normal subjects 
while Chesterman et al (1951) drew their 
conclusions from observations on one vitamin 
B ^  deficient patient and ten normal subjects. 
Acceptable evidence justifying the conclusion 
that there is no significant difference in the 
amounts excreted by vitamin deficient and 
normal subjects was provided by Sokoloff et al 
(1952) who studied six vitamin B ^  deficient
(73)
/patients and six normal subjects receiving 
injections of vitamin B12 in the dose range 
42 - 211 ug, by Mollin & Ross (1953a) who 
studied five vitamin B ^  deficient patients and 
five normals in the dose range 40 - 1000 ug 
and by Reizenstein (1959b) who studied six 
vitamin deficient subjects and fifteen 
normals in the dose range 0.3 - 1.0 ug. When 
evaluating these results it must be noted that 
no allowance was made for the fact that renal 
function may be severely impaired by chronic 
anaemia (Bradley & Bradley 1947). These results 
therefore form a basis not for comparing the 
amounts excreted by normal and by vitamin B ^  
deficient subjects but only for comparing amounts 
excreted by normal and by vitamin B ^  deficient 
subjects with renal insufficiency due to chronic 
anaemia. It was for this reason that a third 
group of patients who were chronically anaemic 
but had normal serum vitamin B ^  levels was 
included in the present investigation.
Ideally a group of patients with low serum 
vitamin B ^  levels and other stigmata of
(7k)
/vitamin B^p t>nt who were not anaemic,
should also have been studied: such patients
have been described by Adams (1957a) and
Killander (1957b) but are uncommon and a
sufficient number of results from such patients
could not be obtained. The alternative of
treating vitamin B1 deficient patients with
folic acid or blood transfusion to eliminate
the effect of anaemia on renal function,
was not considered justifiable•
When the results obtained in the
investigations reported in Chapter 1 were
analysed, it was noted that the mean values of
radioactivity excreted by the vitamin
deficient subjects did not apparently differ
greatly from those excreted by normal subjects
58given the same dose of Co vitamin B-^. It 
was appreciated that a detailed analysis of these
results would not have yielded a valid result, 
as, amongst other things, the population of, as 
opposed to the number of results obtained from, 
the vitamin B ^  deficient patients in each dose 
group was small. The present method of
(75)
/investigation was therefore chosen to clarify
the point and it is clear from the results that
the amounts of radioactivity excreted after
58injections of 100 ug and 1000 ug Co vitamin 
B12 are not affected by chronic anaemia or by 
chronic anaemia and vitamin deficiency: 
it seems extremely unlikely therefore that 
vitamin B ^  deficiency in the absence of anaemia
would affect the amounts of radioactivity 
excreted.
It would not have been surprising to find
that the amounts excreted by the vitamin B
deficient groups of patients were significantly
less than the amounts excreted by the normal
groups of patients, suggesting that depleted
58tissues 'soaked up 1 the injected Co vitamin 
B 1 2  but this is plainly not the case. The 
reason for this is not clear. Several factors
may be involved and the rate of excretion of 
58injected Co vitamin B12, the rate of binding 
58of injected Co vitamin B-^ to tissues, the
capacity of the tissues to bind injected
^8Co vitamin B12 a n d  the blood level of injected
/58„ ^ ^/ Co vitamin B ^  must all be considered.
If the renal excretion of injected Co vitamin B.^
were very rapid it is conceivable that a
proportion could be swept out on the renal tide
before it could be bound to tissues whether
depleted or not. Although the renal excretion 
58of injected Co vitamin B ^  is rapid (see 
Chapter 4) it does not occur at such a rate as
to provide such an explanation for the results
unless it were also shown that the process of
58binding of injected Co vitamin B^  to tissues 
took some time. This is very unlikely in view 
of the rapid clearance of injected Co vitamin B ^  
from the blood stream, (Miller et al 1957,
Estren et al 1958, Hall I960) and the 
rapid uptake by tissues as shown by external 
counting (Estren et al 1958, Glass 1959, Brody 
et al I960). Apart from the rate of binding of 
injected Co vitamin B^2 to tissues there is the 
possibility that the capacity of the tissues
to bind injected Co vitamin B12 is limited whether 
the tissues are depleted or not. This factor 
alone is unlikely to be of much importance as
58/the amount of J Co vitamin B1 retained after
an injection of 50 ug is about 40 ug whereas
about 800 ug is retained in the same period after
an injection of 1 0 ,0 0 0 ug: it might be a major
factor however, if the amount bound were also
related to the concentration of free injected 
58Co vitamin in the blood stream. The blood 
concentration is greater after injection of a 
large dose and as a general rule the actual 
amount, as opposed.to the percentage of the 
dose retained, increases as the dose injected 
is increased. If the binding capacity and amount 
bound were related to the blood concentration 
one might expect a greater amount to be retained 
after an intravenous dose than after intramuscular 
administration of the same dose. This does not 
occur with doses of 100 ug and 1000 ug at least 
(Chapter 3) but this is not necessarily evidence 
against this theory as the rate of excretion 
is faster after intravenous than after intramuscular 
administration leaving less injected vitamin 
available for binding. Other factors too may be 
involved. It has been suggested that vitamin B-^
(7a)
/does not exist as such in the body and that 
injected vitamin is converted to an active 
form (Chapter 1. Adams 1961a). It would be
reasonable to expect depleted tissues to 
retain more injected active form than normal 
tissues but not necessarily reasonable to 
expect a difference when an inactive form or 
precursor was injected. The fact that the 
inactive form, is converted to the active form 
in, or after the process of binding is not 
evidence against this explanation. When the 
active form or forms of vitamin B-^ are 
established beyond doubt it will be important to 
study the amounts excreted by normal and by
vitamin B ^  deficient subjects as was done in 
this study to determine if this is a relevant 
factor.
From this discussion it is obvious that no 
single factor can explain the results and that 
the answer probably lies in a complex 
inter-relation of several factors all operating 
simultaneously. Further investigations on this 
problem are in progress.
(79)
/Second experiment
It has been shown that vitamin 3 ^  
deficient subjects in haematological relapse
do not excrete significantly different amounts 
58
of injected Co vitamin B-^ from normal
subjects at least as far as the first 
58injection of Co vitamin given to vitamin B^ 
deficient subjects is concerned. This does not 
imply that the proportion of injected vitamin 
Bf2 which is excreted will not increase as the 
body stores are augmented by repeated injections 
and this, in fact, has been reported to occur 
in vitamin B-^ deficient patients (Sokoloff 
et al 1952, Mollin & Boss 1953a), in normal 
subjects (Chesterman et al 1951* Sokoloff et al 
1952, Estrada et al 1954), in one leukaemic 
patient (Mollin & Boss, 1953a) and in one rat 
(Harte et al 1953). In all but one of these 
investigations the technique adopted was to 
measure the urinary loss, after a single injection 
of vitamin microbiological assay, to
give 'saturating* intramuscular doses ranging 
from 20 ug daily for two weeks (Chesterman et 
al 1 95 1) to 1000 ug daily for seven days
( S O )
/(Mollin & Ross 1953a) and then to measure the 
urinary loss after a second injection, fhe 
conclusion that the proportion excreted increased 
as the body stores were increased was based 
on the finding of an increased amount excreted
after the second injection. In only one 
investigation was the possibility considered 
that the amount excreted by any one patient 
might vary from day to day. Mollin & Ross 
(1953a) measured the daily excretion after 
injections for four days and then, finding that 
there was no significant variation, 'saturated' 
the patient and then measured the amounts 
excreted after two further injections and found 
that the amounts excreted were greatly increased. 
It is obvious from the results shown in Figs. 
d - 42 that this could have occurred by chance
and it is likely that this is the explanation 
for the findings of the other authors who have 
investigated this problem.
In a few cases studied in this series 
there was an apparent trend to excretion of 
greater amounts with repeated injections of
(81)
5b
/ Go vitamin B-j.2 5 in a few o1;ileriB reverse 
appeared to be the case, From the overall 
picture, however, it seemed likely that these 
apparent trends would have disappeared had the 
observation period been extended. The results 
were submitted to I)r. R. A. Robb who advised
that they were such clear evidence against a
constant trend to the excretion of greater or
smaller proportions of the amounts injected
that statistical analysis was unnecessary.
The results also show that it is very unlikely
that there is any stage of tissue saturation with 
58Co vitamin or its active form at which
the amount excreted increases in a plateau
like manner. Had there been such a stage it
might not have been obvious when larger doses
alone were given but would have been obvious when
smaller doses were given. The overlap of total
58amounts of injected Co vitamin retained
in the body shown in Table 4 is additional evidence
58in this connection. The amounts of Co vitamin 
B-j^ 2 retained were calculated by subtracting the 
amount excreted in the urine from the amount
(82)
/injected and range from values much less to
very greatly in excess of those found in normal
tissues by microbiological assay (see Chapter 7).
To secure retention of amounts in excess of the
normal stores it was necessary to give large 
58doses of Co vitamin B-^: such doses were given
to patients with vitamin B ^  deficiency states
in haematological relapse and for reasons
already given in Chapter 1 it can be assumed
with confidence that the radioactivity excreted
58was a true measure of the amount of Co
vitamin B ^  excreted.
The extraordinary capacity of vitamin B
deficient subjects to retain very large amounts 
58of injected Co vitamin B ^  has not been 
described previously. As the amounts retained 
were often greatly in excess of those present 
in normal tissues it seems probable that this 
capacity is also enjoyed by normal subjects.
If this is the case it is surprising that this 
phenomenon has not been utilised by nature. It 
may be that the extent of the body stores of 
vitamin B^^ or active form is limited by
(83)
/the small amounts which can be absorbed from 
the intestinal tract and that the amounts present 
in normal tissues represent a nice balance 
between intake and expenditure allowing for all 
eventualities other than complete deprivation.
The ease with which very large amounts
58of Co vitamin B-^ can be stored in tissues 
is particularly interesting in relation to the 
treatment of patients with vitamin B ^  
deficiency states and the findings suggest that 
it would be a practical therapeutic proposition 
to treat patients by massive injection therapy, 
the so called *stosstherapy1, to ensure retention 
of enough vitamin B ^  to meet the demands for 
years. Bo toxic effects were observed in any 
patient in this series at any time and all have 
been followed up for at least one and a half years 
and the majority for longer periods. One 
obvious problem with massive injection therapy 
however, lies in the difficulty of knowing how 
much vitamin B-^ any one patient will retain 
from an injection or series of injections.
It is clear from the results that the proportion
/of each dose which is excreted varies not only 
from patient to patient but also in the same 
patient at different times. Unless the amounts 
excreted were measured, and the amount retained 
known, such a method of treatment would be of 
limited value. To some extent this problem 
has been overcome (see Chapter 6 ) but other 
factors such as the utilisation of injected 
vitamin must also be considered* This form 
of therapy is discussed again in conjunction 
with observations on these factors in 
Chapter 8 .
(25)
SUMMARY
The amount of vitamin B ^  excreted after
intramuscular doses of 100 ug and 1000 ug has
been studied in normal subjects, in vitamin B-^
deficient patients in haematologieal relapse and
in patients with chronic anaemia and normal
serum vitamin B-^ levels using the direct
58isotope method of measuring the Co vitamin 3  ^
excreted in the urine. No significant difference 
was found between the mean values obtained 
from the three groups of patients in each dose 
group. The findings and possible explanations 
for the findings are discussed.
A series of vitamin 3 ^  deficient patients 
in haematologieal relapse and a smaller series 
of patients who had been treated with parenteral 
vitamin B ^  were given repeated injections of 
vitamin B ^  in doses ranging from 54 ug 
to 3 0 ,0 0 0 ug and the urinary excretion of 
radioactivity was measured. There was no 
constant trend to an increase or decrease in 
amounts excreted with repeated injections as 
might have been expected. The amounts of
58/ Co vitamin retained in the body ranged 
from 400 ug to 83,000 ug. The findings are 
discussed, particular reference being paid to 
the significance of the findings in relation 
to massive therapy with vitamin
(8-7)
CHAPTER III
OBSERVATIONS ON THE EFFECT OP SOME DRUGS 
AND THE ROUTE OP ADMINISTRATION ON THE 
URINARY EXCRETION OP INJECTED 58CO 
VITAMIN B12 AND ON THE DIURETIC EPPECT OP 
INJECTED 58CO VITAMIN B^.
(880
Prom the therapeutic and economic aspects 
the urinary loss of injected vitamin 
represents a waste which is considerable when 
large doses are given. It seemed worthwhile
therefore, investigating the effect of some drugs
58on the r e n a l  excretion of injected Go vitamin 
B- 2^ in o r d e r  t o  find out if they affected the 
amounts excreted and thus to gain information 
relating to the m o d e  of e x c r e t i o n  a n d  to any 
possible means of r e d u c i n g  t h e  a m o u n t  excreted.
At the same time it seemed l o g i c a l  t o  c o m p a r e  t h e  
effect of intravenous a n d  i n t r a m u s c u l a r  
injections on the e x c r e t i o n  o f  t h e  i n j e c t e d  
vitamin and to investigate t h e  c l a i m s  t h a t  
vitamin B^^ has a diuretic action.
PATIENTS, MATERIALS & METHODS 
The effect of drugs or different routes of 
administration was studied in thirteen patients. 
All came under observation with a macrocytic 
anaemia and megaloblastic erythropoiesis seen 
on marrow biopsy smears and all had other 
diagnostic criteria of vitamin B ^  deficiency 
states. Nine patients were studied when they
{39)
/were first seen in haematologieal relapse; 
four (Cases P.A., J.McF., I.E. & A.S.) had been 
treated and were in haematologieal remission when 
the investigation was begun. Details of the 
patients are given in the Case Reports in the 
Appendix. The study of Cases I.R. & P.A. was 
interrupted and during this time they received 
1000 ug vitamin B ^  intramuscularly each month. 
All patients were cognisant of the nature and 
objects of the experiments and all cooperated 
willingly.
The method of investigating the effect of 
the drugs was to compare the mean value of the 
amounts of radioactivity excreted in 24 hour 
collections of urine after injections of
Co vitamin B ^  with the mean value of the 
amounts of radioactivity excreted by the same 
patient in the 24 hours after injections of 
^8Co vitamin B-^ given with the drug being 
tested. Similarly the method of investigating 
the effect of differing routes of administration 
was to compare the mean values of amounts of 
radioactivity excreted in the urine in the
(90)
/24 hours after intramuscular administration with 
those obtained in the 24 hours after intravenous
administration. During the investigation,
injections, or a series of injections of
58 ^
Co vitamin were given with or without the
drug or by different routes of administration
alternately or at random. Each patient received
58at least twelve injections of Co vitamin
of which half were given without the drug and
half were given with the drug or by a different
route. The drugs studied were probenecid
(Benemid - Merck, Sharp & Dohme), mersalyl
(Mersalyl Injection B.P. - British Drug House),
chlorothiazide (Saluric - Merck, Sharp & Dohme)
and vasopressin tannate (Pitressin Tannate in Oil -
58Parke Davis). The doses of Co vitamin B12 
used were 100 ug 0.2 uc, 1000 ug 0.2 uc and 
1140 ug 0.2 uc.
The effect of probenecid was studied in 
five patients. Cases P.A .  and A * S .  were given 
probenecid orally 0.25 g* q.i*d. for 48 hours 
prior to, and 24 hours after, intramuscular 
injections of 58Co vitamin B12 which were given
(91)
/at intervals of at least one week. Cases I.e.,
J.S. & C.B. received short courses of probenecid
0.25 g. orally q.i.d. during which time two
58or three intramuscular injections of Co
vitamin were given at 24 hour intervals:
each course of probenecid began 24 hours before
the first injection and ended 24 hours after the
last injection of the series.
The effect of mersalyl was studied in three
patients. The drug was given intramuscularly
in a dose of 2 ml. at a different site but at
the same time as the intramuscular injection of 
58Co vitamin
The effect of chlorothiazide was studied in 
two patients, both of whom received 2.0 g. orally
one hour prior to the intramuscular injection of 
58Co vitamin
The effect of vasopressin tannate was studied
in one patient who was given 2 ml. intramuscularly
one hour before the intramuscular injection of 
58Co vitamin B ^  at a different site.
58The excretion of Co vitamin B ^  after 
intramuscular and intravenous administration was
/studied in four patients; the effect of drugs
58on the excretion of Co vitamin B^2 given
intramuscularly was also studied in two of these
patients (Cases M.C. & J.S*)
The diuretic effect of vitamin was
investigated by analysing the values for volumes
of urine excreted in 24 hour periods by vitamin
B- 2^ deficient subjects in haematologieal relapse
58who were given repeated injections of Co
vitamin B ^  in doses ranging from 100 ug 0.2 uc
to 3 0 ,000 ug 0.1 uc at intervals of 24 hours or
longer. The mean values of urine volumes
excreted in the 24 hours after injections of 
58Co vitamin B ^  were compared to the mean values
of 24 hour urine volumes excreted on days when
no radioactivity was found in the urine and to
mean values of 24 hour urine volumes for the
periods 2 4 - 4 8 - 7 2  hours after injection when
some radioactivity was excreted.
58The preparation of Co vitamin B ^  for 
injection and other technical methods used are 
described in the Appendix. A t test was used to 
compare two mean values and an analysis of
(93)
/variance to compare three mean values obtained 
from the same patient.
RESULTS
The results of the investigation into the
effect of drugs or differing routes of
administration on the renal excretion of injected 
58Co vitamin are shown diagramatically in
Pigs. 43 - 55 and the essential statistical
results are set out in Tables 5 & 6. Pull
details of individual results are given in
Tables A.7, A.9, A.10, A.l8, A.19, A.21, A.30,
A.31, A.33, A.34, A.36 - 38 in the Appendix.
None of the drugs tested had any significant
58effect on the amounts of injected Co vitamin 
Bf2 excreted and no significant difference was 
found between the mean values excreted after 
intramuscular and after intravenous administration* 
The results of the investigation into the
diuretic effect of vitamin B-^ are given in Table 7 
with the discussion of the findings. Details of 
individual results are given in Tables A.8, A.17*
A.31, A.41 & 42, A.45 - 48. No significant 
diuretic effect was found.
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5 8 CoB |2 inj 5 8 coB 12 inj
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weeks
Fig. 43 Fig. 44
1.140 M9 50CoB|2 Injection
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Fig. 45
Pigs. 4 3 - 4 5 :  showing amounts of radioactivity excreted
by three patients given repeated injections of 
58
Co vitamin B.^ alone or with probenecid. Cases P.A. 
and A.S. were given 1000 ug and Case C.D. 1140 ug
58
Co vitamin B ^  intramuscularly (see Tables A.21,
30 & 37) •
The plain rectangles indicate the amounts excretedrO
after administration of Co vitamin B■ g only and the 
hatched rectangles the amounts excreted when oral 
probenecid was also given.
(95)
100 yug 5 ®CoB |2 in je c tio n
ill ill ill II ill ill
0 1 2 3 4 5 6 7 8 9  10 I f 1213 141516 17 18 19 20 22 24
days
Pigs, 1+6 & 475 showing amounts of radioactivity excretedrO
by two patients given repeated injections of Co
vitamin alone or with probenecid (see Tables A.7 & A.19)•
The plain rectangles indicate the amounts excreted 
58
after intramuscular Co vitamin B ^  only, the hatched 
rectangles the amounts excreted after intramuscular
58
Co vitamin B10 and oral probenecid, the stippled
58
rectangles after intravenous Co vitamin B ^ only.
1,000 yug38 Co B12 injection
|0 0 jug5BCo 8(2 injection
I J I
0 1 2  3 10 II 12 13 14 15 16 17
Pigs, 48 & 49: showing amounts of radioactivity excreted
„  58„by two patients given repeated injections of Co 
vitamin ^ 2* (see Tables A,10 & A,3l).
The plain rectangles indicate the amounts excreted 
after intramuscular administration and the hatched 
rectangles the amounts excreted after intravenous 
admini stration,
1,000 yug 58c o B |2 in je c tio n
(96)
100 /jg 5®Co B|2 injection 1,000 >ug 5SCoB|2 Injection
lllllllll
u
Fig. 50 Fig. 51
, «p _ _ .... »-asc s.a.1,000 /ig 58CoB|2 Injection
111 J J 1 i I 1 1 1 J 1 1
O 5 10 IS 20 25 30 35 40 45 50 55 00 05 70 75 80 85 ©0 05 100 105 110
Fig. 52
Figs. 5 0 - 5 2 :  showing amounts of radioactivity excreted
by three patients given repeated injections of
5®Co vitamin B 2 intramuscularly, alone or with mersalyl.
(see Tables A*9> A.l8 & A.38).
The plain rectangles indicate the amounts excreted 
58after intramuscular Co vitamin only and the 
hatched rectangles the amounts excreted when mersalyl 
was given also.
(97)
1,000 pg 58coB|2 Injection
1,000 /jg  ^®CoB|2 in jectlo
Case E.McB
0 I 2 3 4  5 6 7 8 9 10 II 12 13 14 15 16 17 18
Fig. 54
Case l.R
5 8 C oB|2 ln j 5 8 C oB |2 *nj
I I  Ulllllllilll
8 0
60
4 0
20
0
4 0 7 020 30 50 60 80I 5 10
Fig. 55
Figs. 53 - 55s showing the amount of radioactivity excreted
by three patients given repeated intramuscular
58
injections of 1000 ug Co vitamin (s®e Tables
A.33, 34, & 36),
The plain rectangles indicate the amounts
58
excreted after injections of Co vitamin only 
and the hatched rectangles the amounts excreted when 
oral chlorothiazide was also given to Cases J.McF. and 
l.R. and when intramuscular vasopressin was also given 
to Case E.McB.
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DISCUSSION
In the study of the effect of various
drugs and different routes of administration
58on the excretion of injected Co vitamin
any information gained would have been
particularly relevant to the treatment of
patients with vitamin B_^ deficiency states and
for this reason it was decided to confine the
investigations to patients who required treatment
with vitamin resul^s reported in
Chapter 2 had made it clear that there was no
constant trend to an increase or decrease in the
58amounts of injected Co vitamin excreted 
with repeated injections, whether the patients
were in haematological remission or relapse when
treatment was begun, and the precaution of randomizing
or alternating injections with or without drugs
was therefore unnecessary although probably desirable
on general principles. The study of the diuretic
effect of vitamin B ^  was confined to patients
receiving vitamin B ^  being in the nature of a
preliminary investigation. The results made it
clear that further investigations in other
(101)
/patients were unlikely to be of value.
Effect of drugs
The lack of effect of probenecid is 
disappointing from the practical aspect. This
drug is best known as a uricosuric agent, its effect
being due to inhibition of resorption of filtered
urate but is also inhibits tubular excretion of
a wide variety of chemically unrelated substances
(see ‘Benemid* Annotated Bibliography 1957).
Detailed investigation of the effect of this
drug on the excretion of injected vitamin B-^
was clearly desirable in view of its unique
properties and it was disappointing to find
that it was without effect. Had it been found
that probenecid reduced the amount of injected 
58Co vitamin B-^ excreted it would have been
58
reasonable to assume that injected Co vitamin
B12 is, in part at least, excreted by the tubules;
however, the fact that probenecid does not affect
58the excretion of injected Co vitamin B ^  
cannot be held as conclusive evidence that there 
is no tubular component to the excretion of 
vitamin B^^> particularly as it has been shown
(102)
/that probenecid does not affect all tubular
secreting mechanisms (Beyer et al 1951).
When treating patients with vitamin B ^
deficiency states in haematological relapse with
58repeated injections of Co vitamin B i t
58was noted that the amount of Co vitamin B ^  
excreted was not related to the urine volume,
(see Tables A.2 - 4, A.6 - 10, A.14, A.15,
A.17 - 19, A.21, A.22, A.29 - 48). This did not, 
of course, mean that a drug-induced diuresis 
would necessarily fail to affect the amount 
excreted and it was necessary to study this point 
in detail. The mode of action of chlorothiazide 
and mersalyl is not fully understood but it is 
likely that their main action is to interfere 
with tubular function causing decreased resorption 
of water and electrolytes (Lewis 1961, Spencer 
1961) the former acting on the proximal tubule 
and the latter on both the proximal and the distal 
tubule (Lewis 1961). Part of the action of 
chlorothiazide is due to carbonic anhydrase 
inhibition but there is evidence that its diuretic 
effect is not solely due to this action (Matheson
/& Morgan 1958) and there is also evidence that 
while it shares a method of action with mersalyl 
it also has an action via a further mechanism 
which is not related to carbonic anhydrase inhibition
(T Q
(Ford 1957). Tbe amount of injected Co vitamin
B12 excre'be<i was no"t significantly affected by
chlorothiazide or by mersalyl and it appears
therefore that the excretion of injected 
58Co vitamin B-^ is unaffected by the common
mechanisms by which a diuresis is provoked.
In view of the results obtained using
probenecid and the diuretics it seemed unlikely
that vasopressin, which causes tubular resorption
of water, would affect the amount of injected 
58Co vitamin B e x c r e t e d  and this proved to be 
the case.
It has already been noted that the failure
of probenecid to affect the amount of injected 
58Co vitamin B-^ excreted is not, in itself, 
evidence against the presence of a tubular 
component in the excretion of injected vitamin B-^* 
This also applies to the lack of effect of the 
other drugs. Taken separately these negative
(i<%)
/results are of little value. Taken together 
however, the results at least give rise to a 
suspicion that the amount of injected vitamin 
excreted is predominantly a function of the 
glomerular mechanism with little or no tubular 
component. The fact that the glomerular filtration 
rate may be reduced by chlorothiazide is not 
important here as this effect is small in the 
absence of renal disease (Spencer 1961).
If it is the case that the urinary loss of 
injected vitamin B ^  is a function of glomerular 
filtration only, it follows that the only method 
of reducing the loss is by reducing the blood flow 
through the kidney. The only practicable method 
of doing this at present is by using hypotensive 
drugs and it is clear that the attendant risks 
far outweigh any advantages which might be gained 
by their use. It seems reasonable therefore
to conclude that at present there are no 
practicable methods of reducing the loss of 
injected vitamin B-^ in urine other than by 
reducing the amount which is presented to the 
kidney for excretion. This might be achieved
(105)
/by very slow administration o v e r  a long period 
or by the use of *slow release1 depot preparations. 
The former method can scarcely be called 
practicable and has not been investigated; the 
value o f  the latter method has been investigated 
and some comments will be made on the value of 
a depot p r e p a r a t i o n  in Chapter 6.
Effect o f  d i f f e r i n g  r o u t e s  o f  a d m i n i s t r a t i o n
It is u s u a l l y  t h e  c a s e  that w h e n  a d r u g  is
given intravenously the amount excre ted  is greater
than when it i s  g i v e n  intramuscularly. This is
58clearly not t h e  c a s e  w i t h  ' Co vitamin in 
the doses used a n d  i t  i s  o f  s o m e 1 p r a c t i c a l  
importance to know t h a t  t h e  amount l o s t  i n  the 
urine is no greater w h e n  t h e  intravenous route of 
administration is preferred to the intramuscular 
route. The most likely explanation for this 
finding is simply that absorption from an intra­
muscular site is very rapid and t h e r e  i s  evidence 
that this is the case (Glass et al 1955» Glass
1959). Whether this is the complete explanation 
for the finding is not clear. Other factors may 
well be involved but their nature and significance
(106)
/is obscure and unimportant at this stage.
The diuretic effect of vitamin B ^
A diuresis often occurs when patients with 
pernicious anaemia in haematological relapse 
are treated with vitamin B^. This is usually 
ascribed to an enforced reduction in the 
circulating plasma volume as a result of the 
increase in circulating red cell mass. A
diuretic effect, as distinct from this 
phenomenon, has been claimed for vitamin B ^  
by Barnard & Weitzner (1949) who attributed it 
to the effect of the cobalt ion on the renal 
vascular tree. This claim was refuted by 
Jalili (1950) and Bedford (1951) who also 
studied normal subjects and patients with a variety 
of diseases not including vitamin B^^ deficiency 
states in haematological relapse. Support for 
vitamin B ^  as a diuretic however, still exists 
(Mascherpa et al 1957).
The problem was investigated by analysing
results obtained from patients with vitamin B-^
deficiency states in haematological relapse given
58repeated injections of Co vitamin B-^ on
(107)
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/alternate days or at longer intervals. The
post treatment diuresis was clearly seen in some
cases but these values are still suitable for
analysis. The results in Table 7 show that the
mean urine volumes for the 24 hours after 
58injections of Co vitamin B-^ were always greater
than those which did not contain radioactivity
but this difference is not statistically significant
58
(P = ^ 0.05). The conclusion that Co vitamin B ^  
given parenterally in doses ranging from 
100 ug to 30 ,000 ug, has no significant diuretic 
effect in patients with vitamin B ^  deficiency 
states is therefore unavoidable. When these 
findings are considered together with those of 
Jalili (1950) and Bedford (1951) it seems very 
unlikely that vitamin B-^ has any significant 
diuretic effect in any circumstance.
SUMMARY
The loss of vitamin "B in urine after
parenteral injections may be considerable. As
a method of blocking or reducing this loss would
probably be of therapeutic value the effect of
some drugs on the renal excretion of injected 
58Co vitamin was studied to find out if the 
drugs affected the amounts excreted and to gain 
information about the mechanism of excretion.
The effect of probenecid (Benemid), 
chlorothiazide (Saluric), mersalyl and vasopressin 
(Pitressin Tannate in Oil) was studied by 
comparing the amounts of radioactivity excreted
58
after injections of Co vitamin B ^  given with 
and without these drugs. No drug had a significant
effect on the amount of radioactivity excreted.
58The findings suggest that injected Co vitamin 
B ^  may be excreted by glomerular filtration only. 
Methods of reducing the urinary loss of injected 
vitamin B12 are discussed in the light of the 
findings. It is concluded that the only 
practicable method of reducing the loss is by the 
use of depot preparations.
(no)
/ The effect of intramuscular and intravenous
administration on the amount of injected 
58
Co vitamin excreted was studied by a
similar method. It was found that the mean
amounts excreted were not significantly different.
Reasons for this finding are discussed.
The claims that vitamin has a diuretic
effect were investigated by comparing the values
for 24 hour urine volumes excreted after injections of 
58Co vitamin with those when little or no
radioactivity was present. No significant difference
58was found implying that Co vitamin B ^  has no 
significant diuretic effect in the doses used.
(Ill)
CHAPTER IV
OBSERVATIONS ON THE MODE AND RATE OP 
EXCRETION OP INJECTED 5 CO VITAMIN B. 
BY THE NORMAL KIDNEY AND BY AN 
ARTIFICIAL KIDNEY.
The failure of various drugs to affect the 
58
amount of injected Co vitamin excreted
in urine stimulated some further enquiries
into the mode of excretion of injected vitamin
by the kidney. It was convenient to investigate
the rate of excretion of injected vitamin B ^
at the same time.
Observations on the mode and rate of
58excretion of injected Co vitamin B ^  by the 
human kidney and by an artificial kidney are 
reported in this chapter.
PATIENTS, MATERIALS M B  METHODS
Observations were made on five patients
admitted to hospital with a macrocytic anaemia,
megaloblastic erythropoiesis seen on marrow
biopsy smears and low serum vitamin B^^ level.
Details of these patients are given in the Case
Reports in the Appendix. With one exception all
58had been treated with parenteral Co vitamin 
prior to the present study. The doses of 
^ C o  vitamin B, 0 given to these patients in this
■Lc.
study ranged from 100 ug 0.2 uc to 1140 ug 0.2 uc 
and were the same as each patient had received
(113)
/previously. Case J.G.G. had not been treated 
prior to the present study and he was given
5000 ug 0.2 uc ^ C o  vitamin
Urine was collected for 24 hours prior
58to the injection of Co vitamin B ^  and for
hourly or half-hourly periods for the next
6 - 8  hours and from then until 24 hours after
the injection. One patient (Case M.W.) had a
catheter in situ for reasons unconnected with the
experiment: in the others urine was voided naturally
during, and at the end of, each collection period.
All patients were encouraged d o  drink a,s much as
possible during the observation period. The
patients were cognisant of the nature and objects
of the study and all cooperated willingly.
58The preparation of Co vitamin B-^ for 
injection, and other technical and statistical 
methods are described in the Appendix.
The excretion of vitamin B.^ by an artificial 
kidney was studied during haemodialysis performed 
to relieve uraemia in six patients with anuria 
due to renal failure. Details of these patients 
(Ca ses AK 1 - 6) are given in the Case Reports
(1)4 )
/in the Appendix. A Kolff twin coil artificial 
kidney unit was used: operating instructions and 
details of this machine are given in the Appendix. 
Samples of blood and bath fluid were obtained 
before injecting 1000 ug vitamin into the 
cannula connecting the machine outflow to the 
patient, that is, intravenously. Samples of 
bath fluid were taken at intervals thereafter 
and the vitamin B ^  content was estimated by 
microbiological assay. All samples were assayed 
together in at least two different assay batches 
and the results given are the mean values
of the assays. Recovery experiments were done 
on the bath fluid to detect the presence of 
inhibitors to the grov/th of Euglena Gracilis.
RESULTS
The results are shown in Figs. 56 - 61 
and the essential statistical results are given 
in Tables 8 & 9. Detailed results obtained in 
individual cases are given in the Appendix in 
Tables A.49 & A.50. No radioactivity was 
found in any pre-injection collection of urine.
Recovery experiments with bath fluid taken
(115)
/ f r o m  t h e  a r t i f i c i a l  k i d n e y  a t  t h e  b e g i n n i n g  a n d  
the e n d  o f  t h e  d i a l y s e s  d i d  n o t  s h o w  a n y  e v i d e n c e  
o f  i n h i b i t o r s  t o  t h e  g r o w t h  o f  E u g l e n a  G - r a e i l i s .
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Pigs. 56 & 57* showing amounts of radioactivity excreted
by two patients at intervals after intramuscular
58
administration of Co vitamin Case K.McD.
received 100 ug and Case M.W, 1000 ug. The amounts 
excreted in hourly or half hourly periods are shown 
by plain rectangles and the cumulative amounts excreted 
by solid circles joined by continuous lines (see 
Table A.i+9) •
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®®Co B |2  inj
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Fig. 58
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Fig. 59
5 8 C o B |2 in j
1001
Pig* 60
Pigs* 58 ~ 60: showing amounts of radioactivity excreted 
by three patients at intervals after administration
58,of 'Co vitamin Case J.D* received 1000 ug
intravenously, Case C.D. 1140 ug intravenously and 
Case J.G.G. 5000 ug intramuscularly. The amounts 
excreted in hourly periods are shown in plain 
rectangles and the cumulative amounts excreted by 
solid circles joined by continuous lines (see 
Table A.49)*
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Fig. 6l: showing amounts of assayable vitamin B ^
in the artificial kidney bath fluid found at intervals 
after intravenous injection of 1000 ug vitamin B g 
to six anuric patients undergoing haemodialysis (see 
Table A.50).
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DISCUSSION
It was obvious in both experiments that 
the amount of injected vitamin excreted 
per unit time was greatest soon after injection 
and that it diminished later (Pigs. 56 - 61).
This suggested that there might be a correlation 
between the logarithm of time and the amount 
of vitamin B ^  excreted.
In the case of the results obtained from the 
vitamin B-^ deficient patients, analyses showed 
that there was a coefficient of correlation, 
which differed significantly from zero in all 
cases, between the amount excreted in each collection 
period, expressed as a percentage of the dose 
given and the logarithm of the mid point of the 
collection period i.e. log. 3*5 in the case of 
the collection from the end of the third hour to 
the end of the fourth hour after injection.
The coefficient of correlation differed significantly 
from zero in 8,11 the analyses when the values 
for the final collection period to 24 hours after
injection were excluded and was significantly 
different from zero in all but one of the analyses
(121)
/when the values for the final collection 
period were included (Table 8). It is obvious 
that this correlation would also apply if the 
amounts excreted were expressed in absolute 
terms instead of as percentages of the dose 
of radioactivity excreted.
In the case of the results obtained from 
the artificial kidney experiment a coefficient 
of correlation differing significantly from zero 
was obtained in all cases between the total
assayable vitamin in the bath expressed in 
miprogrammes and the logarithm of the time in 
minutes at which the samples were taken (Table 9).
The relationships are not exponential in 
the true mathematical sense but are of a type 
commonly referred to as exponential in biological 
work and will be referred to as such for the sake 
of brevity.
Significance of results in relation to the mode 
of excretion of injected vitamin
The artificial kidney can be regarded 
conveniently as an atubular nephron in which 
excretion occurs by filtration only.. Because
(122)
/the excretion of vitamin 3^ by the human
kidney is exponential, as is the excretion of
vitamin 3 ^  by the artificial kidney, it does not
necessarily follow that the excretion of vitamin B12
by the human kidney also occurs by a process of
filtration only. The results show that the two
patients, Cases J.D. & C.D., who were given 1000 ug 
58and 1140 ug Co vitamin 3^ intravenously, 
excreted 276 ug (27.6 and 24.2% of the dose 
respectively) in the first hour after injection 
(Table A.49) whereas the artificial kidney 
excreted 75 > 100.5, 138 and 172 ug in the same 
period after an injection of 1000 ug vitamin 
given by the same route (Table A.50): as there is 
no question of resorption of excreted vitamin 
by the artificial kidney and as the ‘dialysing 
area* of the artificial kidney is somewhat 
greater than that of the human kidney these 
results appear to imply that the human kidney 
excretes injected Co vitamin B^2 not only by 
glomerular filtration but also by tubular excretion. 
It must be appreciated, however, that the blood 
flow through the type of artificial kidney used
•(123>
/is much less than through the human kidney. 
Unfortunately it was not possible to measure the 
flow rate through the artificial kidney during the 
experiments as flowmeters were not available: 
the only method of measuring the flow rate was
to drain the machine outflow into a measuring 
cylinder at the end of the dialysis: by this 
crude method flow rates in the region of 250 ml. 
per minute were obtained and subsequent experience 
with the same machine fitted with a flowmeter 
has shown that it is extremely unlikely that the 
flow rate would have exceeded 400 ml., per minute 
during any of these dialyses. It will be 
appreciated that a flow rate of even 400 ml. per 
minute is almost certainly very considerably less 
than that through the kidneys of the non anuric 
patients studied. The fact that some of the
non anuric patients were anaemic is not important
here as this has been shown to be without effect
5 bon the amount of injected Go vitamin 
excreted in the urine (Chapter 2). With these 
facts in mind the results are more in accord with 
the concept that vitamin is excreted by
(124)
/glomerular filtration only, rather than by
glomerular filtration and tubular excretion, in
keeping with the finding that drugs which are
known to act on the tubules do not affect the
58excretion of injected Go vitamin B ^
(Chapter 3).
The pattern of excretion with different routes 
of administration
The greatest amount of injected
58Co vitamin B ^  excreted in any collection period
was found in the first hour after injection when
this was intravenous, as in Cases C.D. & J.D.
(Bigs, 58 & 59) and later when this was
intramuscular as in the other cases (Bigs. 56,
57 & 60). This is probably due to flooding of
the blood stream and presentation of a large 
58amount of Co vitamin B ^  "to kidney after 
intravenous administration whereas after 
intramuscular administration the delay in 
absorption, short though it is, (Glass et al 1955, 
Glass 1959) entails a delay in the presentation 
of the injected ^ C o  vitamin B ^  to the kidney 
so that the greatest amount excreted is found
(125)
/in the second hour after injection.
Excretion in the 24 hours following injection 
It has been stated by Smith (i960) that 
an appreciable proportion of an injection 
of vitamin B12 is excreted in the first 8 hours 
after injection but that little more appears 
after 8 hours. There is good evidence for this 
in the report by Mollin & Eoss (1953a) as far
as doses of 40 - 80 ug are concerned. It is
obvious from the results presented here however, 
that this is not the case with injections of the
order of 1000 ug or more. The facts that
excretion is exponential and that the proportion 
excreted increases as the dose injected is 
increased (see Chapter 6) are the main reasons 
why significant amounts should be excreted in the
8 - 2 4  hour4 period after large injections but not 
after small injections. Another factor which may 
influence the amount excreted in the 8 - 2 4  hour 
period after large injections is the route of 
administration: the delay in absorption attending 
intramuscular administration will naturally 
prolong the entire process. It is interesting to
(126)
/note that the amounts excreted in the 
6 - 2 4  hour period after the intravenous 
administration of 1000 ug to Case J.D. and 
1140 ug to Case C.D. were 13.9% and 10.6% 
of the dose respectively whereas the amount 
excreted by Case M. W. in the same period after
intramuscular administration of 1000 ug was 
22.5% of the dose.
The fact that significant amounts are 
excreted in the 8 - 2 4  hour period must be 
appreciated in any investigation of the amounts 
of vitamin B excreted after parenteral therapy. 
Had an 8 hour collection period been used when 
investigating the effect of different routes of 
administration on the amount excreted it is likely 
that an erroneous conclusion would have been 
reached - probably that greater amounts were 
excreted after intravenous injection. The formula
relating the amount excreted to the amount 
injected put forward by Chesterman et al (1951) 
was based on amounts excreted in the 0 - 8  hour 
period after injection only and will therefore 
underestimate the amount excreted when large
/doses are given. This point will be referred to 
again in Chapter 6.
Excretion later than 0 - 2 4  hours after injection 
It is convenient to consider the question 
of excretion of injected vitamin in the 
period following the 24 hours after injection 
at this stage. During the investigations 
reported in Chapters 1 & 2 many patients were 
given injections at intervals of one or more days. 
When injections were given daily the final 
collection period was usually the 24 - 48 hour 
period after the last injection: when injections 
were given at intervals of more than one day the 
amount of radioactivity, and in some cases the 
amount of assayable vitamin excreted, was
measured in several 24 - 48 hour periods. It 
is not possible to summarise the findings but 
reference to Tables A.2 - 4, A.6 - 10, A.14 & 15,
A.17 - 19, A.21 & 22, A.29, 31 & 32 will show 
that significant amounts of radioactivity were 
rarely found in the 24 - 48 hour period when doses 
of 54 - 1140 ug 58Co vitamin B±2 were given and 
reference to Tables A.7 - 9, A.17 - 19, A.21& 22
(128)
/will show that the amount of assayable vitamin 
excreted in this period was very small. Prom 
these results it is clear that excretion after 
injections of up to 1140 ug is complete within 
24 hours for practical purposes in the vast 
majority of cases. Note however should be taken
of one exceptional case: on nine occasions after
58sixteen injections of 1000 ug Go vitamin B1 
Case I.C. excreted in the 24 - 48 hour period, 
amounts of up to 22$ of the dose injected 
(Table A.l8). No obvious reason for this was 
apparent. The injections were given in the usnal 
manner and there was no reason to doubt the 
accuracy of the urine collections. Poor absorption 
from the injection site is an obvious factor 
but different sites were used. No explanation 
can be given other than suggesting that this 
constitutes a biological abnormality not previously
described.
Prom what has been said one might expect 
the excretion of significant amounts of injected 
58Co vitamin in the 24 - 48 hour period when 
large doses were given. Reference to Tables
(129)
/A.40 - 48 will show that this does occur
but the amounts excreted in this period, or later,
after doses of from 5000 to 30 ,000 ug were very
small and insignificant in most cases.
The fact that excretion may although rarely,
continue for more than 24 hours is relevant to
some other investigations reported in this thesis.
Firstly, in relation to the study of the amounts
excreted by patients given repeated injections of 
5bCo vitamin reported in Chapter 2. A false 
impression of a constant trend to the excretion 
of increasing amounts might have resulted from 
the excretion of significant amounts in the period 
24 - 48 hours after injection in some cases 
although it is unlikely that this could have 
been ‘carried over* from day to day to such an 
extent as to have caused misleading results.
It is obvious that this did not occur. Secondly 
in relation to the calculation in Chapter 6 of
average daily loss by patients given repeated
58
injections of large doses of Co vitamin
in all cases the collections were continued until
significant amounts of radioactivity were no
(130)
/longer excreted so that the results presented 
are accurate*
'The effect of r e n a l  d i s e a s e  o n  t h e  e x c r e t i o n  o f  
injected v i t a m i n
It is c o n v e n i e n t  t o  m e n t i o n  this p o i n t  
here* It i s  k n o w n  t h a t  t h e  S c h i l l i n g  t e s t  m a y  
give f a l l a c i o u s  r e s u l t s  i n  t h e  p r e s e n c e  o f  r e n a l  
disease, (Rath et a l  1957 > D u n n  e t  a l  1 9 5 8 )  
particularly when t h e  b l o o d  u r e a  i s  g r e a t e r  t h a n  
100 mg.$> (Bull et a l  1956).
5 8The excretion of injected Co vitamin
was studied in two p a t i e n t s  k n o w n  to h a v e  g r o s s
renal disease. T h e  f i r s t  p a t i e n t ,  a  f e m a l e
aged 27, was i n  t h e  t e r m i n a l  s t a g e  of c h r o n i c
n e p h r i t i s ;  i n  t h e  2 4  h o u r s  a f t e r  a n  i n t r a v e n o u s
5 8
injection of 100 u g  Co vitamin s^e
excreted 1.6^ > of the dose o f  r a d i o a c t i v i t y  i n
450 ml. of u r i n e .  T h e  blood u r e a  a t  t h e  t i m e  o f
the test was 3 4 8  m g . f * .  T h e  s e c o n d  p a t i e n t ,  a
male aged 51, a l s o  h a d  c h r o n i c  n e p h r i t i s ;  a f t e r
56,
an intramuscular i n j e c t i o n  o f  1000 u g  C o  
v i t a m i n  h e  e x c r e t e d  4 * 4 ' ! h  o f  t h e  dose of 
r a d i o a c t i v i t y  i n  t h e  f i r s t  2 4  h o u r s  ( u r i n e  volume
(131)
/9$5 ml.) and 2.8$ in the second 24 hours 
(urine volume 735 ml.). A second injection of 
the same amount was given five days after the first 
and no radioactivity could be detected in the 
following 24 hour urine collection (volume 
450 ml.). The blood urea at the time of the 
first test was 328 mg.$ and at the time of the 
second test 376 mg.$. As will be shown later, 
and indeed is obvious from the results already 
presented, the amounts excreted by these patients 
are grossly subnormal. The exact mechanism 
whereby the chronic nephritic kidney fails to 
excrete injected vitamin B is clear and 
it would be superficial to relate it to a 
reduced glomerular filtration rate only and 
unwise to compare the excretion of injected 
vitamin with that of other solutes. The 
results raised the possibility that a test of 
renal function, based on the amount of injected
58Co vitamin B±2 excreted in the 24 hours after 
an injection, might be of some value in the 
assessment of the severity of renal disea,se. 
Preliminary investigations suggest that such a
(13?)
/test is only likely to be of diagnostic value 
by the time that conventional tests show marked 
damage and would therefore be of little clinical 
value: further studies in this subject are in 
progress.
(133)
SUMMARY
The mode and rate of excretion of injected
58
Co vitamin B^ by the human kidney was
investigated in five patients by collecting the
urine at intervals after injection. A linear
correlation with a coefficient of correlation
differing significantly from zero was found
58between the amount of ' Co vitamin B ^  excreted, 
expressed as a percentage of the dose injected
and the logarithm of time.
The excretion of injected vitamin by 
an artificial kidney was studied on six occasions 
during haemodialysis. A linear correlation with 
a coefficient of correlation differing significantly 
from zero was found between the amount of assayable 
vitamin B ^  excreted and the logarithm of time.
The significance of the findings in relation 
to various aspects of the renal excretion of 
injected vitamin B ^  is discussed in detail. It 
is considered that the findings are in keeping 
with the concept that the excretion of injected 
vitamin B±2 is a function of glomerular filtration 
only. The different patterns of excretion after
(13*)
/intramuscular and intravenous administration
are considered to be due to flooding of the
bloodstream after intravenous administration.
It is shown that excretion continues for more
than eight hours particularly with doses of the
order of 1000 ug or more but that it is usually
complete in 24 hours in the majority of cases.,
Note is taken of one patient who excreted significant
amounts later than 24 hours after injection.
The effect of renal disease on the amount of 
58injected Co vitamin B12 is considered with 
reference to results obtained from two patients 
with chronic nephritis.
CHAPTER V
OBSERVATIONS ON THE BILIARY AND FAECAL 
EXCRETION OF INJECTED 5 CO VITAMIN B12
(136)
Until recently little attention had been
paid to the excretion of injected vitamin B ^
in bile and faeces. Recent work on the biliary
and faecal excretion following injections of 
58
0.5 ug Co vitamin B ^  in normal and vitamin
312 deficient subjects raised the possibility
that there might be a considerable loss by this
route when larger doses of vitamin B-^ were 
given. This possibility did not appear to have 
been investigated and, since it was relevant to the
theme of the present investigations, it was
58decided to investigate it using Co vitamin B-^ 
in doses commonly used in clinical practice.
PATIBUTS, MATERIALS AND METHODS
58The faecal loss of injected Co vitamin 
Bf2 was studied in nine patients who had come 
under observation with a macrocytic anaemia, 
megaloblastic erythropoiesis seen on marrow 
biopsy smears and low serum vitamin B ^  level 
and one patient, Case W.R., who had an iron 
deficiency anaemia, following partial gastrectomy 
and whose serum vitamin B ^  level was normal. 
Details of these patients are given in the Case
(137)
/Reports in the Appendix. The vitamin 3
deficient patients were treated exclusively
58
with parenteral Co vitamin and Case W.fi. 
received six daily injections of ^Co vitamin 
B12 before iron "tberapy was begun. The doses 
of Co vitamin given ranged from 54 ug 
0,3 uc to 20,000 ug 0.1 uc. All patients 
received at least three injections of *^Co
vitamin B12 before the faecal collections were 
begun and most patients received at least five 
injections: the injections were continued while
the faecal collections were made. Great care
was taken to ensure that the faeces were not
contaminated with urine. With one exception
collections were made for three days. The
faeces were homogenised and the radioactivity
measured by the method described in the Appendix.
58The biliary loss of injected Co vitamin 
B12 was studied in seven patients who had under­
gone biliary tract surgery at least four days 
previously. All had a normal serum vitamin B^2 
level. Biliary drainage, by a T-tube inserted 
into the common bile duct, had been established
(138)
/at operation for purely surgical reasons. Bile
was collected for 24 hours prior to the injection 
58of ' Co vitamin B12 and for at least 24 hours after
c o
injection. The doses of Co vitamin 3 ^  given 
ranged from 1000 ug 0.2 uc to 5000 ug 0.2 uc.
The radioactivity in the collections was measured 
by the method described in the Appendix.
All patients were aware of the nature and 
objects of the experiment and all cooperated 
willingly.
RESULTS
The detailed results of the faecal excretion 
study are given in Table 10 and of the biliary 
excretion study in Table 11.
(139)
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DISCUSSIOH
Direct measurement, by microbiological assay, 
of the vitamin B-^ excreted in bile and faeces
following a parenteral injection is not a reliable
procedure as large amounts of vitamin are
normally present in the faeces (Bethell et al
1948, Callender & Spray 1951, Pennington 1951,
G-irdwood 1956a) while bile, in addition to
vitamin B^, (G-rasbeck & Okuda 1957, Okuda et
al 1958) also contains substances which inhibit
the growth of Euglena gracilis (Reizenstein 1959a).
The isotope technique was therefore employed
although there is no direct evidence that the
radioactivity in bile and faeces after parenteral
“^ Co vitamin 3 ^  is in the forrn of ^ Co vitamin
58
^12 ra"tiier ‘k*lan °^iier Co. containing compounds. 
Prom the evidence marshalled by Reizenstein 
(1959c) however, and from the finding that the 
radioactivity in urine following parenteral 
^ C o  vitamin B-^ is a direct measure of the amount 
of assayable vitamin 3 ^  present (Adams 1961a, 
Chapter l) it can be assumed with reasonable 
confidence that any radioactivity found in bile
/and faeces following parenteral 5^Co vitamin 3^
58is m  fact due to intact Co vitamin molecules.
The results give a clear indication of the
magnitude of the biliary and faecal loss after 
58
parenteral Co vitamin 3^ in the doses used. It
is obvious from the results in Table 10 that the
faecal loss, that is the total loss from the
gastro-intestinal tract, is negligible from the
therapeutic aspect. There are reasons for
believing that the results may in fact exaggerate
the faecal loss. If the amounts of radioactivity
58excreted were proportional to the Co vitamin
blood levels then the amounts excreted by the 
patients in this series would be unduly high due 
to repeated injections given before and during 
the faecal collections. That this may be the 
case is suggested by the fact that, although the 
percentage of the dose of radioactivity excreted 
in the faeces is much the same in each dose 
group, the absolute amount excreted is, of course, 
much greater following large doses when the 
■^Co vitamin B ^  blood levels would be higher than 
after smaller doses. It should be noted that there
(14*3)
/is some evidence which has been interpreted as
suggesting that the faecal loss of injected
vitamin may be greater in patients with
pernicious anaemia than in normals. Grasbeck
et al (1959) found that gastrectomised rate
excreted more radioactivity in faeces after 
58
parenteral Co vitamin than normal rats and
they attributed this to lack of intrinsic factor
58and hence to diminished resorption of Co
vitamin B^^ excreted in bile. The limit to the
amount of vitamin which can be absorbed
with the aid of the intrinsic factor mechanism,
as opposed to simple diffusion, is so great
however, that it is unlikely that the presence
of intrinsic factor would have materially altered
the amounts excreted in faeces by the patients,
58particularly those given large doses of Co 
vitamin in this series all of whom had
deficient secretion of intrinsic factor as 
judged by the Schilling test, except Case W.R. 
who was not tested. An alternative explanation 
for the results obtained by G-rasbeck et al 
(1959), and not considered by them, is that
(144)
/gastrectomy may affect the faecal loss of
injected vitamin by some mechanism independent
of a reduction in intrinsic factor secretion,
or in association with a reduction in intrinsic
factor secretion. The greatest faecal loss in
the present series was observed in Case J.G-.G.
who had previously undergone high partial
gastrectomy; on the other hand Case W.R. who
had undergone a standard partial gastrectomy
did not have a greater faecal loss than the
patients with intact stomachs. The position is
complicated by the facts that the doses of 
58Co vitamin given to these patients differed 
greatly and that the ability of Case W.R, to 
secrete intrinsic factor was not measured: it 
would therefore be unwise to draw any conclusions 
from these results. Interesting though these 
points are it is clear that the faecal loss is 
trifling under conditions when it might be 
expected to be greatest and further investigations 
have seemed to be of academic value only and have 
not been pursued. There is no particular reason 
to believe that the faecal loss could be affected
(145)
/by anaemia and similar studies in non anaemic
patients whether capable of secreting intrinsic
factor or not, were not considered necessary
particularly as the biliary excretion studies on
non anaemic patients served to check the results
obtained in the faecal excretion study*
Theoretically the faecal loss might be due
to biliary excretion alone, to excretion from or
seepage through the intestinal wall, to
desquamation of intestinal epithelium or to a
combination of these factors. This point has
been studied by Grasbeck et al (1957> 1958)
and by Reizenstein (1959b) using small 40*5 ug)
56parenteral doses of Co vitamin B^2* They have 
produced evidence that the faecal loss is in 
part biliary and in part intestinal. In addition 
they have shown that the biliary excretion is 
much greater than the faecal excretion and from 
this they conclude that there is considerable 
reabsorption of the vitamin B excreted in bile. 
The biliary excretion studies summarised in 
Table 11 were not undertaken with a view to 
studying the question of an enterohepatic
/circulation but were done simply as a check on 
the intestinal loss after large parenteral
58
doses of Co vitamin B ^  in man. Ideally 
these studies should have been dxme on patients 
with pernicious anaemia as the object of the 
experiments was to determine whether there was 
any significant loss from the therapeutic 
aspect. Bor obvious reasons this was not 
possible and 'normal* patients, that is, those 
with normal serum vitamin B ^  levels had to be 
studied. The large doses used were resorted 
to in an attempt to demonstrate a biliary loss 
when it might have been expected to be greatest 
and the assumption was made that with the doses 
used there was no equilibration of injected 
*^Co vitamin with the body stores. The 
results in Table 11, when compared to those 
in Table 10, do not appear to support the view 
that there is an entero hepatic circulation but 
it should be noted that Grasbeck et al (1957, 
1958) and Reizenstein (1959ab) allowed for the 
fact that bile collected by drainage of the 
common bile duct or by duodenal lavage does not
(147)
/represent the total daily output of bile and
calculated their values for biliary excretion
accordingly. Furthermore, they studied the
biliary and faecal excretion in the same patient.
It should also be noted that even with a T-tube
in the common bile duct a significant amount of
bile passes to the duodenum and the values for 
58Co vitamin in such collections will
therefore be an underestimafe of the total
excreted in bile. The value of the biliary
studies reported here is simply that they confirm
the view, obtained from the faecal studies,
58
that the intestinal loss of parenteral Co 
vitamin B ^  doses used is trivial from
the therapeutic aspect.
(us)
SI3MMABY
58The loss of injected Co vitamin B ^  in
faeces was studied in ten patients receiving
58frequent injections of  ^Co vitamin in the
dose range 54 - 20,000 ug by measuring the
radioactivity in faecal collections. By this
technique the amount lost ranged from 0.6 -
1.8$ of each dose injected. Seasons are given
for believing that these values may be an over-
58estimate of the faecal loss of injected Co 
vitamin B.,
58The biliary loss of injected Co vitamin
Bl2 was studied in six patients given injections 
58of Co vitamin B12 in the dose range 1000 - 
5000 ug by collecting bile via a T-tube inserted 
into the common bile duct. The radioactivity 
in the collections was usually less than 1$ of
the dose injected.
The results are discussed and it is concluded
that the loss of injected 58Co vitamin B12 
in bile and faeces is negligible from the
therapeutic aspect.
(149)
CHAPTER VI
OBSERVATIONS OH THE RELATIONSHIP BETWEEN THE 
58
AMOUNT OF CO VITAMIN B12 INJECTED AND THE 
AMOUNT EXCRETED IN THE URINE.
(150)
In the course of investigations carried out
during a period of four years a large number of
58patients were given Go vitamin parenterally
in doses ranging from 0.5 ug to 30,000 ug. In
nearly all cases the urinary excretion of
radioactivity had been measured for at least 24
hours after the injection. Inspection of the
values of radioactivity excreted showed that
there was clearly no correlation between the 
58amounts of Co vitamin injected and the 
amounts of radioactivity excreted, expressed as 
a percentage of the dose of radioactivity injected. 
It seemed possible, however, that there might be 
a correlation between the logarithms of the
amounts of Go vitamin B ^  injected and the amounts 
of radioactivity excreted. Because of the obvious 
practical and academic importance of such a 
correlation it was decided to collect and analyse 
all results.
MATERIALS ALB METHODS 
Values relating to amounts excreted after 
injections of 3 0,0 00, 20,000, 10,000, 5000,
1140, 1000, 540, 100, 54, 50, 5, 2, 1 and 0.5 ug
(151)
/were available for analysis. Only tv/o patients
had received injections of amounts greater than
10,000 ug and the urinary excretion of radioactivity
had been measured in only a few of the cases
given doses of less than 50 ug. It was therefore
decided to restrict the investigation to results
obtained in the dose range 50 - 10,000 and to
pay particular attention to the results obtained
in the dose range 50 - 1000 ug as this is the
range commonly used in current clinical practice.
It has already been shown that normal and
vitamin B.^ deficient subjects do not excrete
significantly different amounts of radioactivity
58expressed as a percentage of the dose of Go
vitamin B ^  injected, after injections of 100 ug
and 1000 ug (Chapter 2). It has also been shown
that there is no constant trend to an increase or
decrease in the amount of radioactivity excreted
when vitamin B ^  deficient subjects are given
58repeated injections of Co vitamin B-^ in the 
dose range 54 - 30,000 ug (Chapter 2). It was 
acceptable therefore to include in the analyses 
all results obtained from normal and vitamin B-^
(152)
/deficient subjects in the dose range 100 - 1000 ug.
As it seemed a reasonable assumption that these
findings would also apply in the case of 50 ug,
54 ug, and 1140 ug doses, all results from these
dose groups were also included. The results
relating to 5,000 and 10,000 ug injections were
obtained from vitamin deficient patients
who had low serum vitamin B-^ levels prior to
58the injection(s) of Co vitamin B^ and it was
valid to include these results for reasons given
in Chapter 1. It has also been shown that the
58route of administration of Co vitamin B ^  
does not affect the amount excreted after 
injections of 100 ug and 1000 ug (Chapter 3) and 
it was assumed that this also applied to other 
dose groups. The vast majority of results were 
obtained from patients over the age of 50 and 
inspection of the results did not show any obvious 
age-wise differences. Results from all age groups 
were therefore included in the material to be 
analysed. Results obtained from patients known to 
have renal disease were excluded for reasons 
given in Chapter 4.
(153)
/ The technical methods and statistical 
techniques used are described in the Appendix.
Results available for analysis
In all, 727 results, obtained from 176 
patients, were available for analysis. Many 
patients had received more than one injection 
of the same dose and several had received
injections of different doses.
DOSE
INJECTED
u g .
NUMBER OF 
PATIENTS IN EACH 
DOSE GROUP*
NUMBER OF 
RESULTS IN EACH 
DOSE GROUP
5 0 1 6 32
5 4 2 2 5 4
1 0 0 6 3 1 7 1
5 4 0 1 6 4 7
1 0 0 0 6 6 270
1140 3 4 62
5,000 8 4 4
10,000 3 4 7
Table 125 showing disposition of results available for 
analysis. As noted in the text several patients 
appear in two or more dose groups: the true total of 
patients is 176.
(154)
/Purther selection and grouping of results
Several problems presented when further
selecting or grouping the results available for 
analyses.
The first problem was whether to limit the 
investigation to values known to be total amounts 
excreted or to include values for the amounts 
excreted in the first 24 hours only after an 
injection. Nearly all the results in the 
5000 ug and 10,000 ug dose groups and some in the 
1000 ug, 100 ug and 50 ug dose groups were 
obtained from continuous 24 hour urine collections 
from patients receiving daily injections and 
therefore account for all the radioactivity
excreted. In the cane of many of the results in 
the 1000 ug and lower dose groups the results were 
obtained from collections made for the first 
24 hours after injection only; at such dose levels 
however, excretion is usually complete in this 
period (Chapter 4) and it seemed reasonable to 
accept these results representing as the total 
amount excreted. Prom observations made in 
Chapter 4 it is obvious that any underestimate
(155)
/of the total amount excreted by inclusion of the 
results for amounts excreted in the first 24 hours 
after injection only is so small as to he negligible. 
All available results were therefore included in 
the material to be analysed.
The second problem was whether to include
all results obtained from patients who were given 
different doses on different occasions or to 
limit the results obtained from such patients 
to only one dose group. There seemed to be no 
good reason for not including all the results 
obtained from the same patient and this policy 
was adopted.
The third problem related to the grouping 
of results for analysis and was more difficult 
to solve. Three courses were opens
(1) to analyse only the mean values of all 
results obtained in each dose group.
(2) to analyse all results obtained in all dose 
groups.
(3) to analyse all results from patients given 
single injections of one dose and all the mean 
values of results from patients given multiple
(156)
/injections of the same dose in each dose group.
There did not appear to he any clear cut 
solution t o  t h i s  problem, although the last 
method seemed more logical and the results were 
therefore a n a l y s e d  b y  e a c h  method with the 
following results:
a )  analysis of mean values of all results 
obtained in each dose group 50 - 10,000 ug 
inclusive, the dose groups being 50,54, 100,
540, 1000, 1140, 5000 and 10,000 ug.
Y . 27.1929x - 19.0316
(n = 8, r = 0.9465, P =< 0.001) 
where x = logarithm of the dose injected in ug 
and y = the percentage of the dose of radioactivity 
excreted.
(2) analysis of all results obtained in all dose 
groups 50 - 10,000 ug inclusive.
Y = 26.6873x - 16.3952
(n - 727, r = 0.7512, P = <0.001)
( 3 )  analysis of all results from patients given 
single injections of one dose and all mean values 
of results from p a t i e n t s  g i v e n  m u l t i p l e  i n j e c t i o n s  
of the same dose in t h e  dose g r o u p s  50 - 10,000 u g
(157)
/inclusive.
Y - 26.6511x - 14.6840
(n = 228, r = 0.6795, P - <0.001)
Prom these analyses it is clear that there
is a highly significant correlation between the
58logarithm of the amount of Co vitamin 
injected and the amount of radioactivity excreted 
expressed as a percentage of the dose given, in
the dose range 50 - 10,000 ug regardless of 
the method of grouping the results for analysis. 
Prom the findings reported in Chapter 1 this 
implies that there is a significant correlation 
between the logarithm of the amount of vitamin B-^ 
injected and the amount of assayable vitamin B ^  
excreted in the dose range 50 - 10,000 ug.
Attention was then focused on the results 
obtained in the dose range 50 - 1000 ug, that is, 
the range encompassing the doses commonly used 
in clinica.l practice. A total of 574 results 
obtained from 136 patients was analysed and the 
following results obtained:
(i) analysis of mean values of all results
(153)
/obtained in each dose group 50 - 1000 ug 
inclusive, the dose groups being 50, 54, 100,
540, and 1000 ug.
Y = 37.lOOlx - 39.8523
(n = 5, r - 0.9521, P = <0.02) 
where x = logarithm of the dose injected in ug 
and y s the percentage of the dose of 
radioactivity excreted.
(2) analysis of all results obtained in all 
dose groups 50 - 1000 ug inclusive.
Y = 30.3092x - 24.8588
(n » 574, r = 0.7349, P « 40.001)
(3) analysis of all results from patients given 
single injections of one dose and all mean values 
of results from patients given multiple injections 
of the same dose in dose groups 50 - 1000 ug 
inclusive.
Y s 30.1899x - 27.8132
(n * 183, r - 0.7805, P = <0.001)
It is again clear that in this limited
dose range there is a highly significant
correlation between the logarithm of the amount 
58of Co vitamin B ^  injected and the amount
(159)
/excreted, regardless of the method of grouping, 
the results for analysis.
Further investigations showed that the 
regression coefficients of the six equations did 
not differ significantly from each other 
(t = <.1.9* P = >0.05 in all cases).
The findings are shown in Figs. 62 & 63.
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Fig* 62s showing the relationship of the logarithm of the
58
dose of Co vitamin B ^ injected to the percentage of 
the dose of radioactivity excreted in the dose range 
50 - 1000 ug. with the regression line and 95$ 
confidence limits. Single results and mean values 
of multiple results are shown by solid circles. 
Rectangles indicate areas where many values coincide 
or overlap.
The regression equation is Y ■«= 30.1899* - 
27.8132 where x is the logarithm of the dose 
injected and y is the percentage of the dose of 
radioactivity excreted.
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Fig, 63: showing the relationship of the logarithm of 
58
the dose of Co vitamin injected to the percentage 
of the dose of radioactivity excreted in the dose range 
50 - 10,000 ug. The continuous lines are the regression 
line and 9 confidence limits for the dose range 
50 - 1000 ug and the broken line the regression line 
for the dose range 50 ~ 10,000 ug. Single results 
and mean values of multiple results are shov/n by 
solid circles: rectangles indicate areas where many 
values coincide or overlap.
The regression equation of the 50 - 10,000 ug 
series is Y s 26.6511x - 14*68ifO where x is the logarithm 
of the dose injected and y is the percentage of the 
dose of radioactivity excreted.
(162)
DISCUSSION 
Significance of the findings
The value of the findings is obvious. They 
establish a relationship between the amount of 
vitamin injected and the amount excreted and 
they enable predictions to be made with confidence 
about the amount of vitamin which will be 
excreted and hence, as intestinal excretion can 
be disregarded for practical purposes (Chapter 5) 
the amount which will be retained, after any 
injection within the dose ranges studied. In 
addition a range of normal values, hitherto
lacking, is now available. It must be emphasised 
that predictions from the equations will refer 
to a rather abstract mathematical value. It is 
obvious from Figs. 62 & 63 that the statistical 
range (mean f 2 SB) obtained in each dose group is 
considerable. This however, does not detract 
from the value of the findings. The majority 
of patients with pernicious anaemia receive 
many injections of vitamin initially at
short intervals and later at longer intervals.
Over a period therefore the mean value excreted
/for several injections will approximate 
reasonably closely to the value obtained from the 
equations. Significant differences between mean 
values obtained from patients given repeated 
injections might be expected to occur, and have 
in fact been demonstrated formally by analyses 
of variance, but these values do not differ 
significantly from the value calculated from the 
equation. The extent of the range in mean values 
from patient to patient is shown in Table 13.
Interest particularly centres round the 
dose group 50 - 1000 ug as this is the range 
in which most doses used in clinical practice 
are found. The most satisfactory equation for 
this dose group is probably:
Y = 30.1899x - 27.8132 
where x = logarithm of dose injected and 
y = percentage of dose excreted i.e. the equation 
obtained from analysis of all results obtained
from patients given single injections of one dose 
and all mean values of results from patients 
given multiple injections of the same dose in 
each dose group. This equation tends to even out
CASE Ho. OP 
INJECTIONS
MEAN PERCENTAGE 
DOSE EXCRETED
F.A . 13 71.2
J.A. 13 66*5
C.B. 6 66*0
i . e . 16 74.5
J.D. 12 73.9
J.O.G. 9 62*9
J.O.H. 6 62.6
S.J. 10 70*5
W.L. 6 39.0
E.McB. 12 52.0
J.McF. 12 62.7
M.P. 13 67.4
I .R . 18 65.3
J.S . 24 71.3
A.S. 12 64*4
s .s . 14 66.1
R.T. 12 58.2
Table 13s showing the mean percentage of the dose 
excreted by seventeen patients each given at 
least six injections of 1000 ug 58q0 vitamin 
The value calculated from the equation 
Y *» 30.1899* - 27«8l32 where x is the logarithm 
of the dose injected and y is the percentage of 
the dose of radioactivity, is 62*7*
(16$)
/any bias introduced by including all results
obtained from every patient particularly as
many patients had received many injections of
the same dose and is more precise than the
equation calculated from the mean value of
all results in each dose group only. Using
this equation the amounts excreted and retained
after injections of 50 - 1000 ug are shown in
Tables 14 & 15. As shown in Chapter 5 the
58amount of injected Co vitamin B^2 lost in the 
faeces is trivial and can be disregarded for
practical purposes; the values for retained
doses were therefore calculated on the assumption
58that all injected Co vitamin B ^  not excreted 
in the urine was retained in the body.
Previous literature
It is relevant to review the literature 
on this subject with these results in mind.
There are several reports concerning the amount 
of vitamin B ^  excreted in the urine after
parenteral injection and in all cases the amount 
excreted was measured by microbiological assay.
The literature is summarised in Table 16.
(166)
DOSE
INJECTED CALCULATED DOSE EXCRETED
u g $ DOSE ug HEAR - 2 SD ug
50 23 12 0 - 2 5
100 53 33 7 - 5 8
200 42 83 32 - 135
250 44 111 47 - 168
300 47 141 63 - 219
400 51 203 100 - 306
500 54 268 150 - 397
600 56 336 182 - 491
700 58 407 226 - 587
750 59 442 242 - 636
800 60 479 272 - 685
900 61 552
-4-
00c—10C\J
1000 63 628 369 — 886
Table 14s showing results obtained by calculating from 
the formula Y « 30*1899* * 27*8132 where y » 
percentage of dose excreted and x = logarithm of 
injected dose in the dose range 50 - 1000 ug.
The results were calculated to the fourth decimal 
place and rounded off to whole numbers for the sake 
of clarity.
DOSE
INJECTED CALCULATED DOSE RETAINED
ug $ DOSE ug MEAN - 2 SDug
50 77 38 25 - 50
100 67 67 4 2 - 9 3
200 58 117 65 - 168
250 5 6 139
KNOOvJ1CO
0
0
300 53 159 81 - 237
400 49 197
00K
N1-4"
O
N
500 46 232 103 - 350
600 44 264 109 ~  418
700 42 293 113 - 474
750 41 308 •£" i O 00
800 40 321 115 - 528
900 39 348
O00ITS1
VO1—1 
r-H
1000 37 372 114 - 631
Table 15* showing results calculated from formula
Y m  30*1899* - 27.8132 where x » logarithm of dose 
and y ■ percentage of dose excreted in the dose 
range 50 - 1000 ug and assuming that all the 
injected vitamin not excreted in the urine 
is retained in the body. The results were calculated 
to the fourth decimal place and rounded off to 
whole numbers for the sake of clarity.
(168)
/Estimations of the amounts excreted after other
intermediate doses have been reported by
Sokoloff et al (1952) and Mollin & Boss (1953a).
In some of these papers it is clear that 
the authors appreciated that the amount
excreted could vary considerably not only from
patient to patient but s.lso in the same • patient:
in others however, this point does not appear
to have been fully, if at all, appreciated and
for this reason, as well as on the findings
reported in Chapter 2 the conclusion reached
by Sokoloff et al (1952) that the proportion
excreted increases with repeated injections
is suspect. Likewise, the conclusion reached
by Lang et al (1953) that patients with 
diabetic neuropathy excrete less than normal
subjects, by Estrada et al (1954) that the 
Mexican excretes significantly less than the 
North American and by Baker et al (1956b, 1958) 
that patients with hepatic disease excrete 
less than 20$ of an injection of 50 - 60 ug as 
opposed to the normal 50 - 80$ may require 
revision in the light of the wide range of results
(169)
PARENTERAL DOSE 
ug
AMOUNT EXCRETED 
$ DOSE
50
100
1000
6.4 - 8.2 (Chesterman et al 1951)
15*4 - 22.0 (Lang et al 1953)
8.8 - 29*4 (Watkin et al 1953)
7.6 - 28*0 (Estrada et al 1954)
14*5 - 31*5 (Unglaub et al 1954)
1.0 - 76.0 (Baker et al 1956a)
9*8 - 19*5 (Sheely et al 1957)
0 - 25.0 (present series)
50 - 68 (Chow et al 1950)
19 - 49 (Conley et al 1951)
40 (Krevans et al 1951)
51 - 98 (Reisner & Weiner 1952)
30 - 37.8 (Unglaub et al 1954)
7*0 - 58 (present series)
33 - 47 (Chesterman et al 1951)
38*5 - 67 (Mollin & Ross 1953a)
51 - 98 (Reisner & Weiner 1952, 1953;
36.9 - 88.6 (present series)
Table 16s showing estimates of amounts excreted following 
parenteral injections of vitamin B ^  in man. The 
range for the present series is obtained from the mean 
value calculated from the equation Y « 30*l899x - 
27*l832 - 2 SD where y ■ percentage of dose excreted 
and x a logarithm of the injected dose in the dose 
range 50 - 1000 ug*
(170)
/presented here. Mention should also he made of 
the formula E = D - 1.2D^’^ ,  where D s dose and 
E ss amount excreted, propounded by Chesterman et 
al (1951) from 20 results in the dose range 
5 - 1000 ug and measuring excretion for 8 hours 
after injection only, a procedure which, as 
already noted (Chapter 4) will lead to an under­
estimate of the amount excreted, particularly 
with large doses. Using this formula the 
calculated amount excreted after 50 ug is 11 ug, 
after 100 ug is 27*7 ug and after 1000 ug is 
439 ug. values much lower than those found in this 
investigation.
Application of the results
The value of the results in defining a normal 
range has already been mentioned. A more 
practical value is easily seen. It is known that 
patients presenting with vitamin deficiency 
states in haematological relapse have only a 
trivial amount of assayable vitamin B^ in their 
livers and as the liver is the main storage organ 
for vitamin if is reasonable to believe that
the tissues of these patients are grossly depleted
(m)
/of vitamin B^„ or its active principle. It 
seems logical therefore that the initial 
treatment of such patients should he directed to 
restoration of the depleted body stores to normal. 
If the normal body stores are known then a 
satisfactory plan for initial treatment can be
established on the basis of the results presented 
in this chapter. This point will be discussed 
further in the next chapter.
Economic aspects of the results
It is often stated that the use of large 
doses of vitamin B-^ in clinical practice is 
wasteful and uneconomic because of the greater 
urinary loss. Although it is true that the 
amount excreted increases as the dose is 
increased it should be noted that the absolute 
amount retained also increases (Table 15).
It is pertinent to examine the economic aspects
of this phenomenon. Calculating from the basic 
N.H.S. cost of single ampoules of vitamin B^2 
('Cytamen1 - Glaxo) and from the values for 
retained doses after injections of 50 - 1000 ug 
given in Table 15 and similarly for retained doses
(172)
/after injections of 5000 and 10,000 ug, it 
appears that the best value in terms of 
microgrammes of vitamin retained per penny 
spent is obtained by using doses in the range 
250 - 1000 ug (Table 17). On these results 
alone there seems to be a case for using doses 
in this range in routine clinical practice in 
preference to larger or smaller doses. However, 
in these crude calculations no account is taken 
of the number of injections which will be 
required in a period of say a year and this 
factor amongst others, must be considered when 
discussing the economic aspect of maintenance
therapy with vitamin The matter is taken up
again and allowance made for this and other 
factors in Chapters 7 & 8.
The results in relation to the use of depot 
preparations of vitamin B-^
The calculated loss of vitamin B-^ in 
urine after an injection of 1000 ug is 
628 t 259 ug. It is logical to believe that an 
effective method of reducing this loss would be 
of therapeutic and possibly of economic value.
(173)
DOSE
INJECTED
COST CALCULATED
AMOUNT
RETAINED
•VALUE* |
ug pence ug ug retained/pence
50 3.5 38 10.1
100 5 67 13.5
250 7 139 19.8
500 14(2 x 7) 232 16*5
1000 20 372 18.6
5,000 100(5 x 20) 720 7.2
10,000 200(10 x 20) 808 4*0 I
Table 1?s showing 1value* of various doses of vitamin 
in terms of micrograitaies retained per cost of 
vitamin injected* The cost is the basic f.BUS* 
cost of single ampoules of vitamin (Cjtamen - 
Glaxo) no allowance being made for reductions in 
bulk purchasing etc*
(I7fc)
/The loss is -unaffected by several drugs acting 
on the kidneys (Chapter 3), and it was concluded 
that the only practicable method of reducing the 
amount excreted is by the use of slow release 
depot preparations (Chapter 4). It has been 
claimed that, by 1complexing1 vitamin B w i t h  
zinc and tannic acid, absorption from an injection 
site is delayed and excretion drastically reduced 
(Thompson & Hecht 1959» Davis et al 1959). A 
brief trial of such a preparation was carried out.
The daily urinary loss of vitamin 
following an intramuscular injection of 1000 ug 
vitamin B^^ zinc-tannic acid complex ('Depinar' - 
Armour) was measured by microbiological assay in 
three patients. It would have been simpler 
and more accurate to use a radioactive preparation 
but the manufacturers were unable to supply this. 
Two patients had pernicious anaemia in 
haematologieal relapse and the third (Case M.J.S.) 
had an iron deficiency anaemia and normal serum 
vitamin B level. The results shown in Table 18 
certainly give evidence of continued absorption 
(and excretion) of vitamin B ^  from the injection 
site for longer periods after injection than occurs
(175)
DAY
ASSAYABLE VITAMIN Bl2 EXCRETED PER DAY - ug
CASE
J.S.G.
CASE
J.T.
CASE
M.J.S.
0 0.06 0.06 0.15
1 112*4 73.1 691.0
2 159.6 5.1 12.2
3 114.3 57.1 10.7
4 46.5 15.6 15.9
5 1.7 0.6 33.5
6 0*7 0*4 16.0
7 0.5 0.3 4.5
435-7 152.4 783.9
Table 18s showing amounts of vitamin excreted
in the urine by three subjects after intramuscular 
injection of 1000 ug vitamin B^g zinc tannic acid 
complex (’Depinar* - Armour)*
(176)
/with conventional preparations but are at variance 
with the manufacturers claim that less than 
of the injected dose is excreted in the urine 
in the week after administration. There was no
obvious reason why these patients should have 
excreted more than 2% of the dose apart from 
inconsistencies in the manufacture of the 
preparation and three different batches, obtained 
from the hospital pharmacy and stored as advised 
by the manufacturers were used. In its present 
form therefore, there do not seem to be any grounds 
for advising the use of this preparation in routine 
clinical practice, (Adams 1961b) and further 
investigations into this product have not been 
considered worth while.
It is convenient to note a different approach 
to the problem at this point. In a search for 
a long acting vitamin preparation various
cobalamins in various media and in various 
modifications were studied. It was found by 
Glass et al (1961), and confirmed by Killander 
& Schilling (1961) that the amount of 
hydroxoeobalamin (vitamin B-^a or ^12b^ excreted
(177)
/is much less than the amount of vitamin B ^  
excreted after injections of the same dose. In 
addition it has been shown that blood levels 
attained and sustained for at least three weeks 
after an injection, are greater following an 
injection of hydroxocobalamin than after an 
injection of the same dose of vitamin ^ 2 * As 
hydroxocobalamin exerts a haemopoietic effect 
equivalent to that of vitamin B ( L i c h t m a n n  et 
al 1949, Schilling et al 1951) these findings 
suggest that there may be a good case for using 
hydroxocobalamin in preference to vitamin 
provided that the cost of treatment is not 
increased. The place of hydroxocobalamin in the 
treatment of patients with pernicious anaemia is 
being investigated at the present time. The 
explanation for the greater retention of hydroxo­
cobalamin appears to be that tissues which bind 
vitamin B-^ will bind much greater quantities of 
hydroxocobalamin apparently by a different 
mechanism (Bauriedel et al 1956).
(178)
STOMARY
The relationship between the amount of
vitamin injected and the amount excreted
in the urine has been investigated by analysing
a large number of results from patients given 
58Go vitamin in doses of 50 - 10,000 ug.
A linear correlation between logarithm of
the amount injected in ug and the percentage of
the dose of radioactivity excreted was found*
The coefficients of correlation of the regression
equations did not differ significantly when the
dose ranges 50 - 1000 ug and 50 - 10,000 ug were
considered separately.
On the basis of the findings a normal
range of values for amounts of injected 
58Co vitamin B ^  excreted in urine have been
calculated and, as the amount of injected 
58Co vitamin B e x c r e t e d  in faeces is trivial,
a normal range of values for amounts of injected 
58Co vitamin B-^ retained in the body has also 
been calculated.
The literature is reviewed in the light of the 
results and comments are made on the economic
(179)
/aspects of parenteral vitamin therapy, on the 
initial treatment of patients with vitamin B^^ 
deficiency states and on the urinary losses with 
depot preparations of vitamin B-j^.
(180)
CHAPTER VII
OBSERVATIONS ON THE BODY STORES OP 
ASSAYABLE VITAMIN B12 IN NORMAL AND 
VITAMIN B12 DEFICIENT SUBJECTS.
With Notes on the Significance of Low 
Serum Vitamin Levels and on the 
Initial Treatment of Patients with 
Vitamin Deficiency States.
(181)
When planning the treatment of patients 
with vitamin deficiency states it is obviously
desirable to have some knowledge of the total 
amount of vitamin or its active principle,
stored in the tissues of normal subjects. Such 
knowledge is also desirable for more academic 
purposes such as calculations of vitamin B-^ 
turnover in man. It is relatively easy to measure 
the assayable vitamin B ^  in biopsy material or 
in tissues obtained at operation or post mortem 
examination but the value of such results is 
limited. The obvious procedure of homogenising 
corpses and measuring the vitamin B ^  content of 
the homogenates is distasteful, scarcely 
practicable and probably illegal.
A previously undescribed method of measuring 
the total assayable vitamin B ^  in the body was 
devised. The basic assumption of the method is 
that when a subject is given Go vitamin 
parenterally the proportion which is retained 
in the body is distributed throughout the tissues 
in proportion to the amounts of non radioactive 
vitamin B-^ or its active principle already present
(18?)
/in these tissues. Thus if 50f> of the retained 
dose of radioactivity were found in the liver 
this would imply that 50^ of the total body 
stores were present in that organ: if the total 
assayable vitamin content of the liver was 
found to be 2000 ug then one would assume that 
the total body stores were 4Q00 ug.
An experiment based on these concepts, 
was planned with the object of measuring the total 
assayable vitamin B ^  in man and the results 
are reported and discussed in this chapter. In 
addition, observations on tissues from two 
patients who had evidence of abnormal vitamin B-^ 
metabolism, are also reported and discussed.
PATIENTS, MATERIALS AND METHODS 
The 'normal* patients studied had been
admitted to a hospital in the terminal stages of 
disease. In all cases the disease was one in which 
deranged vitamin B ^  metabolism is not a 
recognised feature and in most the primary lesion 
was "anatomical" rather than "metabolic".
Details of these patients are given in Table 19. 
After blood had been taken for serum vitamin B ^
(183)
/estimation an injection of Go vitamin 
was given intravenously. Urine was collected 
for 24 hours after injection from the two patients 
who were given doses greater than 1.0 ug. The 
time elapsing between the injection and death 
was noted as accurately as possible. The liver 
was secured at post mortem examination, weighed, 
and a generous amount was homogenised as described 
in the Appendix. The radioactivity in an aliquot 
of the homogenate was measured by the technique 
described in the Appendix and the total hepatic 
radioactivity expressed as a percentage of the 
dose of Co vitamin B-^ given was calculated.
Suitable dilutions of the homogenate were assayed 
by the technique described in the Appendix. The 
values for total assayable body vitamin B-^ 
were calculated from the values for the total 
hepatic radioactivity and the total hepatic 
assayable vitamin B ^ .  In "two patients the 
observations were extended to include other tissues.
Recovery experiments were done on the liver 
homogenates obtained from patients who died with 
evidence of metabolic upset such as uraemia.
(I82f)
Observations on tissues from two patients 
with abnormalities of vitamin B ^  metabolism 
who came to post mortem examination were made 
using the same techniques.
The clearance of intravenously injected
58Co vitamin B-^ and the hepatic uptake of 
radioactivity as determined by surface, or 
external, counting was studied in two patients; 
details of these patients are given in the case 
reports in the Appendix. Blood was taken from a 
vein in the opposite arm before, and at intervals 
after, an intravenous injection of Co vitamin B ^  
and the radioactivity in 5 ml. aliquots of plasma 
or blood haemolysed by the addition of saponin, 
was measured as described in the Appendix. The 
total blood volume was measured by the Evans blue 
dye (T 1824) technique during the experiment and 
the total blood, or plasma, volume radioactivity 
expressed as a percentage of the dose given, 
was calculated using this value. External counting 
of hepatic radioactivity was done by the technique 
described in the Appendix.
(185)
RESULTS
The results obtained from the normal 
subjects are shown in Table 19.
The results from the subjects with 
abnormalities of vitamin metabolism are 
more conveniently given together with a 
discussion of these results at a later stage
Recovery experiments on liver homogenates 
did not show the presence of inhibitors to the 
growth of Euglena gracilis.
(18'6)
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DISCUSSION 
Review of the literature
The method used appears to he original and 
no comparable study has been reported apart from 
that by Adams (196ld) on which this chapter is 
based. The only relevant papers are those by 
Estren et al (1958) and Brody et al (i960) both 
of whom mention finding 50$ of the dose of 
radioactivity in the liver of a patient who died 
one week after an injection of Co vitamin B-^ 2*
It appears that both papers refer to the same 
patient. The vitamin B^ content of the liver 
of this patient was not measured.
Method and techniques
Considerable caution must be exercised when 
interpreting the results. Obviously not one of 
these patients could be regarded as normal in 
the accepted sense, even if the assumption that 
there was no upset of vitamin B^2 metabolism
is correct. Study of the truly normal subject 
however, presents almost insuperable difficulties., 
It is possible to obtain enough h e p a t i c  tissue 
by biopsy to allow accurate assay measurements
(188)
/but this alone gives no information about the 
total body stores. To combine the assay and 
isotope techniques in the study of biopsy 
material is impossible as the amount of 
radioactivity in the sample of tissue obtained would 
be too small to be detected unless enormous doses 
of radioactivity were injected. A combination 
of biopsy to obtain material for assay and 
external counting to evaluate the hepatic
radioactivity appeared to be a technique worth
investigating and this was done in two patients.
The first, Case T.H., was not anaemic but had a
low serum vitamin level (40 uug/ml) when
58studied. He was given 4.0 ug 4.0 uc Co 
vitamin B ^  intravenously and the hepatic count 
rate reached a plateau in a few seconds and remained 
there for the subsequent two hours during which 
time frequent observations were made: in that 
period the amount of radioactivity in the blood 
declined from 47$ of the dose at 2 minutes after 
injection to 8$ of the dose at 120 minutes after
injection (Fig. 64). These results are good 
evidence that external counting, at least by the
(1?9')
Case T.H.
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Figs. 64 & 65: showing clearance from the blood or plasma
58
and uptake by the liver of Co vitamin B^  given
intravenously.
(190)
/technique used, does not give a quantitative
measure of the Co vitamin 33 accumulated in
12
liver unless one postulates that 53$ of the
dose was taken up by the liver in the two
minutes after injection, and that 39$ was taken
up entirely by other tissues in the period
2 - 120 minutes after injection.
The second patient, Case N.McL., was not 
anaemic and had received 1000 ug vitamin
intramuscularly each month for over a year, 
the last injection being three days before the
intravenous injection of 4.0 ug 4.0 uc 
58Co vitamin kepatic count rate reached
a peak five minutes after injection and declined
over the next two hours. During this period the
plasma radioactivity fell from 64$ of the dose
at 2 minutes after injection to 9$ of the dose
at 120 minutes after injection (Fig. 65). Unless
one also postulates that in this case there
58was a discharge of accumulated Co vitamin B 
from the liver in the period 5 - 120 minutes it 
is impossible to avoid the conclusion that external
counting, at least by the technique used, is of
(191)
/little value in giving a quantitative measure
58
of the Go vitamin accumulated in the liver.
A probe inserted into liver substances might
enable the uptake to be measured quantitatively 
but this is not a practicable proposition in man 
at present.
The assay technique used appears to be 
acceptable. Ross & Mollin (1957) have shown that 
the results obtained using Euglena gracilis in the 
assay of tissues are comparable to those obtained 
with Ochromonas malhamensis which is more certainly 
specific for vitamin B-^ than other assay organisms 
(Ford 1953)* Large masses of liver and large 
volumes of homogenate were used to avoid errors 
inherent in the use of small samples. Whole 
homogenates or dilutions of whole homogenates 
were used: this method is stated to give a higher 
yield than using extracts (Ross & Mollin 1957). 
Digestion of tissues with papaih or other enzymes, 
advocated by Shenoy & Ramasarma (1954) when using 
Lactobacillas leichmannii as a test organism, 
was not used as the author has not found that 
this procedure gives a higher yield when using
(192)
/Euglena gracilis.
In many cases the general condition of the 
patient made it difficult to collect urine with 
accuracy in the post injection period and in 
all but two •normal1 cases it was assumed that 
no radioactivity had been lost in the urine.
This assumption seems justified on the findings of 
Mollin et al (1956), Miller et al (1957), Brody 
et al (i960) and Hall (i960) who reported that 
the amount of radioactivity excreted after an 
injection of up to 4.0 ug Co vitamin is 
small, usually less than 2% of the dose. Even 
if as much as 5% were excreted it is obvious that 
the calculations would be substantially unaffected. 
The urinary loss in the 24 hours after injection 
was measured in Case 1 , who received 4.0 ug 
and was found to be 0.19% of the dose and in 
Case 2 who was given 2.0 ug and was found to be 
0.44% of the dose.
It is unlikely that the age of the patients 
is of importance as Swendseid et al (1955) have 
shown that hepatic assayable vitamin B ^  is 
unaffected by ageing. It should be noted that
/no patient had cirrhosis of liver, a condition 
in which the assayable vitamin content of the 
tissue is lower than normal (Swendseid et al 1957).
Ideally two or more organs should have been 
analysed to ensure accuracy in the calculation 
of total body vitamin B^. Detailed study of two 
cases however, showed that the amount of 
radioactivity in tissues, other than the liver, 
was very small. (Table 20). It was therefore 
decided to use the liver as a single reference 
organ.
A point of great importance is whether the 
time which elapsed between the injection of the 
Co vitamin B ^  and death was adequate to allow 
complete clearance from the blood stream and
distribution to tissues. It is known that the 
initial clearance of injected Co vitamin B^^ 
from the blood stream is rapid and the results 
obtained from Cases T.H. and N.McL. are similar 
to those reported by Miller et al (1957), Estren 
et al (1958), Brody et al (i960) and Hall (I960). 
The rate of clearance has been studied in detail 
by Brody et al (I960) who found that in normal
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/subjects there was an initial rapid loss of 
plasma radioactivity in the 30 minutes after 
injection, followed by slower loss in the next 
30 - 90 minutes and a final phase of slow loss 
with an average half time of disappearance
(Tj) of approximately 24 hours: their results 
obtained from 10 'normal' patients given 0 .5 - 
1.0 ug Go vitamin intravenously showed that 
2 - 5$ of the injected dose was still detectable 
in the plasma at 8 hours after injection and the 
average amount present in plasma at 24 hours was 
3$ of the dose. These results suggest that it 
would be unwise to assume that complete clearance 
from the blood stream occurs before at least 
48 hours after injection.
Even when complete clearance from the blood 
has occurred it cannot be assumed that the
distribution of injected Go vitamin B-^ to tissues, 
is complete and final and in proportion to the 
non-radioactive stores. The possibility of 
selective uptake in one or more organs and 
subsequent slow redistribution to other tissues 
must be considered - the problem of 'relocation'.
(196)
/This problem was originally raised by Glass
(1 9 5 9 )  who noted a peak of hepatic radioactivity 
by external counting on the fifth day after an 
injection of Co vitamin and ascribed this to 
relocation. The observations on Cases T.H. and 
N.McL. already reported suggest external counting 
is of little value as a quantitative measure and 
it is doubtful if Class' (1959) evidence justified 
his conclusions. There is however, other evidence 
that redistribution of injected Co vitamin B-^ 
may occur. If all the vitamin B ^  or its active 
form in the body were in one pool or compartment
then injected Co vitamin B ^  would equilibrate 
with the stores rapidly. There is evidence however, 
that the vitamin B ^  in the body is in at least 
three compartments each of which has a separate 
turnover rate (Reizenstein 1959c). With an 
open type multicompartment system isotopic 
equilibrium may be attained quickly if internal 
transfer rates are rapid: if internal transfer 
rates are slow then equilibrium may never be 
attained. Further studies by Reizenstein et al 
(1961) using an analogue computer to analyse
/data obtained by whole body counting have led 
to the conclusion that with vitamin internal 
transfer rates are slow and that isotopic equilibrium
of injected Go vitamin B-^ and tissue stores 
does not occur in a convenient time period.
At first sight this conclusion seems to be at 
variance with the demonstrably rapid uptake of 
injected Co vitamin B ^  by liver (cf. Figs. 64 &
65) but this is not necessarily so. It appears 
therefore that the basic assumption in the study, 
that the injected Co vitamin B ^  retained in the 
body equilibrates with the tissue store, is not 
valid and this casts doubts on the value of the 
results. The assumption may not be valid but the 
results are none the less of some value for several 
reasons. In a multicompartment system with slow 
internal transfer rates the specific activity will 
be higher initially in the compartment with the 
most rapid turnover and later higher in the compartment 
with the slowest turnover reaching a peak value 
in each compartment at some time. The plasma 
compartment, which is minute in terms of vitamin 
B12 content, has a rapid turnover: the liver,
/which, is a vast compartment in terms of 
vitamin B-^ content, has a slow turnover, about 
the same as the body as a whole (see Chapter 8).
If the results were significantly affected by 
slow internal transfer rates one would expect a 
steady rise in values for hepatic radioactivity 
over along period: the extent of this rise, 
and later fall, would give some indication of the 
errors resulting from the methods used. To 
examine this point the results were analysed 
allowing for increasing time intervals between 
injection and death, and the results are set 
out in Table 21. It will be seen that there is 
a rise in mean hepatic radioactivity from 43.4# 
of the dose at 48 hours by which time clearance 
of injected Co vitamin B-^ from the blood stream 
would be virtually complete to 49.9# of the dose 
at 15 days or more. This rise is relatively small 
and suggests that the results, although not as 
precise as would be preferred, do give an acceptable 
indication of the body stores.
The values for assayable vitamin B^2 are in 
keeping with most previous estimates which are
(199)
TIME
INTERVAL
INJECTION 
TO DEATH
No.
OP
CASES
MEAN
HEPATIC
RADIO­
ACTIVITY
dose
injected
MEAN
HEPATIC
ASSAYABLE
VITAMIN
B
12
ug.
MEAN 
CALCULATED 
TOTAL 
VITAMIN B_p 
IN BODY 1
ug.
> 11 hours 17 40.9 888 2221
> 1 day 12 43-4 876 2043
> 2 days 12 43-4 876 2043
> 3 days 10 45-3 871 1922
> 4 days 10 45-3 871 1922
> 5 days 9 45.1 880 1949
> 6 days 6 48.6 1049 2150
>15 days 5 49*9 1112 2236
Table 21s showing values for mean hepatic radioactivity,
mean hepatic assayable vitamin B ^  &&& mean calculated
total body vitamin B ^  allowing for increasing time
58intervals between injection of Co vitamin B ^  and 
death*
(2CQ.)
/summarised in Table 22. They are higher than 
those reported by Pitney et al (1955) Woi 
Thau I or "(1990) and lower than those reported
OKI ■* ^ o^o*.
by Boss & Mollin (1957 )y^ The reason for this is 
not obvious. The increase in mean hepatic 
assayable vitamin found in patients who 
survived six or more days after injection is an 
odd finding and is probably fortuitous.
The results suggest that the liver contains 
about half of the assayable vitamin B i n  the 
body and that the total body stores range from 
1000 - 4000 ug with a mean of about 2000 ug. This 
value is lower than previous estimates of 3000 ug 
(Estren et al 1958) or 3900 ug (G-rasbeck et al 
1958) which were obtained by microbiological 
assay of tissues and by multiplying the mean 
tissue values by the average weights of the tissues. 
It is difficult to decide which method gives a 
more accurate result both having obvious faults 
and sources of error. Not unnaturally the author 
prefers the method used in the present investigation.
(201 )
HEPATIC ASSAYABLE 
VITAMIN Bl2
No. OF 
CASES
REFERENCE
0*14 - 0.90 ug/g 5 Drouet et al (l95l)
200 — 250 ug/organ 2 Haussman (1951)
0.47 - 1.14 ug/g - Wolff et al (1951)
0.24 - 0.74 ug/g 3 Girdwood (1952)
0.28 - 0*74 ug/g 2 Heinrich & Lahann (1954.
0.11 - 0.47 
(mean 0.28) ug/g 10 Pitney et al (1955)
0.54 - 1*40 ug/g 25 Swendseid et al (1955)
0.4 - 2 . 6  
(mean l.l) ug/g — Blum Sc Heinrich (1957)
486 - 4330
(mean 1500)ug/organ 13 Ross & Mollin (1957)
0.17 - 1.41
(mean 0*7) ug/g 122 Swendseid et al (1957)
0.5 - 1«14 ug/g - Wolff (1957)
1*41 - 2.58
(mean 1.94) ug/g 13 Nelson Sc Doctor (195^)
0.302 - 1.091 
(mean 0.588) ug/g
514 - 1910 
(mean 888)ug/organ
17
17
Adams (l96ld) 
(Present Series)
Table 22s values for assayable vitamin B ^  in hepatic 
tissue obtained by biopsy or at post mortem 
examination from ’normal* subjects*
(202)
OBSERVATIONS ON VITAMIN B1C DEFICIENT SUBJECTS 
Results from two patients are presented 
and discussed under this heading. Although 
neither patient was vitamin B d e f i c i e n t  at 
the time of death the title is a convenient one.
CASE REPORTS 
Case M.S., female, aged 68, was admitted to 
hospital with a macrocytic anaemia, Hb. 44$, 
megaloblastic erythropoiesis was seen on 
marrow biopsy smears, serum vitamin level 
42 uug/ml and a histamine fast achlorhydria.
She was given a single intramuscular injection 
of 1000 ug Co vitamin and 61.0$ of the 
radioactivity was excreted in the subsequent 
24 hours. An optimal reticulocyte response was 
observed and progress was uneventful until the 
12th day after injection when she died, suddenly 
and unexpectedly, in acute left ventricular 
failure. Post mortem examination disclosed a 
large myocardial infarct, presumed to be the 
cause of the cardiac failure; the gastric mucosa
was atrophic. The liver contained 9.22$ of the 
dose of radioactivity injected, equivalent to
(203)
58/92.2 ug Co vitamin assay the total
vitamin B content of the liver was found to 
12
he 112.1 ug. The possibility that the injected 
58Co vitamin B-^ retained in the body was not 
distributed to the tissues in proportion to the 
non radioactive stores does not affect the 
conclusion from these findings that the liver 
contained only 20 ug assayable vitamin B o r  
0.015 ug/g prior to treatment, values which are 
in close accord with those previously reported 
(Table 23)• When an allowance was made for the 
amount of radioactivity excreted in the urine in 
the 24 hours after injection the radioactivity in 
the liver was calculated to be 23$ of that retained 
in the body. This value is much less than that 
found in 'normal1 subjects who died about the same 
time after injections of Co vitamin B^^. The 
significance of this finding is not clear. In 
view of the conclusions reached by Reizenstein et 
al (1961) and the fact that this patient received 
a large amount of Co vitamin B-^ whereas the 
'normal* subjects received a small amount it 
would be unwise to draw conclusions from it.
HEPATIC ASSAYABLE 
VITAMIN B12
No. OP 
CASES
REFERENCE
about 1.0 ug/organ 1 Haussman (1951)
0.023 - O.li+O ug/g 5 Drouet et al (l95l)
0 ug/g 1 Girdwood (1952)
0 ug/g 1 Heinrich & Lahann (1954)
0.10 ug/g 2 Swendseid et al (1957)
10 ug/organ 1 Ross & Mollin (1957)
0.030 ug/g 3 Nelson & Doctor (195&)
0 - O.O85 ug/g 3 Girdwood (1960b)
Table 23s showing values for assayable vitamin
in hepatic tissue obtained by biopsy or at post 
mortem examination from untreated vitamin B ^  
deficient subjects in haematological relapse*
(205)
/It cannot of course be assumed that the 20 ug 
calculated to be present in the liver prior to 
treatment represented 23$ of the body stores and 
the exact extent of the pretreatment body stores 
cannot be estimated.
Case T.H. had undergone total gastrectomy for 
carcinoma of stomach six years before he died.
He came under observation two years after 
operation when he was not anaemic but had a low 
serum vitamin level (100 uug/ml) and 
megaloblastic erythropoiesis was seen on marrow 
biopsy smears. He was given parenteral vitamin 
B ^  but attended for maintenance treatment 
irregularly. Five years after operation he 
was readmitted to hospital with symptoms 
suggestive of a myocardial infarction and this 
diagnosis was confirmed by electrocardiography.
A routine chest X-ray showed secondary deposits 
in the lung fields. His serum vitamin level 
was subnormal and after the clearance study 
reported earlier no further vitamin B ^  was given. 
He made a satisfactory recovery from his cardiac
lesion and was discharged and resumed work. Nine
(206)
/months later he was readmitted in the terminal 
stages of neoplastic disease. He was not anaemic 
and the serum vitamin level was still 
subnormal. Treatment with nitrogen mustard 
conferred little benefit and he died six years 
after operation. Three days before death his 
peripheral blood values were Hb. 83$, P.C.V. 41$. 
Samples of serum obtained in the ten months 
before death were assayed in the same batch and 
the results are shown in Table 24. Post mortem 
examination confirmed the presence of secondary 
deposits in the lungs but no deposits were 
found in the abdominal cavity or organs. The 
total assayable vitamin B ^  in the liver was 
356 ug or 0.254 ug/g. These values for total 
assayable vitamin B ^  in liver are less than any 
obtained in the •normal1 subjects studied by the 
same methods (Table 19) and greater than those 
reported for vitamin B ^  deficient subjects in 
haematological relapse (Table 23).
DISCUSSION 
Significance of results
The results obtained from the *vitamin B ^  
deficient* subjects are relevant to the problem
(207)
BAYS BEFORE 
BEATH
SERUM
VITAMIN
*12
uug/ml
302 70
218 42
86 35
37 37
Table 24: showing serum vitamin B ^  levels
in Case T.H* in the ten months preceding 
death* All samples were assayed together 
in three separate assays and the value 
given is the mean of the three estimations*
(208)
/of the significance of a low serum vitamin B^_ 
level. Mollin & Ross (1953b) and Pitney & Beard 
(1955) suggested that the serum vitamin 
level only falls to an unequivocally low level, 
less than 80 uug/ml. by the method used (Mollin 
I96 0), when the tissue stores are depleted.
This view has been challenged by Booth & Spray
(i960) who found that the fall in serum vitamin 
B12 levels in rats after total gastrectomy was 
more rapid than the fall in hepatic assayable 
vitamin B^^ and suggested that the serum vitamin 
B ^  level may not provide an index of the body 
stores. The findings in Case M. S» are in keeping 
with the theory of Mollin & Boss (1953b) and 
Pitney & Beard (1955) as are the findings of 
others who have analysed tissues from patients 
with megaloblastic anaemia in haematological 
relapse (Table 23). The findings in Case T.H. 
however, are in keeping with the observations on 
rats and do not support the belief that a low 
serum vitamin B-^ level necessarily implies tissue 
depletion. Although the amount of assayable 
vitamin B ^  found in the liver was less than that
(209)
/found in any 'normal' subject, being just under 
half the mean value for this group, it cannot be 
regarded as insignificant and representing tissue 
depletion. The amount found was much greater than 
that observed in the livers of patients with 
megaloblastic anaemia in haematological relapse 
(Table 23) the highest value found in such patients 
being 0.14 ug/g. (Case 5 Drouet et al 1951) and 
it may be relevant that this patient had also 
previously undergone gastrectomy for carcinoma. 
Although there is no particular reason to believe 
that the neoplastic process, treatment with a 
cytotoxic drug a month before death or altered 
intestinal anatomy are factors which might have 
upset a normal balance between tissue and serum 
vitamin ^ e c0^110^ 6110® ‘t*ie circumstances
of this case and Case 5 of Drouet et al (1951) 
suggest that it would be unwise to disregard them. 
It should also be noted that Case T.H. was not 
anaemic at any time and this raises the further 
possibility that a low serum vitamin B-^ level 
may in fact reflect tissue vitamin B12 depletion 
but only when there is coincident megaloblastic
(210)
/anaemia. Further study of this problem is clearly 
desirable and analysis of liver biopsy material 
from patients in the pre-anaemic stages of pernicious 
anaemia (Adams 1957a) might be particularly 
rewarding in resolving this problem.
Practical application of the results
Whether the serum vitamin B-^ level does,
or does not, provide an index of the body stores 
it is virtually certain from the findings summarised 
in Table 23 that the tissues of patients with 
pernicious anaemia in haematological relapse 
are grossly depleted. It seems logical to believe 
that the initial treatment of such patients 
should be the administration of enough vitamin B ^  
to ensure retention of the amount normally present 
in the body as suggested by Mollin & Boss (1953b). 
Taking the normal body store as 2000 ug and 
calculating from the formula relating dose of 
vitamin B ^  injected to the percentage of the 
dose excreted (Table 14, Chapter 6 ) the number 
of injections of any one dose required to 
replenish the body stores can easily be calculated. 
The results of such calculations considering
(211)
/doses used in current clinical practice are 
shown in Table 25. Although it might be possible 
to replenish the body stores by a single massive 
dose a series of not less than five injections 
is probably preferable in view of the variation 
in amount excreted not only from patient to patient 
but in each patient. The most convenient routine 
for initial treatment therefore appears to be 
a daily injection of 1000 ug vitamin B f o r  
five days, a routine scarcely different from 
that suggested by Mollin & Ross (1953b). This 
routine should be regarded as the minimum treatment
required to restore body stores to normal and there 
is no reason why more injections should not be 
given although it is probably unnecessary and 
wasteful to give more than twelve daily injections 
of 1000 ug which should ensure retention of nearly 
4 ,5 0 0 ug which is the maximum value for total 
body vitamin found in the 'normal1 subjects.
There is no obvious reason why these 
conclusions should be modified in respect of 
treatment of patients with vitamin B d e f i c i e n c y  
states other than pernicious anaemia. The deficiency
(212)
BOSE
INJECTED
ug.
CALCULATED
BOSE
RETAILED
ug.
No. OP INJECTIONS 
REQUIRED
50 58 53
100 67 30
250 139 40
500 232 9
1000 372 5
Table 25: showing number of injections of varying
doses of vitamin B ^  required to ensure retention of 
about 2000 ug. The values for calculated dose 
retained are taken from Table 16, Chapter 6»
(213)
/is unlikely to be more marked in other conditions 
and ill effects do not result from retention 
of very large amounts of injected vitamin
Calculation of the cost of initial treatment 
taking into account only the basic N.H.S. cost 
of an ampoule of vitamin B ^  (Cytamen - G-laxo), 
shows that, in theory, the most economic routine 
is fourteen injections of 250 ug or five injections 
of 1000 ug (Table 2 6). When other costs, notably 
the cost of giving an injection in terms of 
material and labour, are considered, it is obvious 
that the method of choice is injections of 1000 ug. 
The most impressive feature of these calculations 
is the trivial cost of the dramatic benefits which 
result from vitamin B-^ therapy in suitable cases.
(214)
HOSE
INJECTED
ug
COST
pence
No. OP INJECTIONS 
REQUIRED
COST
50 3k 53 15/51
100 5 30 12/6
250 7 14 8/2
500 14(2 x 7) 9 10/6
1000 20 5 8/4
Table 26s showing cost of treatment designed to ensure 
retention of about 2000 ug* Ho allowance has been 
made for the actual cost of the injection, the cost 
being the basic N.H.S. cost of an ampoule of 
vitamin 2^ (Cytamen - Glaxo) only.
(215)
SUMMARY
A method of determining the total 
assayable vitamin in the body was devised.
The assumption was made that the amount of
injected vitamin which is not excreted is 
distributed throughout the body in proportion 
to the body stores. By measuring the radioactivity 
and estimating the assayable vitamin B-^ content 
of liver obtained at post mortem examination, the 
total assayable vitamin B ^  in the body can be 
calculated.
Results from a series of sixteen 'normal1 
patients are reported. The techniques used and 
the problems apparent in such an investigation 
are discussed in detail. The results are analysed 
to allow for clearance of injected Go vitamin B-^ 
from the blood stream and 'relocation* in tissues. 
The findings suggest that the liver contains 
about half of the total assayable vitamin B ^  
in the body and that the mean value of the total 
assayable vitamin B ^  ^ e body is in the region
of 2000 ug. Observations made on tissues obtained 
from patients with abnormalities of vitamin B ^
(216)
/metabolism are reported and discussed particularly 
in relation to the concept that the serum 
vitamin level only falls to a subnormal 
level when the tissue stores are depleted.
The initial treatment of patients with 
vitamin deficiency states is discussed in 
the light of the findings and certain conclusions 
about the treatment of such patients are drawn.
(217)
CHAPTER VIII .
THE RELATIONSHIP OP THE AMOUNT OP VITAMIN B 
RETAINED IN THE BODY FOLLOWING PARENTERAL 
INJECTION TO THE DURATION OF EFFECT.
With Some Notes on the Treatment of Vitamin 
Deficiency States and on Utilisation of 
Vitamin in Man.
(219)
At present there is general agreement that 
the treatment of choice of vitamin deficiency 
states is parenteral vitamin Reference
to the standard textbooks of medicine and 
haematology and also to the literature on 
vitamin B ^  metabolism in man however, show that 
there is doubt as to what constitutes adequate 
treatment.
It was decided therefore, to study the 
duration of therapeutic effect of varying doses 
of vitamin B ^  given intramuscularly to patients 
with vitamin B-^ deficiency states with the 
object of defining principles on which the 
treatment, particularly the maintenance treatment, 
of such patients should be based.
THEORETICAL CONSIDERATIONS
Patients with pernicious anaemia absorb 
little, if any, of the vitamin B^^ in their 
diet and from the therapeutic point of view 
the amount of vitamin B-^ which they absorb 
from a normal diet is negligible. Eor practical 
purposes therefore, their ‘intake* of vitamin B ^
(219)
/is that given by injection. The loss after 
injection is almost entirely by excretion in 
the urine in the subsequent 24 hours, the loss 
in faeces being trivial (Chapters 4 & 5). It is 
very unlikely that the vitamin which is 
excreted in the urine after parenteral 
administration has any therapeutic effect. Thus, 
for practical purposes, the amount of vitamin B ^  
which exerts a therapeutic effect in such patients 
is the amount injected minus the amount lost in 
the urine in the 24 hours after injection - the 
retained or effective dose. It seems reasonable 
to believe that the duration of effect of this 
retained or effective dose is the time after 
injection for which the serum vitamin B ^  level 
remains within normal limits. Until fairly 
recently the objects of treatment of patients 
with pernicious anaemia were simply the 
restoration and maintenance of normal peripheral 
blood levels and the avoidance of signs or symptoms 
suggestive or indicative of vitamin B ^  deficiency
such as glossitis or neuropathy. It is now obvious 
that peripheral blood values alone are only a
(220)
/crude index of the efficacy of treatment as 
normal, or near normal, peripheral blood values 
have been found in the presence of megaloblastic 
erythropoiesis, subnormal serum vitamin B-^ 
levels and even neuropathy (Thomson 1944. 
Bastrup-Madsen 1954, 1956ab, Girdwood 1956b,
Victor & Lear 1956, Adams 1957ab, Killander 
1957b, 1958abd, Pedersen et al 1957, Adams & 
Timbury 1959). Under these circumstances it is 
entirely reasonable to believe that one of the 
objects of therapy, possibly the main biochemical 
object, is the maintenance of a normal serum 
vitamin B ^  level.
With these considerations in mind three 
experiments were devised with the object of 
investigating the relationship, if any, between 
the effective dose of injected vitamin and 
the duration of effect of this dose.
Each experiment will be described, the results 
presented and a brief comment made on the results. 
The results will then be analysed and the findings 
and their significance discussed in detail.
All except two patients studied had pernicious
(221)
/anaemia. One (Case J.McQ.) came under 
observation with a post gastrectomy megaloblastic 
anaemia and in one (Case C.D.) the final diagnosis 
was the loop syndrome. All patients were aware 
of the nature and objects of the experiments and 
all cooperated willingly. It was found convenient
to use some patients for more than one experiment.
5bThe methods of preparing Go vitamin for 
injection, other technical methods and the 
statistical techniques used are described in the 
Appendix.
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FIRST EXPERIMENT 
The object of the experiment was to find
out if the duration of effect of the first 
58injection of Co vitamin B^2 given to a 
vitamin deficient patient in haematological 
relapse was similar to that obtained from a 
second injection of the same dose given when the 
serum vitamin B ^  level was higher.
Five patients were studied and the doses of
58Co vitamin B^2 given ranged from 50 ug 0.3 uc
to 1000 ug 0.2 uc. Prior to treatment a 24 hour
collection of urine was made. After the first 
58injection of Co vitamin B^2 the amount excreted
was established by measuring the urinary excretion
of radioactivity for at least 24 hours. The
serum vitamin B^2 level was estimated frequently
and when it fell to about the lower limit of
58normal, 140 uug/ml, a second injection of Co 
vitamin B^2 of the same dose was given and the 
cycle repeated. At the end of the observation 
period all samples of serum obtained from each 
patient were assayed in at least two different 
assay batches; the results given are the mean
(223)
/ v a l u e s  o f  t h e  d i f f e r e n t  a s s a y s .  T h e  r e s u l t s  
a r e  s h o w n  i n  P i g s .  6 6  -  7 0  a n d  T a b l e  2 7 .  
D e t a i l s  o f  i n d i v i d u a l  r e s u l t s  a r e  g i v e n  i n  
T a b l e s  A . 5 1  -  5 5  i n  t h e  A p p e n d i x .
C a s e  J . K .
2 8 0
2 4 0  -
a> 200 -
c 1 4 0
8 0  -
4 0  -
3 53 02 52015105O
d a y s
Pigo 66: showing serum vitamin B 0 levels after injections of
58
Co vitamin in Case J.K. For clarity the levels 
after the second injection joined by the interrupted line 
BC have been superimposed on the levels after the first 
injection joined by continuous line AB. See Table A.51* 
Pigs. 67 - 70 also follow this convention.
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S’* Co & '«j. Case C.J.
I
400-i
350-
§> 300-
250-
o 2 0 0 -
i B
100-
00
353020 25151050
days
Pig, 67: results in Case C.J, See Table A.52.
5® C o B |2 in j. C a s e  C . R .
3 5 0  -I
3 0 0 -
cn 2 5 0 -
™  200 -
>»c4 0
100-
5 0 -
3 52 5 3 020151050
d a ys
Fig. 68: results in Case C.fi. See Table A.53
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Case M.T.
350 -i
300 -
250
200 -
40
100 -
50 -
20 25 30 35 40
days
Fig. 69s results in Case M.T. See Table A.54
woo pg58coB|2inj. CaseJ.McQ.
450
400
350-
300-
250-
2 0 0 -
140
100- N l .
50-
Weeks
Fig. 70s results in Case J.McQ. See Table A.55.
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In all five patients the duration of effect, 
in terms of maintaining a serum vitamin 
level above 140 uug/ml, the lower limit of normal 
by the method used (Mollin I960) was markedly 
less after the first injection than after the 
second injection. In four cases this was clearly 
not related to a larger effective dose after the 
second injection and this was probably not a 
factor in the other case. Unfortunately the 
number of cases studied was too small for 
statistical analysis to be carried out with 
confidence. This is particularly regrettable 
as there is a marked variation in the duration 
of effect with the same effective dose even when 
the injections are given to the same patient at 
the same serum vitamin level as will be shown 
later. The possibility arises therefore that 
the observed difference in duration of effect 
may be no greater than might occur by chance. 
Careful scrutiny of the results however, leaves 
a strong impression that the duration of effect 
of the first injection is likely to be constantly
(228)
/less than that obtained with a subsequent 
injection given when the serum vitamin 
level is higher. It seems unlikely that any 
alteration in peripheral, blood values is a 
relevant factor. It is probably unduly simple 
to ascribe the increased duration of effect to 
the raised serum vitamin B ^  level alone but 
the available evidence permits no more profound 
conclusion. An increase in tissue stores may 
be a factor but it would be most unwise to 
attempt to correlate this with an increase in 
serum vitamin B ^  levels in view of the findings 
reported in Chapter 7.
(2?9)
SECOND EXPERIMENT
The object was to compare the duration of
58effect of different doses of Co vitamin
in the same patient. Treatment was witheld
from patients who had already been treated
and were in full haematological remission. The
serum vitamin B^^ level was estimated frequently
and when it fell to an arbitrary level, usually
the lower limit of normal, an injection of 
58Co vitamin B ^  was given and the urinary loss 
of radioactivity in the subsequent 24 hours was 
measured. Following the injection the serum 
vitamin B ^  level was estimated frequently and 
when it again fell to about the original preinjection 
level a further injection was given and the cycle 
repeated. At the end of the observation period 
all samples of serum obtained from each patient 
were assayed in at least two different batches.
The results given are the mean values of the 
different assays. Twenty two patients were
studied, some on more than one occasion, and the 
58doses of Co vitamin B ^  used ranged from 
50 ug 0.3 uc to 1000 ug 0.2 uc. In some cases
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/ t w o  i n j e c t i o n s  o f  t h e  s a m e  d o s e  w e r e  g i v e n  a t  
a n  i n t e r v a l  o f  2 4  h o u r s .
T h e  r e s u l t s  a r e  s h o w n  i n  P i g s .  7 1  -  9 2 ,  
d e t a i l s  o f  i n d i v i d u a l  r e s u l t s  b e i n g  g i v e n  i n  
T a b l e s  A . 5 3  &  5 4 ,  5 6  -  7 5  i n  t h e  A p p e n d i x .  I n  
t h e  f i g u r e s  t h e  r e t a i n e d  d o s e  i s  g i v e n  i n  
p a r e n t h e s e s  a f t e r  t h e  i n j e c t e d  d o s e .
50(35-1) jug 1,000(310) yug I00(59 5)jug Cqse H.C.
58CoB|2 in j- 5®CoB|2 lni  8 8 Co B|2 inj-
E
I
CD
C
E
>
E
14  O -  ~3
i)cn
weeks
Pig. 71: results in Case H.C. See Table A.56.
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I00(58)pg 1,000 (461) /jg 100(52-3)/ig Case H.F.
350 -i
300-
250-
200 -
40
00-
5 0 -
6 10 12O 2 4 8 14 16 18 20 22 24
Fig. 72s results in Case H.F. See Table A.57.
50(32-4) u g  1,000(312)>ig 100(56-i)/jg  Case M.F.
*®CoB|2 Inj. ^sCoB|2 inj.
400-
E
OJ
II
CD
C
E
>
E
3 I4 0 - -
itV)
100-
5 0 -
10 12 14 16 18 20 22 24 26 28 300 2 4 6 8
Fig. 73: results in Case M.F. See Table A.58,
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</)
50 -
8 9 10 I] 12 13 14 15 16 17
w e e k s
Pig. 74* results in Case J.G* See Table A.59*
100 yug 
(6 3  6)
5 0  /ug 
( 3 3  4 )
1,000 jag
(2 5 9 )
1 I
5 0  / jg  
(3 7  8 )
1
Case J.O.G.
3 5 0 - i
in je c t io n  o f
38coB|23 0 0 -
£ 2 5 0 -
I 200-
°  140
IOO-
5 0 -
weeks
Fig* 75s results in Case J.O.G* See Table A.60.
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330-
100 1,000 Mg 100 Mg Case J.O.H.
(36  9) (3 2 6 )  (3 9 )
J i I
IOO -
—|-------------- 1-----------1-----------1-------- 1------------1-----------1----------- 1----------- 1-----------1--------1--------------1------------1----------T - -------1
o 2  4  6 8 1 0  12 14 16 18 20 22 24 26 28
weeks
Fig. 76: results in Case J.O.H. See Table A.6l.
1,000 M9 
(238)
1,000 p g  
(900)
50 yug 
(351)
100 M9 
(67-2)
Case D.J.
1  1 1 1 1 1------- 1------- 1------- 1------- 1------- 1
O 5 10 15 20 25 30 35 4 0  45 50
weeks
Fig. 77* results in Case D.J. See Table A.62
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2 x 5 0  (8 0 -5 ) /jg  5 0  (4 3 -9 )  jug
Case J.K.
3 0 0 -1
2 5 0  -
200 -
1 4 0
100-
5 0 -
0  1 2 3 4 5 6 7 8 9  10 I I  12
w e e k s
78: results in Case J.K. See Table A.63*
1,000 09  
(4 6 4 )
100 og  
(6 4 -4 )
5 0  09  
( 4 0  I)
100 09  
(6 2  6 )
I I
5© C oB |2
1 4 0 -
100-
10 |5  2 0  2 5  3 0  3 5  4 0  4 5
weeks
Fig. 79s results in Case J.L. See Table A.64«
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100 yug 
(65-9)
Case M. M cB.1,000 yug 
(320)
100 /ug 2 xlOO yug(5930
in jection of 
5BCoB 12
3 5 0 -
-  3 0 0 -
3 5 0 -
100-
5 10 150 20 25 30 35 4 0 45 5 0
weeks
Fig, 80: results in Case M.McB. See Table A.65,
100(52 8) yug 50(30-4)yjg 1000(337) /ig 100(56 8) yag Case I.McC.
58C o B |2 ln j. 5s C o B |2 in j ^ C o B ^  inj. 58C oB!2 inj.
450
400-
350-
300-
250-
200 -
140-
100-
w e e k s
Fig, 81* results in Case I.McC. See Table A,66,
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100 (51-1) / j g
58coB|2 'nJ-
1.000(291) jug 
^ 8 C o B |2 in j.
E.P.
350-i
300-
250-
20 0 -
140
00-
50 -
0 2 4 6 8 10 14 16 2012 2218
w e e k s
Fig. 82: results in Case E.P. See Table A .67
1 0 0 (5 2  6 )  jug 1 0 0 0  ( 122 ) jug 
5 S C o B |2  in j 5 8 C o B ]2 in j.
Case M.P.
4 0 0  -1
£ 300
£ 200 
E
§ 140
100
5 0 -
0  1 2 3  4  5 6  7 8  9 10
w e e k s
Fig. 83s results in Case M.P. See Table A .68.
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IOO(72)/ag 100(80-2) *ig
58CoB|2 in) 58CoB |2 inj.
1 1
100(52) >ug
58Co B |2 inj.
1
100 (52 0) yug 
^®CoB (2 inj
I
days
Fig, 84; results in Case C,R, See Table A,53*
1,000 (3 4 l)p g . 1 0 0 (7 8 4 )  Mg
Case I. R.
3 0 0  -
2 5 0  -
200 -
140
100 -
5 0  -
2 3  4  5  6 7  8  9  10 II 12 13 14 15 16 170 I
w e e k s
Fig, 85s results in Case I.R, See Table A.69*
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50 50 /jg 
(47 7) (41 7)
50 pg 
(35)
50 pg
(35)
Fig. 86s results in Case M.R. See Table A.70
140 - 
100-
5 0  -
12 14 16
w e e k s
1,0 0 0 ( 161) ;ug IO O (5 3  -7)Aig Case J.S.
5 8 c o B |2  in j.  5 8 C oB |2  in j.
3 0 0 -
2 5 0 -
200-
Fig. 87s results in Case J.S. See Table A.71*
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1,000/jg 1 ,0 0 0 /ag 2 ,0 0 0  /jg  5 0  >ug 
(2 8 8 ) (5 7 0 ) (3 4 -2 )
injection of 
88Co B 12
O 5 10 15 20 25 3 0 4 035 4 5 50
Pig. 88s results in Case A.T. See Table A.72,
100 jug 5 0  jjg  100 jug 2 x  100 >ug
(5 4  4 ) (3 7  5 ) (4 9  5) (114)
injection < 
5 8 CoB|2
E 3 0 0 -
O 5 10 15 20 25 3 0 3 5 4 0
Pig. 89: results in Case A.T. See Table A.73
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1 ------1---- 1----- 1--- 1-----1-----1-----1---- 1---- 1-----1---- 1-----1---- 1-----1
O 2 4  6 8 10 12 14 16 18 2 0  22 2 4  2 6  2 8
w e e ks
100 Mg 
(7 5  9)
C a se  M.T.100 m 9 100 jug 
(81-2) (85)
IOO Mg 
(8 9  5)
100 MS 
(6 3  I)
1
£ 2 5 0 -
O)
3 .
3 .
1 200 -
2 140
IO O -
Fig. 90s results in Case M.T, See Table A.54*
l , 000(38l )Mg  
5 s Co B 12 in j.
I
100 ( 49  5) Mg 
58CoB 12 inj.
1
Case I.W.
4 0 0  ->
3 50  -
£ 3 0 0 -
tj>
3 .
3.
| 2 5 0 -
cvi
CD
E 2 0 0 -  E o -*>
>
|  1 4 0 -
L.*)
V) 100 -
5 0 -
0 1 2 3  4 5 6 7 8 9  10 II 12
weeks
Fig, 91s results in Case I.W, See Table A,74*
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100 yug 2x100 jug Case I.W.
(40-3) (116 8) -------------------
350-i
in je c t io n  o f
38coB|2300-
E 250-
1 200-
o 140
IO O -
50-
10 12 14 16 18 20 22 24 26 28
weeks
O 42 6 8
Fig* 92: results in Case I.W* See Table A.75.
C O M M E N T S
T h e  s t r i k i n g  f e a t u r e ,  a p p a r e n t  i n  e v e r y  c a s e ,
w a s  t h a t  t h e  d u r a t i o n  o f  e f f e c t  o f  a n  i n j e c t i o n
o f  1 0 0 0  u g  w a s  o n l y  r a r e l y  g r e a t e r  t h a n  t w i c e
t h a t  o b t a i n e d  w i t h  i n j e c t i o n s  o f  5 0  u g  o r  1 0 0  u g
i n  s p i t e  o f  t h e  f a c t  t h a t  t h e  a m o u n t  o f  
5 8 C o  v i t a m i n  r e t a i n e d  i p .  t h e  b o d y  a f t e r  t h e
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/larger injection was from three to ten times 
greater than the amount retained after the smaller 
injection. In other words the duration of effect 
was clearly not directly proportional to the
a. ^ „amount of Co vitamin retained. This 
phenomenon was observed whether the duration of 
effect was calculated in terras of maintaining the 
serum vitamin level above the lower limit of 
normal (140 uug/ml) or above a higher or lower 
value. There was no doubt about these findings 
which have been reported previously on only two 
occasions (Adams 1961 ce) in a smaller series.
As far as was possible the injections were given 
at the same serum vitamin level in each patient 
and the same pattern was seen whether the larger
injection was given before or after the smaller 
injection. In one or two cases it appeared that 
the phenomenon might be related to a difference 
between the serum vitamin B ^  levels at the time 
of the injections as was noted in the first 
experiment but this did not obtain in all cases 
and in some the reverse appeared to be the case.
The phenomenon cannot be explained on the basis
(22,3)
58/of significant loss of injected Co vitamin B ^
in faeces (Chapter 5) and investigations showed
that it was not due to continuing urinary excretion
58after 24 hours. It is known that Co vitamin
may deteriorate in vitro, (Smith 1959) and the
possibility that this was in some way a factor
58was also investigated: deterioration of Co 
vitamin was not observed by weekly microbiological 
assay with any of the batches used and two batches 
were found to have retained their potency between 
the time of injection and the time the sera from 
patients given that batch were assayed. The 
repetition of the same pattern in every case 
suggested that the phenomenon was not due to 
any technical error but was biological.
(2it4-)
fhlBD EXPERIMENT
1'he object was to determine the duration
of effect of a series of injections of "^Co
vitamin given in a short period to patients
in haematological relapse. Alter a 24 hour
collection of urine had been completed several
injections were given and the loss in z4 hour
collections of urine was measured until at least
48 hours after the last injection. Each patient
58received the same dose of Co vitamin B-^ at
each injection. After the treatment period the
serum vitamin level was estimated frequently
until it fell to the lower limit of normal. All
samples of serum obtained from each patient were
then assayed in at least tv/o different assay
batches. The results given are the mean values
of the different assays. Eight patients were
58studied. The total amounts of Co vitamin B ^  
given to and retained by each patient are shown 
in Table A. 8S, details of individual cases being 
given in Tables A.57 & A.76 - 82 in the Appendix.
The results are shown in Pig. 93*
(245)
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Fig. 93s results in Cases given massive therapy. See 
Table A.8S.
COMMENTS
T h e  d u r a t i o n  o f  e f f e c t  o f  t h e  v a r i o u s  
r e t a i n e d  d o s e s  v a r i e d  v e r y  g r e a t l y  f r o m  c a s e  t o  
c a s e .  T h e  m o s t  s t r i d i n g  f e a t u r e  w a s  t h a t  t h e  
d u r a t i o n  o f  e f f e c t  i n  n e a r l y  a l l  c a s e s  w a s  m u c h  
l e s s  t h a n  m i g h t  h a v e  b e e n  e x p e c t e d  f r o m  t h e  
f i n d i n g s  i n  t h e  s e c o n d  e x p e r i m e n t .
(2 46)
FDKTHEK IKVESTI&AiaOI'iS - ANALYSIS Off BESUITS
It is a well established principle in
pharmacology that if a drug is excreted in the
urine in an exponential manner and if the clearance
of the drug from the blood stream is also
exponential in form, that the duration of effect
of the drug is proportional to the logarithm of
the dose of the drug (Wilson & Schild 1959).
Analysis of results obtained from experiments
58on the urinary excretion of parenteral Co 
by the normal and by an artificial kidney had 
shown that there was a linear relationship 
between the amount of vitamin excreted and 
logarithm of the time, the coefficient of 
correlation differing significantly from zero. 
(Chapter 6). The fall in serum vitamin 
levels after an injection of vitamin also 
appeared to conform to this pattern. With these 
factors in mind it seemed worthwhile analysing 
the results obtained in the present experiments 
to find out if there was a relationship between 
the logarithm of the amount of vitamin B ^  
retained in the body and the duration of its effect
(247)
/in days.
In selecting cases for analysis certain 
problems became apparent. The first was whether 
to take the duration of effect as being the period 
for which the serum vitamin level remained 
above the preinjection level or whether to take it 
as the period for which the serum vitamin B ^  
level remained above the lower limit of normal 
(140 uug/ml). It was decided to adopt the latter 
alternative for two reasons: in the first place 
it seemed undesirable, on general grounds, to 
analyse data in which the 'end points* varied 
widely from case to case; in the second place it 
appeared more likely that results relevant to the 
treatment of patients with vitamin B ^  deficiency 
states could be obtained by this technique. It 
was also apparent that if the end point was to be 
140 uug/ml then only results in which the 
preinjection level was also 140 uug/ml also should 
be studied. A review of the results showed that 
there were only a small number of cases which 
satisfied these rather rigid criteria. As it was 
obvious that a large number of results would be
(21£)
/needed for a satisfactory analysis it was decided
to include cases in which the preinjection serum
vitamin B-^ level deviated to a small degree from
the figure of 140 uug/ml. It seemed likely that
any errors accruing from this would cancel each
other out in a sufficiently large series. A
further difficulty in the selection of results
was whether to include results obtained from
58patients given multiple injections of Co
vitamin B w h e t h e r  these were simply two injections
of 50 or 100 ug given at a 24 hour interval or
whether they were repeated injections given over
a period of several days.
In the first place a series of 40 results
obtained from eighteen patients was selected,
mainly from those obtained in the second
experiment. Results relating to multiple injections
were excluded and, for reasons already given,
results relating to the first injection of 
58Co vitamin B ^  given to patients in haematological 
relapse were also excluded. Analysis of these 
values, which-are detailed in Table A.81, showed 
a linear correlation between the logarithm of the
(249)
'retained dose and the duration of effect in days, 
the coefficient of correlation differing 
significantly from zero. The regression equation 
was:
Y = 17.0886x - 0.4270
(n - 40, r = 0.5276, P =40.001)
where y = the duration of effect in days and
x = the logarithm of the retained dose. The
results are shown in Pig.94*
When these 40 results were augmented by 5
obtained in the second experiment from patients
58
given two injections of 50 or 100 ug Co 
vitamin B 24 k°ur intervals (Table A.84) 
the relationship was little changed, the regression 
equation being:
Y * I8.7895x - 2.0727
(n = 45, r = 0.4714, P = 40.01). 
and the coefficients of correlation were not found 
to differ significantly (t = 41.0, P =>0.05).
There were obvious objections to including 
results obtained in the third experiment to those 
already analysed. The main objection was that 
in the third experiment all patients were treated
(250)
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Fig. 94* showing relationship of the logarithm of the 
retained dose to the duration of effect in days. 
Forty observations are plotted and the regression 
line and 95$ confidence limits are also shown. The 
regression equation is Y « 17*0886x - 0.4270 where 
x * the logarithm of the retained dose and y = the 
duration of effect in days in terms of maintaining 
the serum vitamin level about 140 uug/ml.
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/when in haematological relapse with low serum 
vitamin levels whereas in the second experiment 
they were treated when in haematological remission 
with serum vitamin levels at the lower limit 
of normal. There was no reason why the results 
obtained in the third experiment should not be 
analysed alone although the small number of 
observations made it obvious that the value of 
a correlation, if any, would be limited. In 
fact an analysis of six suitable values selected 
from those in Table A.85 showed that the coefficient 
of correlation did not differ significantly from 
zero (r = 0.52, n - 6, P =>0.05).
DISCUSSION
As far as can be ascertained the finding of 
a significant correlation between the logarithm 
of the retained dose and the duration of effect 
has only been reported on one occasion (Adams 
196let). The finding is of considerable practical 
and academic importance, although not entirely 
unexpected, and its significance will be discussed 
in detail.
(252)
Practical application of the results
The immediate practical value of the
correlation between the logarithm of the retained
dose and the duration of effect is that it enables
maintenance therapy with parenteral vitamin
for patients with pernicious anaemia to be planned
on a rational basis. The inclusion in the analysis
of results from one patient with a post gastrectomy
vitamin B d e f i c i e n c y  state does not affect the
value of the findings as absorption tests with
58orally administered Co vitamin B ^  showed that 
this patient had a defect of absorption as 
complete as that found in patients with pernicious 
anaemia•
By calculating from the equation relating 
58the dose of Co vitamin B ^  injected and the 
percentage of the dose excreted in the urine 
(Chapter 6) for doses up to 1000 ug and by 
further calculating from the equation 
Y = 17.0886x - 0.4270 
where y = the duration of effect in days and 
x = the logarithm of the effective dose, the 
calculated duration of effect of doses of vitamin
(255)
/B12 commonly used in clinical practice can be 
obtained (Table 28 ) .  The equation Y - 1 7 . 0 8 8 6 x  
is used in preference to Y = 1 8 . 7 8 9 5 x  -  2 . 0 7 2 7 .  
Although there is little difference between them 
the second equation was obtained by analysis of 
results from patients treated dissimilarly and it 
is preferable to use the first equation which was 
obtained by analysis of results from patients 
treated under comparable conditions. The results 
of the calculations, shown in Table 28, form the 
basis for dose schedules for maintenance treatment 
of patients with pernicious anaemia, where the object 
of treatment is to maintain the serum vitamin 
level at, or above, the lower limit of normal.
It should be stressed that the values in 
Table 28 are calculated mean values. It is not 
proposed to discuss the results in terms of 
statistical ranges as this is scarcely necessary 
when considering the results in relation to long 
continued maintenance therapy. The statistical 
ranges (mean i 2 SB) are large for several reasons. 
Firstly, because the measurement of duration of 
effect is essentially a measurement by
(254)
DO SB 
INJECTED
ug.
CALCULATED
DOSE
RETAINED
ug.
CALCULATED 
DURATION 
OP EFFECT 
days
50 38 27
100 67 31
200 117 35
250 139 36
300 159 37
400 197 39
500 232 ¥>
600 264 41
700 293 42
750 308 42
9oo 321 42
900 348 43
1000 373 43
Table 28: showing calculated duration of effect for
calculated doses retained after injections of vitamin 
commonly used in clinical practice* The 
calculated dose retained is taken from Table 15> 
Chapter 6* The calculated duration of effect was 
found from the equation Y * 17*0886x - 0*4270 where 
y « duration of effect in days and x = logarithm of 
retained dose* The values were calculated to the 
fourth decimal place and rounded off to whole numbers 
for the sake of simplicity*
(255)
/microbiological assay and the results will vary 
widely from individual to individual thereby; 
secondly because the preinjection serum vitamin 
levels varied from case to case and finally because 
there is likely to be a variation from individual 
to individual in any such biological system.
The findings in Table 28 suggest that safe 
economical maintenance therapy will be achieved 
by an injection of 50 ug every 3 weeks, 100 ug 
every 4 weeks, 250 ug every 5 weeks or 1000 ug 
every 6 weeks in the vast majority of patients 
with pernicious anaemia.
There are no comparable studies reported in 
the literature with which the findings can be 
compared. The technique used does not appear to 
have been employed before probably because of the 
difficulty of measuring the urinary loss of 
injected vitamin Bj.2 * Mollin & Ross (1953b) observed 
the duration of effect of varying doses of 
vitamin B ^  given intramuscularly in terms of 
maintaining the serum vitamin B ^  level above 
100 uug/ml which was then regarded as the lower 
limit of normal. However, most of their cases
/were in haematological relapse when first studied 
and the urinary excretion of vitamin was 
not estimated. Their results are summarised 
in Table 29• On the basis of these results 
they suggested that adequate maintenance therapy 
could be achieved by giving 40 ug intramuscularly 
every 10 days or 160 ug every 21 days. It is not 
permissible to extrapolate to obtain a value for 
duration of effect for a 40 ug dose, the smallest 
dose used in the present study being 50 ug which 
gave a mean duration of effect of 26 days; the 
calculated mean duration of effect of a 160 ug 
dose is 33 days . These values differ somewhat 
from those suggested by Mollin & Boss (1953b)•
It is likely that the main reason for the difference 
is that most of their patients were in haematological 
relapse when first studied. It has already been 
suggested on the basis of the results obtained 
in the first experiment that the duration of effect 
resulting from the first injection of vitamin B12 
given to a patient in haematological relapse is 
much less than that obtained by subsequent 
injections of the same dose. Another factor may
(257)
DOSE
ug.
NUMBER OF 
OBSERVATIONS
DURATION OF EFFECT 
IN DATS
20 7 6 - 18 +
40 6 2 — 22
80 9 11 - 35 +
160 7 11 - 48
320 3 39 - 98
1000 3 34 - 58 +
Table 29: results relating the amount of vitamin B ^  
injected and the duration of effect obtained by 
Mollin & Eoss (1955b).
(258)
/be their use of 100 uug/ml as the *end point* 
as opposed to the 140 uug/ml *end point* used 
in this study, although one might expect that the 
use of a lower end point would give a greater 
duration of effect.
The results are also interesting in relation 
to the findings of Kinloch (I960) who tested the 
value of 1000 ug vitamin given intramuscularly 
every 12 weeks as routine maintenance therapy 
and to the studies by Killander & Werner (1961) 
who used doses of 500 ug and 1000 ug every eight 
weeks. From the calculations in Table 28 these 
doses should not have provided effective 
maintenance therapy and the finding that they 
did so would have cast grave doubts on the 
validity of the results and their interpretation 
reported here. In fact these dose schedules, 
as assessed by frequent peripheral blood counts 
and estimations of serum vitamin levels were 
unsatisfactory.
Comparison of the calculated dosage schedules 
and those tested critically by Meyer et al (1953), 
Meacham & Heinle (1953), Lear & Castle (1956) and
(259)
/Will et al (1959) is not feasible because the 
doses used by these authors were small. There is 
however, nothing in these papers which causes one 
to doubt the value of the calculated dose 
schedules - the reverse is in fact the case.
Although the dose schedules derived by 
calculation should prove economical and adequate 
it must not be inferred that these schedules 
represent completely satisfactory maintenance 
therapy. The schedules should prove satisfactory 
in maintaining a serum vitamin level just above 
the lower limit of normal and should therefore 
be regarded as the minimum effective schedules 
and not as the ideal. On general grounds it is 
probably desirable to aim at maintaining the 
serum vitamin B ^  level at, or near, the mean 
normal level rather than just above the lower 
limit of normal. It is not possible to calculate 
* ideal* dose schedules which would achieve this 
purpose from the results obtained in this study.
The effect of giving looo ug 58Co vitamin B12
intramuscularly every 28 days was studied in six 
patients with vitamin B12 deficiency states and
(260)
/the results are shown in Fig. 95. The urinary 
losses after injection were measured and were in 
the range already observed. It will be seen 
that the serum vitamin B ^  levels rose during the 
observation period and such a dose schedule may 
be near the ideal treatment.
Economic aspects of maintenance therapy
Mention should be made of the economic aspects 
of the suggested dose schedules. The annual 
cost of each dose schedule is shown in Table 30 
and it appears that, in theory, the most economical 
dose schedule is an injection of 50 ug every 3 
weeks. The calculations however, do not take into 
account dispensing fees, price reductions for 
bulk buying, the cost of materials such as 
syringes whether disposable or resterilised and 
the cost of labour and other relevant factors.
When these are considered it is probable that the 
most economical dose schedule is an injection of 
250 ug every 5 weeks. The most striking feature 
of the calculations is the trivial cost of 
treatment with regard to the benefits it confers.
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Fig* 95s showing serum vitamin B_Q levels in six patientsrO
given 1000 ug D Co vitamin B12 intramuscularly every 
4 weeks* All samples of serum from each patient were 
assayed together in at least two different assays 
and the results shown are mean values*
DOSE SCHEDULE COST OP 
VITAMIN B 2 
pence
COST OP TREATMEBT 
PEE YEAH
50 ug every 3 weeks 3k 5/1
100 ug every 4 weeks 5 5/5
250 ug every 5 weeks 7 6/1
500 ug every weeks 14 (2 x 7) ll/-.
1000 ug every 6 weeks 20 14/5
1000 ug every 4 weeks 20 21/8
Table 30: showing cost of minimum effective maintenance 
therapy with vitamin per year according to various 
dose schedules and also the cost of treatment per 
year with 1000 ug vitamin B ^  intramuscularly each 
month# The cost of the vitamin B ^  is the basic 
N.H.S. cost of ampoules of vitamin B12 (Cytamen - 
Glaxo) only.
(263)
/The place of massive theraD.v
It is obvious from the results that massive 
therapy — stosstherapy — whether in the form of 
single injections of very large doses or in the 
form of a series of injections given in a short 
space of time, has a very limited place in maintenance 
therapy. With single injections of very large 
doses the bulk is excreted rapidly and the 
duration of effect of the retained dose is little 
greater than that obtained with much smaller 
doses. For example, with injections of 1000 ug 
the mean retained dose is 372 ug and the calculated 
duration of effect is 43 days: with injections of 
10,000 ug the mean retained dose is 808 ug and 
the calculated duration of effect is 49 days - 
an increase of only 14# in duration of effect 
for a tenfold increase in dose injected. It is 
possible that there is some place for multiple 
injections given in a short space of time. It 
has not been established that there is a correlation 
between the logarithm of the total retained dose 
and the duration of effect with this form of therapy 
but it seems likely that this would be obtained
(26k)
/if a sufficient number of cases were studied.
If this were the case it might be possible to 
construct dose schedules with treatment 
consisting of a series of injections of say 
1000 ug given at intervals of six months or 
longer but it is obvious that such a method of 
maintenance therapy would be almost as uneconomical 
as single massive doses and unlikely to appeal to 
a patient or doctor on the grounds of convenience 
alone.
The findings in relation to the treatment of 
vitamin B-^ deficiency states other than pernicious 
anaemia.
The value of the results and findings in 
planning treatment, particularly maintenance 
treatment for patients with pernicious anaemia 
has been discussed and it is pertinent to consider 
whether the conclusions should be modified for 
other conditions requiring treatment with vitamin
In theory at least there should be no need 
for continued treatment of vitamin B^2 deficiency 
states due to inadequate dietary intake. In
(265)
/practice however, it may be neceseary to institute 
maintenance therapy by dietary supplements or by 
parenteral therapy. Absorption of orally ingested 
vitamin is normal in such patients, and a 
dietary supplement sufficient to ensure the 
absorption of 2 ug daily should meet basal need: 
the factors leading to this value will be discussed 
later. The optimal requirement is greater and 
a supplement ensuring absorption of 10 ug daily 
should meet this requirement. If parenteral 
therapy is preferred the dose schedules should 
prove adequate: the defect in such patients is 
comparable to that in pernicious anaemia in that 
the amount actually absorbed is trivial although 
for vastly different reasons. The fact that 
vitamin B ^  is obtained by biosynthesis by 
Streptomyces griseus does not appear to have 
contra-indicated its use by even the strictest 
ultravegetarian - presumably it is not regarded 
as animal produce.
It is not likely that the suggested dose 
schedules need be revised for any of the many 
conditions (G-irdwood 1956b, Herbert 1959) in which
(266)
/malabsorption is the cause of vitamin B^ 
deficiency• The lesion which leads to malabsorption 
and deficiency in pernicious anaemia is 
irreversible and the block to absorption of the 
vitamin B^ normally present in the diet is virtually 
complete. There is some evidence that the block 
to absorption of vitamin B ^  which may occur in 
adult coeliac disease or after partial 
gastrectomy is incomplete and variable (Adams &
Seaton 1961, Adams & Cartwright 1962) suggesting 
that these patients might need less injected 
vitamin than patients with pernicious anaemia.
The variability of absorption however, cannot be 
assumed and prudency dictates that such patients 
should be treated as if the block were complete 
and final.
Increased utilisation of vitamin B12 or its 
active principle would be an indication for 
altering the dose schedules. This is an uncommon 
cause of vitamin B^  deficiency probably by reason 
of the large body stores. There is some evidence 
that hyperutilisation occurs in pregnancy and 
thyrotoxicosis. The need for vitamin B12 appears
(267)
/to be increased in pregnancy, both, in normal 
subjects (Heinrich 1954, Okuda et al 1956,
Boger et al 1957, Izak et al 1957) and in patients 
with pre-existing pernicious anaemia (Adams 1958) 
and this has been ascribed to hyperutilisation 
rather than to foetal parasitisation as the foetus 
has only a small amount of vitamin in its
tissues (Ross & Mollin 1957). Nevertheless 
megaloblastic anaemia during pregnancy solely 
due to hyperutilisation of vitamin is an
exceptional event. From the data given by 
Adams (195&) it seems likely that 1000 ug vitamin 
B -^ 2 intramuscularly each month should be adequate 
treatment. The association of thyroid disease 
and megaloblastic anaemia due to vitamin B ^  
deficiency is now well established (Tudhope &
Wilson I960, McNicol 1961) but the precise part, 
if any, played by hyperutilisation is uncertain. 
There seems to be a prima facie case for 
incriminating some degree of hyperutilisation 
when a vitamin B ^  deficiency megaloblastic 
anaemia is associated with untreated thyrotoxicosis 
in which case the logical course would be to
(268)
/treat the megaloblastic anaemia by the usual
methods and to exhibit antithyroid drugs
concurrently• In myxoedema malabsorption of
vitamin B.^ is said to occur (Leithold et al
1958) but this was not confirmed by Tudhope &
Wilson (I960) and there is no evidence for
hyperutilisation in this condition.
Hyperutilisation of vitamin might play a
part in the megaloblastic anaemia associated with
hepatic cirrhosis (Movitt 1950, Krasnow et al
1957) but upsets of folic acid metabolism are
more likely to be aetiological factors (Jandl
& Lear 1956, Herbert 1959) while Movitt (1950)
and Davis & Brown (1953) stress the part played
by dietary deficiencies. There does not appear
to be hyperutilisation of vitamin B ^  in the
megaloblastic anaemias associated with malignant
disease, leukaemia, haemolysis or myelofibrosis
which are usually due to folic acid deficiency
(Herbert 1959) nor does there appear to be
hyperutilisation in the megaloblastic anaemia
of scurvy (Brown 1955), Di Guglielmo's disease
(Adams & Seaton I960) or anticonvulsant megaloblastic
anaemia although low serum vitamin B levels
12
/have been reported in a few cases (Kidd & Mollin 
1957, Spray & Witts, 1958, Montgomery & Craig
1958).
An excessive loss of vitamin B1 in urine 
or faeces might be an indication for altering 
the dose schedules. Such a condition would imply 
an inability to bind vitamin B ^  and to date 
only one such case has been described (Horrigan 
& Heinle 1952) and the exact nature of the upset 
in vitamin B^^ metabolism in this case was never 
defined (Herbert 1959).
The place of parenteral vitamin B-^ in maintenance 
therapy
Earlier it was stated that parenteral vitamin 
B ^  is the treatment of choice in pernicious 
anaemia. This statement should be discussed 
briefly. It can be said, without fear of 
contradiction, that other methods of treatment 
have never proved as satisfactory as parenteral 
vitamin B ^ .
It is now believed that the haemopoietic 
activity of liver extracts, often clinically 
unsatisfactory (Mollin 1950), is entirely due to
(270)
/their vitamin B ^  content and as this is variable, 
and often minute (G-irdwood et al 1950, Adams & 
Timbury 1959) these preparations should be 
eschewed. A further objection to their use is the 
development of sensitivity which was becoming a 
major problem prior to the introduction of 
vitamin B ^ ,  (Noren 1950, Davis & Brown 1953).
This problem is very rarely encountered with pure 
vitamin B ^ .  A study of thirty eight patients 
with clinical or latent allergy to liver extracts 
showed that none were sensitive to vitamin B-^ 
suggesting that vitamin B^ is non allergic 
(Noren 1950). The case of sensitivity to 
vitamin reported to G-illhespy (1955) however 
was also sensitive to liver extracts but not to 
proteolysed liver given orally. The author has 
investigated a patient who had an allergic reaction 
after an injection of vitamin B ^  but detailed 
study excluded vitamin B ^  as the cause of the 
reaction.
The place of folic acid in the treatment of 
pernicious anaemia is limited to ‘starting* a 
response in the very rare cases which will not
(271)
/respond to parenteral vitamin alone 
(G-irdwood 1959)* There is some evidence that 
folic acid in therapeutic doses may accelerate 
the utilisation of vitamin and that long 
continued folic acid therapy in pernicious anaemia 
may not only be unnecessary but inadvisable 
(Lear & Castle 1956).
Maintenance therapy with vitamin B ^  given 
other than parenterally has only occasionally 
proved satisfactory. Early optimistic reports 
about the use of vitamin B ^  and heterologous 
intrinsic factor (Glass & Boyd 1953, Lowther et 
al 1954, Meulengracht 1954, Bastrup-Madsen & 
Paulsen 1955) were not confirmed by results of 
long-term trials (Blackburn et al 1955, 1959,
Adams 1957b, Kristensen et al 1957, Lowenstein et 
al 1957, Killander 1958bc). The failure of these 
preparations to sustain a haematological remission 
was shown to be due to an acquired block to the 
absorption of vitamin B ^  when this was given 
with heterologous intrinsic factor although 
absorption was still restored to normal when 
homologous intrinsic factor was given (Schwartz
(272)
/et al 1957, Killander 1957c, Stokes & Pitney
1958). Further studies resulted in the 
demonstration of an inhibitor to heterologous 
intrinsic factor in the sera of patients who had 
been treated with oral vitamin and heterologous 
intrinsic factor and also in the sera of some 
patients who had not been so treated (Taylor 1959, 
Schwartz I960) and it was suggested that this 
inhibitor was an antibody. Agreement has not yet 
been reached on the precise mechanisms involved 
in acquired resistance to heterologous intrinsic 
factor but it is now quite clear that these 
preparations have no place in the routine 
treatment of patients with pernicious anaemia.
Oral vitamin B ^  alone in doses as small as 
5 tig per day may induce a remission in pernicious 
anaemia (Estren & Wasserman 1956) and a daily 
oral dose of 100 ug appears to be an effective 
form of treatment (Chalmers & Shinton 1958,
Hemsted & Mills 1958) although there are conflicting 
opinions about the reliability of a dose of 1000 ug 
every week or fortnight (Reisner et al 1955,
Conley & Krevans 1955, McIntyre et al I960).
(273)
/Inhalation therapy, (Monto et al 1953, Monto 
& Rebuck 1954, Israels & Shubert 1954) appears 
to be effective but has never attained popularity 
in therapeutic circles. The vitamin peptide 
complex introduced by Heathcote & Mooney (195b) 
met with considerable criticism (Castle 195b,
Glass 195b, Herbert et al 195b) and has not found 
a place in routine treatment. Of all these methods 
of treatment the only reliable one appears to be 
oral vitamin B ^  alone in a dose of 100 ug daily 
and even those who report favourably on this type 
of therapy state that parenteral vitamin B ^  
is preferable (Chalmers & Shinton 195b).
It is evident therefore, that at present, 
the treatment of choice is parenteral vitamin 
The results and conclusions reported in this 
chapter therefore have a strong practical bias.
The findings in relation to the time taken to 
develop overt vitamin B ^  deficiency after 
deprivation
It must be stated clearly that the findings 
cannot be used as a basis for calculating the time 
interval which will elapse between deprivation of
(274)
/vitamin such as occurs when maintenance therapy
in pernicious anaemia is discontinued or when total 
gastrectomy is performed, and the appearance of 
overt vitamin B^2 deficiency in the form of neuro­
pathy or megaloblastic anaemia. In the first 
place it is well known, although the mechanism 
is not clear, that an unequivocally low serum 
vitamin level may exist for a considerable 
time before clinical stigmata appear. In the 
second place the findings in this investigation 
are based on results relating to serum vitamin 
levels about 140 uug/ml, the lower limit of normal, 
whereas in overt vitamin B^2 deficiency the serum 
vitamin B.^ levels are usually unequivocally low, 
being less than 80 uug/ml (Mollin I960) and the 
difference between these levels relative to time 
is very great, probably representing a late slow 
phase of clearance such as observed by Brody et 
al (I960) in the clearance of small doses of 
Co vitamin B^^ from the blood stream. It is not 
even possible to use the findings to calculate 
the time taken for the serum vitamin B12 level 
to fall to the lower limit of normal after a total
(275)
/gastrectomy as the findings relate to retained 
doses considerably less than the normal body 
stores and extrapolation would be unwise, the more 
so when different groups of patients are being 
considered*
Results in relation to the need for and 
utilisation of, vitamin B-^
Mention must be made of the implication of 
the results in relationship to the metabolism of 
vitamin B-^ or its active principle, by man*
Considerable confusion still exists about 
the question of the daily need for vitamin B.^ 
by man and different experimental approaches, 
exemplified by those adopted by Darby et al (1958), 
by Grasbeck (1959) and by Reizenstein (1959cd) 
have given apparently widely dissimilar results* 
Darby et al (1958) t reated patients with 
pernicious anaemia by daily injections of 0.5 
to 2.0 ug vitamin and observed the effect 
not only on peripheral blood value s but on red 
cell size. In spite of earlier reports to the 
contrary (Larsen 1948, 1951, 1952, Owrens 1951) 
the red cell size in treated pernicious anaemia
(276)
/is normal (Adams 1956) and macrocytosis is now 
regarded as an early sign of vitamin B ^  deficiency 
(Herbert 1959). The patients studied by Darby 
et al (1958) did not have macrocytosis and 
maintained normal peripheral blood values and the 
authors concluded that a daily injection of 0.5 
to 2.0 ug was adequate maintenace therapy and 
therefore that this figure was also the daily 
need for vitamin i*1 man.
G-rasbeck (1957) adopted a different approach.
He assumed the elimination of vitamin B ^
followed first order kinetics and by noting the
time taken to develop clinical evidence of
vitamin B12 deficiency following total gastrectomy
and assuming that the body stores had by then
dropped to less than a tenth of normal, he
calculated that the velocity constant (k) was
-I
0.0015 - 0.0030 days giving a utilisation of 
0.15 - 0.30% of body stores per day. Taking the 
normal body stores to be 3900 ug this was 5.9 - 
11.7 ug/day.
Reizenstein (1959c) obtained his value of 
7.0 ug/day for normal utilisation by analysis of
(277)
/data obtained from patients who had been given 
small (0*5 ug) doses of Go vitamin and whose 
urinary and faecal excretion had been measured 
over long periods*
The link between these apparently discrepant 
findings may lie in the finding of a correlation 
between the logarithm of the retained dose and 
its duration of effect in terms of maintaining 
a serum vitamin B^  at, or above, the lower limit 
of normal. Such a correlation implies that 
utilisation does not occur at a constant rate 
(as it would if the correlation were between dose, 
as opposed to logarithm of dose,retained, and 
duration of effect) but at a rate proportional 
to the concentration (van Gemert & Buyff 1950).
The correlation only applies t o  one compartment, 
the plasma, of a multicompartment system. It 
would not be unexpected to find that it applied 
to other compartments and there i s  already some 
evidence that this occurs in the liver (Glass 
et al 1958, Schloesser et al 1958) which may be 
the m a j o r  compartment. I f  i t  d i d  s o  then there 
c o u l d  be n o  s u c h  t h i n g  as a 1 d a i l y  requirement
(278)
/for vitamin as the amount utilised each day
would depend on the amount in the body. It would 
however, be quite permissible to speak of 
a 'minimum daily requirement', that is, an 
amount just sufficient to prevent the appearance 
of signs of deficiency from appearing but this 
value should not be confused with the amount 
utilised under normal conditions. The calculation 
of 'utilisation values' obtained by dividing 
the amount of vitamin retained by the duration 
of effect in days (Adams 1961c) giving values of 
about 5.5 ug/day after a 1000 ug injection and 
about 1.7 ug/day after a 50 ug injection cannot 
be accepted as mathematically valid in view of 
the fact that the duration of effect as measured 
by the time taken for the serum vitamin level 
to fall to the preinjection value has since been 
shown to be proportional to the logarithm of 
the effective dose as opposed to the effective 
dose but at least it illustrates the point, which 
can be expressed succintly - high logarithm 
concentration - high utilisation: low logarithm 
concentration - low utilisation.
(2?9)
/ Extrapolation from the equation 
Y s 17.0886x — 0,4270 where y s duration of 
effect in days and x = logarithm of dose retained 
to find a retained dose with an effect of one 
day would give a value for minimum daily need 
to maintain a serum vitamin B-^ level at or 
above 140 uug/ml but it would obviously be 
unwise to do this. However, it should be noted 
that after an injection of 50 ug, the smallest 
dose used, the calculated retained dose is 
38 ug and that the calculated duration of effect 
of this retained dose is 26 days suggesting that 
the minimum daily need, that is, the amount just 
sufficient to maintain the serum vitamin B ^  
at or above 140 uug/ml and to prevent the 
appearance of signs of deficiency, is probably 
in the region of that suggested by Darby et al
(1958).
As already noted it is not possible to use 
the results to calculate dose schedules which 
would ensure normal utilisation of vitamin B^2 
by patients with pernicious anaemia. Q-rasbeck
(1959)* working on the assumption that utilisation
/follows first order kinetics, has suggested 
that a retained dose of 300 ug each month 
would ensure normal utilisation. A dose schedule 
of 1000 ug intramuscularly each month, originally 
tested on a purely empirical basis (Fig. 95) 
would certainly ensure retention of the amount 
suggested by Grasbeck (1959) and should probably 
be regarded as more physiologically acceptable 
than the minimum effective dose schedules already 
suggested.
The results in relation to the turnover of
Vitamin in plasma
The correlation of the logarithm of the
retained dose and the duration of effect probably
applies to the plasma compartment only as the
duration of effect was measured only in this
compartment. Information about the turnover
in this compartment can therefore be obtained
by analysing the data further. From the results
and findings already given it can be calculated
by the methods described by Dawes (1956) that the
58
biological half life (T-g-) of injected Go 
vitamin B12 is 5.14 days and that the velocity
(2832)
/constant (k) is 0 .134-7 days. Th.es© values 
correspond closely to Reizenstein's (1959c) 
estimate of T^-^6 days. The closeness of the 
estimates is satisfying particularly as they were 
obtained by totally different methods. Co vitamin 
Bl2 was used in both investigations and it might 
appear that recent work by Reizenstein et al 
(1961) on the equilibration of injected Co 
vitamin B^2 with the tissue stores casts doubts 
on the validity of the results. This is unlikely 
to be so, at least with the results presented 
here. The calculation of biological half life 
and velocity constant depend on the slope of 
the regression line obtained from the regression 
equation and the values used in calculating these 
are independent of the problems of equilibration,
Co vitamin B^2 being used solely to measure excretion 
in the 24 hours after injection, which has been 
shown to be a valid procedure, and the duration 
of effect being measured essentially by 
microbiological assay and not dependent, as in 
Reizenstein1s (1959c) studies, on tissue 
radioactivity or continuing urinary or faecal
/excretion of radioactivity. The short 
biological half life of injected vitamin B^2 
in the plasma compartment contrasts sharply with 
that in the liver, probably , the main storage 
organ, and the body as a whole which have been 
calculated to average about 12 months, (Schloesser 
et al 1958, Glass 1956, Grasbeck 1959>
Reizenstein 1959cd).
( 2 8 j )
SOMMABY
A series of experiments were planned with
the object of defining principles on which
maintenance therapy for patients with pernicious
anaemia should be based.
The common feature of the experiments was the
determination of the duration of effect of an 
58injection of Co vitamin B ^  by estimating the
time for which the serum vitamin level remained
above the lower limit of normal after the
58injection. The amount of Co vitamin B ^  
which produced this effect was estimated by 
measuring the urinary loss after injection and 
assuming that this proportion had no therapeutic 
effect•
In the first experiment the duration of
58
effect of injections of Co vitamin B12 given 
to patients with low serum vitamin B12 levels 
in haematological relapse was compared to the 
effect of subsequent injections of the same 
dose given when the serum vitamin B ^  levels 
were higher. T h e  f i n d i n g s  suggest that the 
effect of the f i r s t  i n j e c t i o n  i s  l e s s  t h a n  the
(28ft)
/effect of the second injection and that this 
effect is not related to a greater amount of 
vitamin B ^  retained in the body after the second 
injection.
In the second experiment the duration of
58effect of different doses of Co vitamin B^2
was observed in the same patients, the methods
used being similar to those in the first experiment.
The results show that the duration of effect of
a large dose is less than might be expected
compared to a small dose and that the difference
is not due to a greater amount retained after the
large injection.
In the third experiment in which a small
number of vitamin B ^  deficient patients in
haematological relapse were given a series of 
58injections of Co vitamin B-^ and the duration 
of effect established, it was clear that the
duration of effect was less than might be expected
58from the amount of Go vitamin B12 retained.
Analysis of selected results obtained mainly 
in the second experiment disclosed a linear 
relationship with a coefficient of correlation
(285)
/differing significantly from zero between the 
logarithm of the retained dose of ^Co vitamin 
Bf2 and the duration of effect.
By calculating from the equation relating
58
the logarithm of the dose of Co vitamin 
injected and percentage of dose excreted in 
urine (Chapter 6) and further calculating from 
the equation relating the logarithm of the retained 
dose to the duration of effect, various dose 
schedules were constructed. Such schedules 
constitute minimum effective treatment, that is 
treatment which should succeed in maintaining 
the serum vitamin level at or above the lower 
limit of normal. The value of these schedules 
is discussed and the place of ideal or optimal 
dose schedules is also discussed.
The literature on the subject of maintenance 
therapy is reviewed in the light of the findings 
and the economic aspects of treatment and the place 
of massive parenteral vitamin B12 therapy are also 
reviewed. The value of the suggested dose 
schedules in the treatment of vitamin 
deficiency states, other than pernicious anaemia,
(286)
/is discussed and the place of other forms of 
vitamin therapy is considered#
The findings are discussed in relation to 
the utilisation of vitamin and the normal 
need for vitamin The half life of vitamin
B ^  i*1 ike plasma compartment was estimated from 
the results and the value obtained approximates 
closely to a value obtained by other methods*
(287)
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CASE A.H. CONTROL PATIENT - 54 ug SERIES
DAT 58cc b 12
INJECTION
24 HOUR URINE COLLECTION
VOLUME
ml*
RADIOACTIVITY 
% dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug.
0 — 630 0 0.015
1 54 ug i.m. 1290 11.5 3.0
2 H 550 1.3 0*3
3 N 600 15.6 6*3
4 tl 1660 15.8 4*0
5 II 1800 13.1 3*9
6 II 2000 10.9 2*7
7 II 1350 17.0 7*0
8 11 2350 23.4 9.3
9 It 1370 7.5 2.0
10 It 1450 21.0 5*3
11 — 1750 0 *•
Table A.2 — showing detailed results obtained from Case A.H. 
Each value for total assayable vitamin is the mean of at 
least two estimations: values have been rounded off to the 
first decimal place*
(4)
CASE HaicS. CONTROL PATIEHT - 54 ug SERIES
DAT 58ro *C B12
INJECTION
24 HOUR URINE COLLECTION
VOLUME
ml*
RADIOACTIVITY
dose
TOTAL 
ASSAYABLE 
VITAMIN Bl2
ug.
0 — 1650 0 <0.04
1 34 ug i.m. 1170 19.6 8.0
2 It 2190 26.0 12.9
3
It 1440 28.1 12*3
4 It 238O 27.3 13.6
5 It 2350 25.7 10.9
6 H 2390 31*4 13.7
7 H 2310 32.4 15.6
8 H 2380 31.4 14.9
9 II 2150 * 28.0 13*4
10 II 2350 33.5 15.7
11 — 2330 0 mm
Table A.3 - showing detailed results obtained from Case H.McG. 
Bach value for total assayable vitamin is the mean of at 
least two estimations: values have been rounded off to the 
first decimal place*
(5)
CASE J.McM. CONTROL PATIENT - 54 ug SERIES
DAT
24 HOUR URINE COLLECTION
58Po -R 
Co 12
INJECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug
0 1680 0 <0.04
1 54 ug i.m* 800 1.4 0.2
2 ti 1350 7.9 2.8
3
n 1440 12.1 4.3
4 it 1030 12.9 4.1
5 n 1060 10.3 3.6
6 H 660 1.0 0.1
7 It 1110 15.8 6.3
8 n 740 4.6 0.7
9
ti 1040 12.8 3-7
10 n 1130 12.5 4.4
11 — 770 0 mm
Table A.4 - showing detailed results obtained from Case J.McM. 
Each value for total assayable vitamin is the mean of 
at least two estimations: values have been rounded off 
to the first decimal place.
(6)
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CASE J.C. C0HT50L PATIENT -  100 n ff SERTWS
DAT 58Pn *
Co 12 
INJECTION
24 HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B 2 
u g
0 - 1050 0 <0.04
1 100 ug i.m. 1110 20.9 26.6
2 - no <collection
3 100 ug i.m. 1950 25.2 22.4
4 n 2090 35.1 32.9
5 H 2070 28.8 26.9
6 »i 1730 29.7 31*1
7 it 2515 30.5 25.6
8 tt 2150 38.7 37.9
9 « 1620 27.2 17.8
10 ti 1520 56.8 33.7
11 M 1270 30.5 29.6
12 II 1410 26.5 17.8
13 If 1970 40.9 44*8
14 I I 2150 39.5 41*3
15 It 1480 27*5 27.7
16 1 620 7.7 4*8
(8 )
CASE J.C. (contd*)
24 HOUR URINE COLLECTION
DAI
58(30 B12 
INJECTION
VOLUME
mlo
RADIOACTIVITY 
io dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug
17 M 1000 20.2 14.7
18 tt 2020 51.0 52.5
19 — 1560 0 —
Table A.6 - showing detailed results obtained from Case J.C• 
Each value for total assayable vitamin is the mean of 
at least two estimations: values have been rounded off to the 
first decimal place*
(9)
CASE M .C» CONTROL PATIEM 1 -  100 ug SERIES
DAT
24 HOUR URINE COLLECTION
58(30 B12
INJECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B 2 
ug
0 0 550 0 0.016
1 100 ug i.m. 400 32.4 30.0
2 ti 600 45.6 48.6
3 it 660 33.1 36.7
4 - 1020 0 0.6
5 100 ug i.m** 1240 27.2 24.7
6 »» * 620 20.0 19.4
7 « * 1160 47.1 57.2
8 - 600 0 0.1
9 100 ug i.m. 970 27 «5 26.8
10 it 790 43.5 48.1
11 ti 910 50.3 53.9
12 - 910 0 0.3
13 100 ug i.m.* 630 33.2 40.0
14 *» * 910 62.0 50.9
15 tt * 800 51.3 58.0
16 - 400 0 0.1
(10)
CASE M .C . (o o n td .)
DAI
INJECTION
24 HOUR URINE OOLL0COTOM ;
VOLUME
ml.
RADIOACTIVITY
f> dose
TOTAL'
ASSAYABLE
VITAMIN BL0 12 I
ug
17 100 ug i.v. 520 43*5 52.5 !
18 tt 810 52.3 61.5
19 ti 1300 51.5 79.7
20 510 0 0 .3
21 1OO 04) t .V. 650 41.2 51.1
22 t 1000 45*2 55*0
23 t 1360 52.1 69.3
24 - 1250 0 -
Table A*7 — showing detailed results obtained from Case M.C* 
Each value for total assayable vitamin is the mean, of at 
least two estimations* values have been rounded off to the 
first decimal place.
* Probenecid was given orally as described in. Chapter' 3»
(1 1 )
CASE J .F .  COHTROL PATIEKT -  ICO ug SERIES
DAI
24 HOUR URINE COLLI
0a0
58Co B12
INJECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug
0 - 760 0 0.019
1 100 ug i.m. 820 42.0 33.3
2 - 625 0 0.1
3 100 ug itin, 815 44.7 42.2
4 - 950 0 0.2
5 100 ug i#m. 920 45.1 47.B
6 - 1310 0 0.2
7 100 ug i.m. 1110 48 .0 50.7
8 - 1130 0 0.1
9 100 ug i .ra. 730 49 o2 50.3
10 - 830 0 0.1
11 100 ug i.m. 1395 66.6 54.7
12 - 1570 0 0.1
13 100 ug i.m. 1890 60.9 63.8
14 - 1460 0 0.1
15 100 ug i.m. 1890 46.2 45.3
(1 2 )
CASE J .F. (contd •)
24 HOUR URINE COLLECTION
DAY 58p *Co B12
INJECTION
VOLUME RADIOACTIVITY
TOTAL 
ASSAYABLE 
VITAMIN B12
ml. *fo dose ug
16 - 860 0 0.8
17 100 ug i.m. 1300 47.2 57.8
18 — 1170 0 0.1
Table A .8 — showing detailed results obtained from Case J.F. 
Each value for total assayable vitamin is the mean of at 
least two estimations? values have been rounded off to the 
first decimal place«
(13)
CASE H .F . CONTROL P A T IE ffl -  100 ug SERIES
M Y
24 HOUR URINE COLLECTION
58
Co B12 
INJECTION
VOLUME
ml.
RADIOACTIVITY 
io dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug.
0 - 710 0 0.001
1 100 ug i.m* 1230 34.0 34.4
2 - 1700 0 0.1
3 100 ug i.m.* 1900 18.3 15.5
4 - 1360 0 0.1
5 - no collection
6 100 ug i.m. 950 52.1 52.4
7 » * 2610 64*4 70.9
8 tt 720 56.7 59.9
9 tt * I960 60.4 62.9
10 u 890 62.9 65.4
11 it * 1670 59.8 63.8
12 t 890 61.3 66.7
13 t * 1730 60.3 64*9
14 it 820 55.1 61.5
15 t * 1620 64.6 69*6
16 t 950 62.8 65.8
(14)
CASE H .F. (contd •)
BAY 58Pn -R 
C° 12 
INJECTION
24 HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY 
io dose
TOTAL 
ASSAYABLE 
VITAMIN B 2 
ug.
17 n * 1770 56.6 64.9
18 ti 900 54.2 59.4
19 H * 1910 51.0 53.9
20 - 1700 0 -
Table A.9 “ showing detailed results obtained from Case H.F. 
Each value for total assayable vitamin is "kke of
at least two estimations: values have been rounded off to 
the first decimal place.
*Mersalyl was given intramuscularly as described in Chapter 3*
(15)
CASE K.McD. CONTROL PATIENT - 1QO ug SERIES
DAY
24 HOUR URINE COLLECTION
58
Co B12 
INJECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B12 
ug
0 - 670 0 0.14
1 100 ug i.m. 495 31.8 32.4
2 " i.v. 650 52.5 57.2
3 M i.m. 430 45.2 49.4
if " i.v* 615 53*6 55.9
5 1 i.m. 825 51.9 51.0
6 " i.v. 1020 62.0 71.0
7 n i.m. 800 53.7 52.8
8 ” i.v. 660 59*8 54.3
9 " i.m. 780 57*8 59.0
10 " i.v. 980 58.8 56.1
11 n i.m. 830 50.5 51.6
12 ” i.v. 970 55-9 54.8
13 " i.m. 1480 55.7 58.4
14 ” i.v. 985 56.3 54.1
15 ” i.m. 970 58.2 58.2
(1 6 )
CASE K.McX). (Contd.)
M Y 58Co B12 
INJECTION
24 HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B 
ug 12
16 " i.v. 670 51.8 47.3
17 " i.m. 910 55.2 50.0
18 — 900 0 —
Table A.10 - showing detailed results obtained from 
Case K.McD. Each value for total assayable vitamin Bg 
is the mean of at least two estimations: values have been 
rounded off to the first decimal place*
(17)
BOBDERLIHE SUBJECTS -  100 ug SEHIES
CASE
24 HOUR URINE COLLECTION
SERUM 
VITAMIN B12
uug/ml•
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B 2
ug
H.C. 199 1700 40.5 a . 6
H.F. 151 1000 43.9 42.3
J.O.G. 192 1360 36.4 38.3
M.G. 172 1380 33.2 31.1
J.O.H. 130 1820 41.0 43.6
J.O.H. 126 1470 43.1 41.7
D.J. 124 980 31*3 35.6
D.J. 151 900 2.0 0.3
J.L. 198 690 35.6 44*1
J.L* 180 2230 37.4 48.3
M.McB. 131 1220 46.3 58o5
M.McB. 109 1245 41.5 31.1
M.McB, 114 1500 34.1 35.6
I .McC . 120 1170 42.3 46.8
I .McC • 145 1000 47.2 45.5
I.McC, 133 1430 43.2 51.0
E.P. 149 1215 42.7 40.0
E.P, 147 1300 48.9 55.9
I.H. 106 1130 21.2 24.6
A.T. 122 2390 50.5 52.6
A.T. 179 1200 45.9 47.4
A.T. 112 1650 45.6 46.5
(1 8 )
BORDERLINE SUBJECTS (Contd.)
CASE
SERUM 
VITAMIN B12
uug/ml.
24 HOUR URINE COLLECTION
VOLUME
ml*
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug
M.T. 104 740 24*1 18*7
I.W. 142 710 47.2 59.2
I.W. 177 1650 50*3 4^ *8
I*W. 137 1320 50*7 49.2
Table A.11 - showing detailed results obtained from
’borderline1 group of patients in the 100 ug series* Each
value for total assayable vitamin is the mean of at
least two estimations: the serum vitamin B^ level was
estimated on a sample taken immediately prior to the
58injection of 100 ug Co vitamin B^2 intramuscularly* 
Values have been rounded off to the first decimal place*
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CASE G.G. CONTROL PATIENT - 540 ug SERIES
DAT
24 HOUR URINE COLIACTION
58rn -r c° B12
INJECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug
0 - 1415 0 <0.035
1 540 ug i.m. 910 55.8 346
2 i 1350 75.3 432
3 n 910 70.3 398
4 ti 1100 70.8 376
5 it 1020 77.8 440
6 n 1450 58.0 301
7 it 1800 76*9 427
8 tt 1750 62.4 346
9 it 1110 72.7 383
10 t 1290 80.4 416
11 H 1730 74.4 409
12 I 1350 75.8 408
13 t 1230 60.2 320
14 t 1290 75.8 422
15 It 1500 64.5 355
(22)
CASE Q.d. (oontd.)
24 HOUR URINE COLLECTION
M Y 58Co B12
INJECTION
VO LIMB 
ml#
RADIOACTIVITY 
% dose
TOTAL 
ASSAYABLE 
VITAMIN B 
u g
16 ti 1470 77-9 448
17 it 1200 71.1 414
18 it 1320 75.6 452
19 - 1230 0 -
Table A#14 - showing detailed results obtained from 
Case G.Gr* Bach value for total assayable vitamin B^2 
is the mean of at least two estimations: values have been 
pounded off to the nearest whole number#
(23)
CASE J.J* CONTROL PATIENT - 540 ug SERIES
DAY 5 8 ° °  B12  
INJECTION
2 4  HOUR U R IN E  C O LLEC TIO N
VOLUME
ml*
R A D IO A C T IV IT Y  
ia dose
TO TAL  
ASSAYABLE  
V IT A M IN  B 2  
ug
0 - 4 0 0 0 < 0 . 0 1
1 5 4 0  ug i*m* 1910 7 5 . 4 4 0 6
2 it 2 3 8 0 6 3 . 9 3 5 1
3
t 1 9 8 0 7 4 . 0 3 4 9
4 t 1 9 4 0 6 8 * 0 3 8 3
5 t 2 3 7 0 6 9 . 7 3 7 6
6 t 2310 68.3 364
7 t 2 3 7 0 7 4 . 3 421
8 tt 2310 7 7 . 1 4 3 9
9
it 2 3 7 0 7 5 . 0 3 4 4
1 0 tt 1 7 1 0 7 7 . 7 4 3 2
1 1 tt 1 7 5 0 7 6 . 2 4 7 0
1 2 1 4 8 0 6 8 * 1 3 8 1
1 3
n 2 3 8 0 7 3 . 5 4 0 5
1 4 tt 2230 7 4 . 1 3 9 3
1 5
ti 1 6 9 0 6 0 * 8 3 4 1  1
1 6 - 2 3 4 0 0
’
Table A.15 - showing detailed results obtained from Case J*J* 
Each value for total assayable vitamin B ^  is the mean of at 
least two estimations: values have been rounded off to the 
nearest whole number*
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CASE J .A .  CONTROL PATIENT -  1000 ug SERIES
DAY 5Srn B c° b12
INJECTION
24 HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B 2 
u g .
0 — 600 0 0.04
1 1000 ug i.m. 1070 48.2 4 86
2 - 2085 0 2
3 - 2970 0 0
4 1000 ug i.m. 3040 80.0 729
5 - 2400 0 5
6 1000 ug i.m. 2920 76.9 757
7 - 1800 0 2
8 1000 ug i.m. 2125 68.0 841
9 - 1930 0 4
10 1000 ug i.m. 1900 71.5 887
11 - 2360 0 9
12 1000 ug i.m. 2390 62.3
00COc—
13 - 2460 0 16 |
14 1000 ug i.m. 2090 25.4 363 j
15 — 2000 0 2 i 1
16 1000 ug i.m. 2260 79.5 861 t1
17 - 1200 0 8 !
18 1000 ug i.m. 1340 40.7 W 2
19 - 2090 0 0
20 1000 ug i.m. 2100 75.0 917
21 - 910 0 1
(26)
CASE J.A. (contd.)
24 HOUR URINE COLLECTION
BAT * C o  .12
INJECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug
22 1000 ug i.m* 1630 88.0 929
23 - 850 0 1
24 1000 ug i.m. 1330 74.4 911
25 1060 0 3
Table A. 17 - showing detailed results obtained from 
Case J.A* Each value for total assayable vitamin 
is the mean of at least two estimations: values have been 
rounded off to the nearest whole number*
(27)
CASE I . e .  CO m O L PATIENT -  1000 ug SERIES
DAT
24 HOUR URINE COLLECTION
INJECTION
VOLUME
ml.
RADIOACTIVITY 
% dose
TOTAL
ASSAYABLE
VITAMIN
12
ug
0 - 1380 0 0.045
1 1000 ug i.m. 550 67.4 843
2 - 475 4.1 32
3 1000 ug i.m.* 1980 55.2 746
4 - 450 6.9 85
5 1000 ug.i.m. 690 59.2 645
6 - 550 22.0 253
7 1000 ug i.m.* 2860 59.0 772
8 - 810 8.2 75
9 1000 ug i.m. 1350 71.5 924
10 - 1570 0 4
11 1000 ug i.m.* 2060 67.9 817
12 - 650 8.2 49
13 1000 ug i.m. 1400 80.0 942
14 - 1240 0 32
15 1000 ug i.m.* 2250 71.3 778
16 - 730 5.5 28
17 1000 ug i.m. 1225 81.2 938
18 - 960 0 28
19 1000 ug i.m.* 2050 52.3 660
(28 )
CASE I . C .  ( c o n td . )
DAY
24 HOUR URINE COLLECTION
58pn *
Co 12
INJECTION
VOLUME
ml.
RADIOACTIVITY 
in dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug
20 — 780 12.7 42
21 1000 ug i.m. 1170 78.6 877
22 - 1420 0 35
23 1000 ug i.m.* 2300 6O.4 795
24 - 650 0 22
25 1000 ug i.m. 920 67.2 763
26 - 1570 17.0 135
27 1000 ug i.m.* 2510 84.5 820
28 - 900 0 20
29 1000 ug i.m. 690 60.9 569
30 - 750 6.6 24
31 1000 ug i.m.* 2300 84.I 897
32 — 670 5.5 9
Table A.l8 - showing detailed results obtained from 
Case I.C. Each value for total assayable vitamin 
is the mean of at least two estimations: values have been 
rounded off to the nearest whole number.
*Mersalyl was given intramuscularly as described in Chapter 3*
(29)
CASE J .S .  CONTROL PATIENT -  1000 ug SERIES
24 HOUR URINE COLLECTION
DAY 585 Co B12 
INJECTION
VOLUME
ml.
RADIOACTIVITY 
io dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug
0 - 1680 0 0.04
1 1000 ug i.m** 510 24.2 262
2 " * 1210 72.2 814
3 » * 1110 67.1 739
4 - 1250 0 1
5 1000 tig i.m. 1850 75.7 875
6 t 1150 76.5 866
7 t 1755 75*3 948
8 - 2350 0 8
9 1000 ug i.m.* 1885 69.4 777
10 tt * 2030 63.3 853
11 tt * 1970 65.4 857
12 - 2000 0 6
13 1000 ug i.m. 1950 65.9 836
14 it liflO 79.7 973
15 t 2360 16.3 1097
16 1000 ug i.v. 1760 59*5 695
17 n I960 61.6 852
18 t 1680 72 #7 907
(30)
CASE J.S. (contd.)
24 HOUR URINE COLLECTION
DAT 58(30 B12
INJECTION
VOLUME
ml*
RADIOACTIVITY 
56 dose
TOTAL 
ASSAYABLE 
VITAMIN B 2 
ug
19 1000 ug i*v* 1750 77.6 936
29 h 2170 114.0 1497
21 it 1500 44.2 543
22 — 1680 0 —
Tal)le A.19 - showing detailed results obtained from Case J*S* 
Each value for total assayable vitamin is the mean of 
at least two estimations: values have been rounded off 
to the nearest whole number*
* Probenecid was given orally as described in Chapter 3«
(31)
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CASE C.D. CONTROL PATIENT - 1140 ug SERIES
DAY
24 HOUR URINE COLLECTION
58Cn -R o B12
INJECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIN B12 
ug
0 — 1330 — < 0.03
1 1140 ug i.m. 1170 68.0 795
2 II 1260 86.0 869
3 t 500 31.1 320
4 - 770 0 6
5 1140 ug i.m.* 1080 71.2 815
6 •• * 510 56.0 698
7 t» * 1050 75-2 887
8 - 900 0 6
9 1140 ug i.m. 1020 75.3 882
10 « 1200 81.5 1068
11 t 750 67.7 878
12 - 1100 0 7
13 1140 ug i.m.* 1700 75.5 943
14 « * 2280 75-6 942
15 t * 2230 70.9 937
16 - 1730 0 4
17 1140 ug i.m. 2020 69.4 969
18 tt 1250 42.1 513
19 1340 0 4
(33)
CASE C.D. (contd.)
24 HOUR URINE COLLECTION
BAY 58°o B12
INJECTION
VOLUME
ml.
RADIOACTIVITY 
% dose
TOTAL 
ASSAYABLE 
VITAMIN B12
ug
20 1140 ug i.m.* 1180 74.5 920
21 « * 1050 77-3 935
22 - 600 0 1
Table A.21 - showing results obtained from Case C.D.
Each value for total assayable vitamin B^ is the mean of 
at least two estimationss values have been rounded off to 
the nearest whole number.
* Probenecid was given orally as described in Chapter 3*
(34)
CASE H .K . CONTROL PATIENT -  1140 ug SERIES
BAY 58Co B12 
INJECTION
24 HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
TOTAL 
ASSAYABLE 
VITAMIK B12
U g
0 - 580 0 CU493
1 1140 ug i.m. 830 71.6 963
2 - no collection
3 1140 ug i.m. 780 66.5 858
4 -  - no collection
5 1140 ug i.m. I63O 77.6 978
6 - 1610 0 4
7 1140 ug i.m. 1780 70.7 912
8 I I 1400 72.1 959
9 I I 1700 76.3 1062
10 I I 2250 77.0 913
11 I I 950 55*0 618
12 It 2280 55.5 611
13 I I 1850 61.8 738
14 H 1950 44*2 585
15 I I 1620 72.8 907
16 I I 1230 47.8 901
17 I I 1110 52.8 402
18 - 1200 0 -
Table A.22 - showing- detailed results obtained from Case H.K.
Each value for total assayable vitamin B^  is the mean of at 
least two estimations; values have been rounded off to the
nearest whole number.
(35)
BORDERLIKB SUBJECTS -  ll ii .0  ug SERIES
CASE
SERUM 
VITAMIN 3 2
uug/ml
24 HOUR URINE COLLECTION
VOLUME
ml*
RADIOACTIVITY 
i* dose
TOTAL 
ASSAYABLE 
VITAMIN B 2
ug
E.C. 90 1710 74.8 872
E.V.C. 178 970 64.9 747
H.C. 178 1900 79.2 846
T.C. 144 1540 72 *6 929
H.F. 197 950 77.9 924
J.G. 120 880 76.1 898
J.O.G. 158 1700 71.1 774
J.O.H. 115 1700 65.3 592
D.J. 131 1020 5 6.6 669
J.K. 93 530 65.3 816
J.L. 191 1430 76.7 909
I.McC. 145 910 76.7 910
T*McG* 138 570 70*4 862
E.P. 190 620 71.4 930
I.H. 160 1040 75.2 880
M.R. 88 1575 70*5 977
M.T. 160 700 44*7 529
Table A *23 - showing details of results obtained from
borderline group of patients 1140 ug series* Each value
for total assayable vitamin is the mean of at least two 
estimations: values have been rounded off to the nearest
whole number. The serum vitamin level was estimated
on a sample taken immediately before the intramuscular
58injection of 1140 ug Co vitamin
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TABLE A.29 - CASE J.A.M.
BAY 58co
VITAMIN B_p ■ 
INJECTION1
ug.
24 HOUR URINE COLLECTION
VOLUME 
ml •
RADIOACTIVITY
EXCRETED
$ dose
0 - 520 0
1 100 im 920 13-2
2 tt 990 20.1
3 11 sample lost
4 ti 1040 15.4
5 - 750 0
6 100 im 1040 40 *4
7 780 0
8 \  o o ltn 450 10.2
9 H 370 40.0
10 ft 740 33.7
11 II 1440 42.7
12 - 1000 0
Table A.29: showing detailed results obtained from
58
Case J.A.M., given repeated injections of Co 
vitamin 2^2* in^ervals one to tw0 days. Tie 
patient was in haematological relapse with a low 
serum vitamin B ^  level on day 0.
(42)
TABLE A.30 - CASE P.A.
WEEK 5 CO
VITAMIN B 
INJECTION
. . . . . . . ................................. — 1 ------------ .
POST INJECTION 
24 HOUR URINE COLLECTION
VOLUME RADIOACTIVITY
ug. ml. $ dose
1 1000 im 1630 66.2
2 n 1900 66.7
3 ti * 1900 75.0
4 1650 55.7
5 2330 80.3
6 11 2180 54.9
7 11 ^ 2140 90.4
8 it 2180 82.5
32 11 1630 62.2
33 II * 1400 92.4
34 tl 1430 81.8
35 1550 82.4
Table A.30: showing detailed results obtained from Case F.A.
58
given repeated injections of Co vitamin at 
intervals of at least one week. The patient had been 
treated with vitamin B ^  and was in full haematological 
remission and not excreting radioactivity prior to this 
study*
*Oral probenecid was given with the injections on weeks 
3, 4, 7, 8, 33 & 35 and vitamin between weeks 8 &
32 as described in Chapter 3*
(43)
TABLE A.3.1 - CASE J.D.
BAY 5^C0
VITAMIN B p  
INJECTION 
___ ug.
21+ HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
0 900 0
1 1000 im 1260 72.9
2 t 980 33.1
3 - 1230 0
4 1000 iv 1520 79.9
■5 t 1600 83.3
6 - 2000 0
7 1000 im 1800 69.8
8 h 2000 84.8
9 - 1530 0
10 1000 iv 1900 82.7
11 t 2030 70.9
12 - 1770 0
13 1000 im 1550 75.9
14 t 1900 89.0
15 - 1120 0
16 1000 iv 1230 61,9
17 t 1700 82,6
18 - 1750 0
Table A .JLi showing detailed results obtained from Case J.D,
58
given repeated injections of Co vitamin intervals
of one to two days. The patient was in haematological 
relapse with a low serum vitamin B ^  level on day 0.
(44)
TABES A.32 - CASE S.J.
BAY CO
VITAMIN B 2 
INJECTION 
u g
24 HOUR URINE COLLECTION
VOLUME 
ml.
RADIOACTIVITY 
io dose
0 680 0
1 1000 im 720 70.0
2 n 740 77.4
3 tt 620 51.2
4 - 1000 0
12 1000 im 1230 83.0
13 i« 1150 63.3
14 n 680 84*8
15 it 940 84.5
16 tt 870 59.3
17 mm 900 0
Table A.32: showing detailed results obtained from
58
Case S.J. given repeated injections of Co vitamin 
at intervals of one to two days. The patient was in 
haematologieal relapse with a low serum vitamin B ^  
level on day 0.
(45)
TABLE A.33 - CASE E.McB.
WEEK v
n 00
o o POST INJECTION
VITAMIN B 2 24 HOUE UHINE COLLECTION
INJECTION VOLUME RADIOACTIVITY
ug. ml* i dose
1 1000 ug im 1770 45.5
2 it 1520 40.0
3 »t 1670 54.3
4 tt 1730 61.2
5 tt * 715 42.4
6 tt ^ 930 19.3
7 tt * 860 62*0
12 tt 1440 61*6
13 « * 840 64.5
15
*tt 1700 55.8
16 tt * 830 63.8
18 tt 1500 53*9
Table A»33* showing detailed results obtained from
58
Case E.McB* given repeated injections of Co vitamin
at intervals of at least one week* The patient was
in haematological relapse and was not excreting
%
radioactivity prior to the study* Vasopressin was 
also given on weeks 5> 6* 7> 13> 15 & 16 as described 
in Chapter 3«
(46)
Table A.34 - CASE J.IicF.
WEEK v_
n OO o O POST INJECTION
VITAMIN B 2 24 HOUR URINE COLLECTION
INJECTION VOLUME RADIOACTIVITY
ug. ml. fo dose
1 1000 im 1500 36.0
2 ii 1510 55.6
3 »i * 2450 54^3
4 u * 2540 52.8
5 ti % 1975 73.9
6
%
It 2355 65.O
11 tt 1550 64.I
12 * 1900 75.7
13 II 1750 71.2
14 1210 56*7
16
*II 2690 70*5
17 II 1230 77.3
Table A.34* showing detailed results obtained from
58
Case J.McF. given repeated injections of Co 
vitamin at internals of at least one week*
The patient had been treated with vitamin B ^
and was in full haematological remission and not 
excreting radioactivity prior to this study* Oral 
chlorothiazide was given with the injections on 
weeks 3> 4> 5» 8, 12, & 16 as described in Chapter 3*
(47)
TABLE A.35 - CASE M.P.
WEEK CO
VITAMIN B ? 
INJECTION
L_____ Ug........
24 HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY 
io dose
1 1000 im 1460 65.3
2 tt 1070 61.5
3 ti 1115 63.9
4 tt 1090 65.0
9 tt 1020 64.3
10 it 900 55.9
li tt 1750 54.6
12 1310 69.0
13 tt 950 72.4
14 tt 1060 72.8
15 tt 1370 62.3
16 tt 1420 81.5
Table A*35* showing detailed results obtained from
58Case M.P. given repeated injections of Co
vitamin B ^  at daily intervals. The patient was in
haemato logical relapse with a low serum vitamin B ^
level and not excreting radioactivity, prior to this 
study•
(48)
TABLE A .36 - GiiBE I.E.
WEEK 5 CO 
VITAMIN B 
INJECTION
_ ug
12
POST INJECTION- 
24 HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
1 1000 irn * 2500 73.4
2 tt
*
I64O 24.1
3 tt 2175 54.5
4 tt
-ifc
950 45.6
5 tt
*
1550 85.1
57 11 2340 48,9
58 ti 1680 46.8
59 w 2320 88.8
61 H 1500 86.7
63 tt 1980 71o5
64 tt 1600 24.7
65 tt
*
2650 76.1
66 tt 1700 80.I
68 It 2040 51.1
70 tt I84O 86.9
71 tt
*
2010 79.9 I
74 tt 2300 69.8
7 6 tt 1350 83.1
Table A.36; showing detailed results obtained from
58
Case I.R. given repeated injections of Co vitamin 
at intervals of at least one week. The patient 
had been treated with vitamin B ^  and was in full 
haematological remission and not excreting radio­
activity prior to the study,* Oral chlorothiazide was
S'*
given 011 weeks 1, 3, 5,j[59, 63, 65, 68 & 74 and vitamin 
B12 between weeks 5 & 37 as described in Chapter 3.
(49)
TABLE A.37 - CASE A.S.
WEEK
r 58
CO POST INJECTION
. VITAMIN B 2 24 HOUR URINE COLLECTION
INJECTION VOLUME RADIOACTIVITY
_____ug..'........ ml. % dose
1 1000 im 780 59o8
2 H 900 58.0
3
*11 1210 53.1
4
*11 1370 69.3
5 1130 61.5
9 II 1130 69.8
10 H 750 61.2
11
*M 1720 55.2
12 It 1280 70 9O
13 ™ * 1360 61.5
■If tt 1120 70.3
1% « * 1160 83.2
Table A.37: showing detailed results obtained from
58
Case A.S. given repeated injections of Co vitamin
at intervals of at least one week. The patient
had been treated wjfli vitamin and was in full
haematological remission and not excreting radio-
*
activity prior to the study. Oral probenecid was 
given on weeks 3> 5> 11> 13 & 16 as described in
Chapter 3»
(50)
TABLE A.38 - CASE S.S.
DAY
58
CO
VITAMIN B
24 HOUR URINE COLLECTION
INJECTION1
ug
VOLUME
ml.
RADIOACTIVITY 
Jo dose
0 - 1350 0
1 1000 im 1750 64*4
5 *1 1930 56.8
9 n 1580 7 6.0
25 n
* 3220 56.1
32 n
*
*
2630 6O .4
39 n 2000 74*7
46 t * 1920 64*4
60 t 960 47 *0
74 n
*
-¥
1920 78.5
81 11 2715 69.3
88 ti 1205 67.1 |
95 »
*
1070 76.7
:.02 it 2490 76.0
:.09 M 1040 57.1
Table A*38s showing detailed results obtained from
58Case S.S. given repeated injections of J Co vitamin
at intervals of four to fourteen days. The
patient was in haematological relapse with a low
serum vitamin B_0 level on day 0. Mersalvl was 
12 81
given on days 25, 32, 39, 46, 102 as described
in Chapter 3*
(51)
TABLE A.39 - CASE R.T.
WEEK 58co
VITAMIN B ?
*t*r.t tm nnrr i\T*^
POST INJECTION 
24 HOUR URINE COLLECTION
INJECTION
Ug
VOLUME
ml.
RADIOACTIVITY 
% dose
1 1000 im 1990 50.1
2 M 1950 65.6
3 11 2040 49.7
4 t 1980 19*8
5 it 2100 44.0
6 n 1880 77.0
7 if 2090 64.O
11 w 2040 71.3
13 it 1840 71.3
14 t 1760 5606
15 n 1770 53.5
16 t 1400 76.4
Table A *39: showing detailed results obtained from
58Case R.T* given repeated injections of Co vitamin 
at intervals of one to four weeks* The patient 
had been treated with vitamin §nd was in full 
haeraatological remission and not excreting radioactivity 
prior to the study*
(52)
TABLE A.40 -  CASE A.E*
BAY 58co
VITAMIN Bl2 24 HOUR URINE COLLECTION
INJECTION
ug
VOLUME
ml.
RADIOACTIVITY 
io  dose
0 5^0 0
1 5000 im 660 80.9
2 ii 1700 80.5
3 n 1370 92.9
4 ii 1170 86.0
5 n 1780 86.0
6 it 1470 88.0
7 ti 1800 11*8
8 n 1190 89.2
9 « 2070 85.7
10 ti 1800 90.5
11 1870 0
Table A.40: showing detailed results obtained from
58Case A.E. given repeated injections of Co 
vitamin B ^  at intervals of one day* The patient 
was in haematological relapse with a low serum 
vitamin level on day 0.
(53)
TABLE A .41 - CASE J.G.G.
BAY » C 0
VITAMIN B 2 
INJECTION
ug
24 HOUR m tlNE COLLECTION
VOLUME 
ml.
RADIOACTIVITY 
io dose
0 — 2000 0
1 5000 im 3200 91.9
2 ii 2020 0
3 5000 im 1940 79.4
4 - 2400 0
5 5000 im 2230 82.4
6 - 1900 0
7 5000 im I87O 83.6
8 it 2050 80.4
9 tt 2040 88.3
10 n 2070 88.9
11 tt 2380 86o5
12 tt 1660 85.I
13 tt 1650 54.8
14 — 1480 0
Table A ,415 showing detailed results obtained from 
Case J.Gr.Gr, given repeated injections of Co 
vitamin at intervals of one to two days.
The patient was in haematological relapse with a low 
serum vitamin B ^  level on day Oo
(54)
TABLE A,42 - CASE J.H.
BAY CO
VITAMIN B_? 
INJECTION
ug,.....
24 HOUR URINE COLLECTION
VOLUME 
ml,
RADIOACTIVITY 
ia dose
0 600 0
1 5000 im 510 63.1
2 - 480 0
3 5000 im 530 76.4
4 - 710 0
5 5000 im 700 78,0
6 - 350 0
7 5000 im 730 86.4
8 — 520 0
9 5000 im 730 90.7
10 - 530 0
11 5000 im 780 90.3
12 - 1040 0
Table A.42: showing detailed results obtained from
58Case J,H. given repeated injections of Co 
vitamin B ^  at intervals of two days. The patient was 
in haematological relapse with a low serum vitamin 
level on day 0.
(55)
TABLE A.43 - CASS J.O.M.
DAY 58CO
VITAMIN Bip
INJECTION
ug
24 HOUR URINE COLLECTION
VOLUME 
ml •
RADIOACTIVITY 
$ dose
0 1050 0
1 5000 im 930 75«4
2 tt 1000 71.1
3 t» 1350 76.0
4 tt 1130 80.2
5 n 2070 93.4
6 it 1120 83.4
7 tt 1200 86.6
8 tt 1130 90.1
9 tt 1300 87.9
10 tt 1630 88.9
11 tt 1220 90.4
12 tt 1450 84.1
13 tt 920 0
Table A .43 s showing detailed results obtained from
58Case J.O.M. given repeated injections of J Co vitamin 
at intervals of one day. The patient was in 
haematological relapse with a low serum vitamin 
level on day 0.
(56)
TABLE A.44 - CASE D.McC.
BAY 58co
VITAMIN B p
INJECTIONug
---------------------------------- 1
24 HOUR URINE COLLECTION j
VOLUME 
ml.
RADIOACTIVITY ] 
$ dose |
0 - 2070 0
1 10,000 iv 2380 94.0
2 n 1070 100.0
3 u 1530 116.8
4 ti 1345 98.6 |
5 tt 2320 110.8
6 i i 2285 109.4
7 tt 1990 103.1
8 ti 2125 114.8 j
9 tt 925 53.1 i
10 n specimen lost
11 tt 2040 124.2
12 tt 1935 IO8.9
13 tt 2125 114.2
14 tt 1280 94.4
15 tt 2225 112.2
16 tt 1360 79 o4 ;
17 tt 1560 105.5
18 tt 1535 84.4
19 tt 1650 110.0
20 tt 1715 0
Table A.44* showing detailed results obtained from
58Case D.McC. given repeated injections of ' Co vitamin 
at intervals of one day. The patient was in 
hacmatological relapse with a low serum vitamin 
level on day 0.
(57)
TABLE A.45 - CASE M»McD.
DAY 5 CO
VITAMIN B ?
INJECTIONug
1s
24 HOUR URINE COLLECTION !
VOLUME
ml*
RADIOACTIVITY 
f> dose
0 - 450 0
1 10,000 im 815 81.6
2 - 865 3.7
3 - 1005 0
4 10,000 im 1610 70.6
5 - 1110 3.1
6 10,000 im 1065 78.5
7 - 1395 4*6
8 10,000 im 810 74.1
9 - 895 4.3
10 10,000 im 1660 74.0
11 - 1220 3.7
12 1455 0
13 10,000 im 1380 69.I
14 — 850 4.2
15 10,000 im 790 65.2
16 - 1050 5.6
17 10,000 im 1100 80.0
18 - 1170 6*0
19 — 790 0
20 10,000 im 1530 66.5
21 - 1400 5.3
22 10,000 im 1520 71.7
23 - 1260 5.5
24 10,000 im 1380 62*5
(58)
CASE M.McD. (contd.)
DAY 58co
VITAMIN B
INJECTION
ug
24 HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY
$ dose
..
25 10,000 im 1235 75.0
26 10,000 im 1415 52.2
27 10,000 im 1445 69.4
28 - 1355 7.5
29 10,000 im 1400 62.1
30 - 1800 8.0
31 — 1250
0
Table A.45* showing detailed results obtained from
58Case M.McD. given repeated injections of Co 
vitamin at intervals of two to three days.
The patient was in haematological relapse with a low 
serum vitamin B ^  level on day 0.
(59)
TABLE A.46:- CASS C.Mcl.
BAY 5 CO
VITAMIN B12
INJECTION
ug
24 HOUR URINE COLLECTION |
VOLUME
ml
RADIOACTIVITY j 
fo dose
0 — 490
0
1 10,000 iv 560 81.0 1
2 - 370 6.5  i
3 - 250 0
4 10,000 iv 880 71.6
5 - 835 5.3
6 - 1870 0
7 10,000 iv 1770 60.9
8 — 1945 8.4
9 - 1220 0
10 10,000 iv 1940 72.5
11 - 1215 5.7
12 - 1025 0
13 10,000 iv 1650 61.7
14 - 1740 0
15 10,000 iv 750 47.4
16 - 1950 0
17 - 1850 0
18 - 1230 0
19 10,000 iv 1115 63.3
20 - 790 3.9
21 - 1500 0
22 10,000 iv 1460 56.5
23 - 1620 0
24 1790 0
(60)
CASE C.Mcl • (contd•)
DAY 58CO
VITAMIN B p
INJECTION1
ug
■
24 HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
25 - 1040 0 !
26 10,000 iv 2260 75.8 |
27 - 1735 0
28 10,000 iv 1470 50.0
29 - 1850 0
30 10,000 iv 1540 66.3
31 - 870 0
32 - 2345 0
33 10,000 iv 1920 66.8
34 - 1970 0
35 10,000 iv 1850 48.8
36 - 1675 0
37 — 2410 0
38 10,000 iv 1570 42.2
39 — 1600 0
Table A *46: showing detailed results obtained from
58Case C.Mcl. given repeated injections of Co 
vitamin B ^  at intervals of two to four days. The 
patient was in haematological relapse with a low 
serum vitamin B level on day 0#
(61)
TABLE A.47 - CASE S.R.
M Y *8co
r^rrPAMTT\F "R
111 11 1 ' ' " . .....
■
24 HOUR URINE COLLECTION
V X AiiMXIN J3« ^
INJECTION
ug
VOLUME
ml.
RADIOACTIVITY
% dose f |
0 - 750 0
1 20,000 im 1125 84.3
2 - 1080 5.3
3 - 690 0
4 20,000 im 1240 67.5
5 - 1770 5.1
6 20,000 im 1745 69.1
7 - 1430 5.6
8 20,000 im 2260 74*7
9 - 1470 4.9
10 - 1360 0
11 20,000 im 1750 66.4
12 - 950 5.1
13 20,000 im 2020 74.7
14 - 960 5.4
15 20,000 im 1290 71.0
16 - 1360 6.6
17 - 1190 0
18 20,000 im 760 60.0
19 - 1660 10.0
20 20,000 im I84O 45.1
21 - i860 0
22 20,000 im 1650 73.5
23 - 1870 0
24 2470 0
(62)
CASE S.R. (contd.)
DAY 5 CO 
VITAMUST B p 
INJECTION1 
u g
24 HOUR URINE COLLECTION
VOLUME
ml.
RADIOACTIVITY 
$ dose
25 20,000 im 1720 78.5
26 - 1790 0
27 20,000 im 1570 66.3
28 - 2000 0
29 20,000 im 1595 75.0
30 - 1000 5.5
31 - 2200 0
32 20,000 im 1750 76.4
33 - 1190 6.3
34 20,000 im 1530 104.8
35 - 1230 9.9 ;
36 - 1375 0 ■
37 - 1770
■
0
46 20,000 im 1625 55.4 !
47 - 1210 5.8 :
48 - 1125 0
49 20,000 im 1160 65.6
50 - 1250 10.0
51 - 1240 0
Table A.47s showing detailed results obtained from
58Case S.R* given repeated injections of J Co vitamin
®12 in'terva^s 'fcwo ‘twelve <lays. (^ e patient 
was in haematological relapse with a low serum vitamin 
Bl2 level on day 0.
(63)
TABLE ~ GADii< C .B*
DAY 58co
: VITAMIN B_p 
INJECTION 
ug
24 HOUR URINE COLLECTION
VOLUME 
ml.
RADIOACTIVITY 
io dose
0 - 720 0
1 30,000 im 735 56.5
2 - 865 3.6
3 - 800 0
4 - 690 0
5 30,000 im 785 57.5
6 - 820 4.0
7 - 860 0
8 30,000 im 740 74.4
9 - 560 0
10 30,000 im 890 93.2
11 - 1500 0
12 30,000 im 2190 60.0
13 - 1460 9.5
14 30,000 im 1340 88.0
15 - 600 8.9
16 - 950 0
17 - 1060 0
18 - 1130 0
Table A.48s showing detailed results obtained from
58
Case C.B. given repeated injections of Co vitamin 
at intervals of two to four days. The patient 
was in haematological relapse with a low serum 
vitamin B ^  level on day 0.
(64)
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(65)
TIME
AFTER
INJECTION
minutes
TOTAL ASSAYABLE VITAMIN B IB 
ARTIFICIAL KIDNEY BATH FLUID - ug
CASE 
AK 1
CASE 
AK 2
CASE 
AK 3
CASE 
AK 4
CASE 
AK 5
C AoE 
AK 6
0 0 0 0 0 0 0'
5 8.5 11.0 7.7 - 19.0 7.3
10 17-4 29.0 19.5 31.4 46.01 91 peZLf. . O
15 32.8 34.0 28.5 45.0 60 4 44*5
20 39.5 47.0 34.0 55.0 76.4 52.0
25 42*0 49.5 45.0 63.0 90.0 64.5
30 55.5 61.0 52.0 75.0 102.0 81.0
35 56.0 75.0 78.0 117.0 88.0
40 62.5 80.0 92.0 120.0 103.0
45 66.0 88.0 94.5 130.0 -
50 76.5 94.0 141.0 130. O'
55 69.O 96.0
6o 75.0 100.5 172.0 138.0
70 - 118.0 199.0 153.0
80 - 133.0 220.0 168.0
85 - - i 155.0
90 94.5 147.0 ! 223.0 i
100 155.0 238.0 I
120 242,0
Table A.50s showing amounts of assayable vitamin B ^  found 
in the artificial kidney bath fluid at intervals after 
intravenous injection of 1000 ug vitamin B^2 to 
six patients undergoing haemodialysis.
(66)
CASE J.K.
TIME
days
SEHUM 
VITAMIN B12
UU:g/m 1.
58co
VITAMIN 3 
INJECTIOU 
u g
0
1
2
3
4
5 
7 
9
11
12
13
16
18
19
23
26
30
34
41
44
47
33
181
127
107 
90 
77 
67 
59 
57 
56
250
189
169
130
108 
98 
97 
90 
71 
61 
55
50 (41*5 ug retained)
50 (39*5 ug retained)
Table A.51: showing serum vitamin B_0 levels in relation
58 ld
to injections of Co vitamin in Case J.K. The
patient was in haematological relapse and had not been
treated prior to day 0*
Each value for serum vitamin is the mean of
two estimations: all samples were assayed in batch.
(67)
CASE C.J.
TIME SERUM 58co
VITAMIN B12 VITAMIN B.p 
INJECTION1
days uug/ml. ug
0 45 100 (80.0ug retained)
1 402
2 367
3 357
4 332
6 250
8 242
10 202
13 168
15 152
17 139
19 130
21 136
23 126
27 126
30 109
34 118 100 (78*Oug retained)
41 272
48 210
55 170
62 157 j
69
1
140
... .............
Table A.52: showing serum vitamin B 0 levels in relation to
58
injections of Co vitamin in Case C.J. The 
patient was in haematological relapse and had not been 
treated prior to day 0. Each value for serum vitamin
B12 is t he mean of the estimations: all samples were
assayed in the same hatch.
(68)
CASE C.R.
TIME
days
SERUM 
VITAMIN B 2
uug/ml.
5 CO 
VITAMIN Bip 
INJECTION 
ug
0 25 100 (72#0ug retained)
1 327
2 255
3 222
4 222
5 193
6 193
7 180
8 156
10 148 100 (80*2 ug retained)
14 299
29 180
32 165
36 161
39 144 100 (52*0 ug retained)
43 352
45 292
52 217
59 180
66 132
73 115
80 109 100 (52*8 ug retained)
87 235
94 173
(69)
CASE C.E. ( contd.)
TIME
days
SERUM 
VITAMIN B
12
uug/ml.
GO
VITAMIN Bip
INJECTION
ug
101 137
108 119
115 111
122 94
Table A.53* showing serum vitamin B_0 levels in relation
58 1
to injections of Co vitamin 3^  in Case C.R.
The patient was in haematological relapse and had not
been treated prior to day 0. Each value for serum
vitamin is the mean of two estimations: all
samples were assayed in the sane batch.
(76)
CASE M.T*
TIME
days
SERUM 
VITAMIN B12
uug/ml*
5 CO 
VITAMIN B ? 
INJECTION 
ug
0 54 100 (8l .2 ug retained)
7 198
14 158
18 147 100 (85*0 ug retained)
21 345
23 332
35 189
42 137
49 112
56 87 100 (89*5 ug retained)
62 193
69 143
77 115
84 86
91 83 100 (63*1 ug retained)
95 199
105 162
112 136
119 136
126 114
133 104 100 (75*9 ug retained)
(71)
CASE M.T. (contd.)
TIME
days
SERUM 
VITAMIN B12
uug/ml.
58co
VITAMIN B p 
INJECTION1 
ug
140 272
147 217
163 139
170 113
177 104
Table A.54* showing serum vitamin B 0 levels in relation
58 1
to injections of Co vitamin B ^  Case M.To
The patient was in haematological relapse and had
not been treated prior to day 0*
Each value for serum vitamin B g is the mean of
two estimations: all samples were assayed in the
same batch*
(72)
CASE J.Mc9,.
TIME
weeks
SERUM 
VITAMIN B12
uug/ml.
58co
VITAMIN B p 
INJECTION 
ug
0 29 1000 (324 ug retained)
1 340
2 287
3 215
4 182
5 167
6 141
7 124
8 127
9 121
10 117
11 115 1000 (485 ug retained)
12 452
14 305
15 260 *
16 183
17 178
18 166
19 143
20 117
21 114
22 94
(73)
CASE J.McQ,. (contd.)
TIME SERUM
oo
G
OIT
\
VITAMIN B12 VITAMIN B 9 
INJECTION
weeks uug/ml. ug.
23 89
24 64
Table A.555 showing serum vitamin B 0 levels in relation
eft
to injections of Co vitamin 3^  in Case J.McQ.
The patient was in haematological relapse and had 
not been treated prior to day 0.
Each value for serum vitamin B ^  is the mean 
of two estimations: all samples were assayed in 
the same batch.
(74)
CASE H.C.
TIME
weeks
SERUM 
VITAMIN B12
uug/ml•
5 CO 
VITAMIN B p 
INJECTION^ 
ug
0 166 50 (35*1 retained)
1 350
2 257
3 231
4 228
5 197
6 197
7 212 1000 (310 retained)
8 418 '
9 380
10 282
11 255
12 270
13 237
15 200
16 199 100 (59.5 ug retained)
17 410
18 340
19 280
20 255
21 221
(75)
CASE H.C. (oontd.)
TIME
weeks
SERUM 
VITAMIN Bl2
uug/ml •
58 
J CO
VITAMIN Bip 
INJECTION1
-.. ug... .
22 192
23 174
24 178
Table A.56: showing serum vitamin B_0 levels in relation
58to injections of Co vitamin in Case H.C.
The patient had been treated and was in full 
haematological remission on Week 0.
Each value for serum vitamin B ^  is the mean 
of two estimations: all samples were assayed in 
the same batch.
(76)
CASE E.F.
TIME
weeks
SERUM 
VITAMIN B 2
uug/ml•
5 CO 
VITAMIN B ? 
INJECTION1 
ug
0 30 16 x 100 ug 5^Co B. 0 .0 12 l.m.
( 726 ug retained)
6 350
10 200
14 147
17 100
23 102
58
100 ug Co
(58.0 ug retained)
24 205
25 152
26 127
27 125
28 115
29 111 1000 ug *^Co B^g i*m.
(461 ug retained)
30 292
31 210
32 207
33 192
34 175
35 161
100 ug ^Co B12
(52.3 ug retained)
36 137
37 257
38 205
(77)
CASE H.P. (contd.)
TIME
weeks
SERUM 
VITAMIN B12
uug/ml.
58co
VITAMIN B 
INJECTION 
ug
39 198
40 154
41 167
42 133
43 117
44 113
Table A.57* showing serum vitamin B10 levels in relation
c O
to injections of Co vitamin B^g in Case H*F*
The patient was in haematological relapse and had 
not been treated prior to week 0.
Each value for serum vitamin B^2 is the mean 
of two estimations: all samples were assayed in 
the same hatch.
CASE M.F.
(78)
TIME
weeks
.......... ' .......
SERUM 
VITAMIN B12
uug/ml.
5 CO 
VITAMIN Blp 
INJECTION1 
ug
0 105 50 (32*4 ug retained)
1 330
2 242
3 189
4 140
5 132
6 128 1000 (312 ug retained)
7 417
8 332
9 285
10 255
11 206
13 170
15 149
16 151 100 (5^*1 ug retained)
17 452
18 280
19 225
20
______________________
197
.................. .
Table A*58: showing serum vitamin B ^  levels in 
relation to injections of ^Co vitamin B ^  in 
Case M.R* The patient had been treated and was 
in full haematological remission on week 0*
Each value for serum vitamin B ^  is the mean of 
two estimations: all samples were assayed in the 
same batch*
(79)
CASE J.G.
TIME
weeks
SERUM 
VITAMIN B12
uug/ml•
58
CO
VITAMIN B-p 
INJECTION1 
ug._
0 112 50 (37*2 ug retained)
1 195
2 135
5 135
6 121
7 117
8 117
9 105
10 108 2 x 50 (76.0 ug retained)
11 283
12 192
13 164
14 163
16 124
17 120
Table A.59s showing relationship of serum vitamin B 0
c-o i t
levels to injections of Co vitamin B ^  in 
Case J.G* The patient had been treated and was in 
full haematological remission on week 0*
Eawh value for serum vitamin B ^  is the mean 
of two estimations: all samples were assayed in 
the same batch.
(80)
CASE J.O.tt.
TIME
weeks
SERUM 
VITAMIN B12
uug/ml.
5 CO 
VITAMIN B-p 
INJECTION1 
______ ug
0 192 100 (63*6 ug retained)
1 292
2 252
3 227
4 204
5 187
6 177 50 (33*4 ug retained)
7 250
8 206
9 192
10 173
11 181 1000 (259 ug retained)
12 302
13 242
14 235
15 237
16 212
17 194
18 200
19 177
20 181
(81)
CASE J.O.G. (contd.)
TIMS
weeks
SERUM 
VITAMIN Bl2
uug/ml•
5 CO 
VITAMIN B ? 
INJECTION1 
ug.
21 171 50 (37*8 ug retained)
22 235
23 210
24 190
25 182
26 162
27 177
28 158
Table A.60s showing serum vitamin B „ levels in
CQ
relation to injections of ^ Co vitamin in 
Case J.O.G. The patient had been treated and 
was in full haematological remission on week 0*
Bach value for serum vitamin is the mean 
of two estimations: all samples were assayed 
in the same batch.
(82)
CASE J.O.H.
TIME
weeks
SERUH 
VITAMIN B12
uu^ r/ml •
58co
VITAMIN B 
INJECTION12 
ug
0 126 100 (56.9 ug retained)
1 212
2 166
3 150
4 138
6 123 1000 (328 ug retained)
7 307
8 193
9 170
10 168
11 152
12 135
13 130
14 121
15 121
16 120
17 143
18 130 100 (59*0 ug retained)
19 245
20 189
21 160
(83)
CASE J.O.H. (eontd.)
time
weeks
SERUM 
VITAMIN B12
uug/ml.
5 CO
VITAMIN B 
INJECTION^ 
ug.
22 147
24 121
25 116
26 115
Table A.6l: showing relationship of serum vitamin B _
58levels to injections of Co vitamin B ^  in
Case J.O.H. The patient had been treated
and was in full haematological remission on week 0.
Each value for serum vitamin is the 
mean of two estimations: all samples were assayed 
in the same batch.
(84)
CASE D.J.
TIME
weeks
SEEUM 
VITAMIN B12
uug/ml•
5 CO
VITAMIN B
INJECTION1ug
0 156 1000 (238 ug retained)
1 397
2 327
3 252
4 227
5 206
6 157 1000 (900 ug retained)
7 370
8 307
9 252
10 227
11 186
12 138
13 147
14 156
15 124 100 (69*0 ug retained)
16 255
17 227
18 188
19 173
21 151 100 (98.O ug retained)
22 277
23 212
(85)
CASE D.J. (contd.)
TIME
weeks
SERUM 
VITAMIN B12
uug/ml*
58co
VITAMIN B_ p 
INJECTION1 
ug
24 174
25 157
26 131
27 134 50 (35»1 ug retained)
28 223
29 166
30 153
31 139
32 132 50 (40Dtg retained)
33 263
34 220
35 204
36 222
37 189
38 185
40 171 100 (67*2 ug retained)
41 332
42 277
43 225
45 148
46 130
47 131
Table A.62s showing relationship of serum vitamin Bno
r Q  J-C
levels to injections of Co vitamin in Case D.J.
The patient had been treated and was in full haematological 
remission on week 0*
Bach value for serum vitamin is the mean of 
two estimations: all samples were assayed in the same batch*
(86)
CASE J.K.
TIME
weeks
SERUM 
VITAMIN B12
uug/ml.
5 CO 
VITAMIN B p 
INJECTION1 
ug
0 86 2 x 50 (80.5 ug retained)
1 232
2 161
3 129 50 (43*9 ug retained)
4 235
5 163
7 106
8 101
9 93
Table A.63: showing serum vitamin B ^  levels in
58
relation to injections of Co vitamin in 
Case J.K. The patient had been treated and was 
in full haematologieal remission on week 0.
Each value for serum vitamin B ^  is the mean 
of two estimations: all samples were assayed in 
the same batch.
(87)
CASE J.L.
TIME
weeks
SERUM 
VITAMIN B 2
uug/ml•
58
CO
VITAMIN B.p 
INJECTION‘S
U£T
0 222 1000 (464 ^  retained)
1 465
2 372
3 322
4 300
5 250
6 232
8 212
14 215
15 198 100 (64*4 ug retained)
18 367
19 307
20 275
21 262
22 250
23 257
24 257
26 225
27 222
28 207
29 204 50 (40-1 ug retained)
30 312
31 292
32 240
33 218
(88)
CASE J.L. (contd.)
TIME
weeks
SERUM 
VITAMIN B 2
uug/ml.
58co
VITAMIN B ? 
INJECTION 
ug
34 207
35 195
36 192
37 179 100 (62.6 ug retained)
38 332
39 277
43 242
45 220
46 217
48 191
Table A.64s showing serum vitamin B10 levels in
eg ■»■<-
relation to injections of Co vitamin ia 
Case J.L. The patient had been treated and was in 
full haematological remission on week 0.
Bach value for serum vitamin B ^  is the mean of 
two estimationss all samples were assayed in the same 
batch.
(89)
CASE M .HoB.
TIME
weeks
SERUM 
VITAMIN B 2
uug/ml.
58™CO
VITAMIN B p 
INJECTION1 
ug
0 114 100 (65*9 ug retained)
1 209
2 193
3 162
4 145
5 149
6 132
7 125 1000 (320 ug retained)
8 292
9 208
10 188
11 178
12 147
13 132
14 131
15 119
16 109 100 (58.5 ug retained)
17 257
18 210
19 184
20 150
21 141
22 136
23 131 2 x 100 (109*7 ug retained)
24 325
(90)
CASE M.McB*(contd.)
TIME
weeks
SERUM 
VITAMIN B
uug/ml*
58co
VITAMIN B 
INJECTION 
ug
25 267
26 222
28 175
29 149
30 136
31 132
32 121
33 117
34 114
Table A *65: showing serum vitamin Bno levels ineg
relation to injections of Co vitamin B ^  ln 
Case M.McB* The patient had been treated and 
was in full haematological remission on week 0* 
Each value for serum vitamin B ^  is the 
mean of two estimations: all samples were 
assayed in the same batch*
(91)
CASE I.HoC.
TIME
weeks
SEBUM 
VITAMIN B 2
uug/ml•
58co
VITAMIN B p
INJECTION1ug
0 145 100 (52.8 ug retained)
1 302
2 257
3 222
4 191
5 156
6 139
7 125
8 127 50 (30.4 ug retained)
9 265
10 222
11 200
12 184
13 153 1000 (337 ug retained)
14 445
15 340
16 312
17 262
18 215
19 165
20 164
22 149
23 140
24 144
(92)
CASE I.McC. (contd.)
TIME
weeks
SERUM 
VITAMIU B12
uug/ml#
CO
VITMII B-« 
INJECTIOir
ug ...
25 133 100 (56#8 ug retained)
26 247
2? 220
28 185
29 175
30 169
31 149
32 159
33 146
34 145
Table A.66: showing serum vitamin B.0 levels in
58
relation to injections of Co vitamin B12 m  
Case I.McC. The patient had been treated and 
was in full haematological remission on week 0* 
Each value for serum vitamin is the mean 
of two estimations: all samples were assayed in 
the same batch#
(93)
CASE E.P.
TIME
weeks
SERUM 
VITAMIN B
uug/ml.
58co
VITAMIN B 9 
INJECTION 
ug
0 147 100 (51*1 ug retained)
1 262
2 220
3 199
4 177
5 162
6 134 1000 (291 ug retained)
7 327
8 260
9 240
10 210
11 186
12 186
13 166
14 149
Table A.67: showing serum vitamin B>0 levels in
c Q
relation to injections of 5 Co vitamin 3^  in 
Case E.P* The patient had been treated and was 
in full haematological remission on week 0* 
Each value for serum vitamin is the 
mean of two estimations: all samples were 
assayed in the same batch#
(94)
CASE M.P.
TIME
weeks
SERUM 
VITAMIH Bl2
uug/ml•
5 CO 
VITAMIH B 
I&JECTI0N12 
ug
0 200 100 (52*6 ug retained)
1 327
2 275
3 227
4 200
5 17 6 1000 (122 ug retained)
6 310
7 255
8 217
9 210
10 194
Table A *68: showing serum vitamin B-0 levels in
r O
relation to injections of Co vitamin B ^  
in Case M#P# The patiait had been treated and 
was in full haematological remission on week 0* 
Bach value for serum vitamin B ^  is the mean 
of two estimations: all samples were assayed in 
the same batch#
(95)
CASE I.R.
TIME ! 
weeks
SERUM
VlfAMXl B_0 12
uug/ml •
Y ifahxi: b l9 
H JE C T io ir^  :
ug !
0 144 1000 (34i 'Ug retained)
1 220
3 220
4 140
5 120
6 108
7 106 100 (78*8 ug retained)
8 24O
9 200
10 128
: 11 92
12 84
fable A . 695 showing serum vitamin levels in
relation to ^Co vitamin 3 ^  injections in Case X.R* 
The patient had been treated and was in full 
haematological remission on week 0*
Each value for serum vitamin 3 ^  is the 
mean of two estimations: all samples were assayed 
in the same hatch*
(96)
CASE U.S.
TIME
days
SERUM 
VITAMIN B12
uug/ml.
58co
VITAMIN
INJECTION1
ug
0 56 50 (47*7 ug retained)
1 235
2 216
3 176 50 (41*7 ug retained)
4 297
6 200
9 160
11 153
16 156 50 (35*0 ug retained)
18 317
20 262
24 252
25 242
27 252
37 212
39 181
a 172
48 130
58 108
65 106 50 (35*0 ug retained)
72 176
77 146
84 134
91 120
(97)
CASE M.E. (coatd.)
TIME
days
SERUM 
VITAMIN B12
uug/ml.
5 CO 
VITAMIN B 9 
INJECTION 
ug
98 107
105 105
112 97
119 85
126 88
Table A.70: showing relation of serum vitamin B.0
eft *-*•
levels to injections of Co vitamin B ^  in 
Case M.R. The patient had not been treated 
and was in haematological relapse on day 0.
Each value for serum vitamin B ^  is the 
mean of two estimations: all samples were 
assayed in the same batch*
(98)
CASE J .S .
TIME
weeks
SERUM 
VITAMIN Bl2
uug/ml.
CO
VITAMIN B 
INJECTED 1 
ug..
0 129 1000 (l6l ug retained)
1 282
2 240
3 220
4 191
5 172
6 153
7 150
8 111
9 113 100 (53*7 ug retained)
10 312
12 237
13 205
14 178
15 161
16 139
17 122
Table A.71: showing serum vitamin B.0 levels in
C O  -u-
relation to injections of Co vitamin 
in Case J.S. The patient had been treated and 
was in full haeraatological remission on week 0.
Each value for serum vitamin B ^  is the mean 
of two estimations; all samples were assayed 
in the same batch.
(99)
CASE A.T.
TIME
weeks
SERUM 
VITAMIN B12
uug/ml.
58co
VITAMIN B - 
INJECTION1 
___ ug.
0 60 1000 ug vitamin
1 316
2 220
3 144
4 100
5 100
7 80
9 92
10 80 1000 (288 ug retained)
11 264
12 208
13 156
14 144
15 124
16 132
17 156
18 152
19 124 2000 (570 ug retained)
20 376
24 220
25 224
26 144
28 116 50 (34*2 ug retained)
30 300
31 208
(100)
CASE A.5?. (o o n td .)
TIME
weeks
SERUM 
VITAMIN B12
uug/ml•
^co
VITAMIN B_p
INJECTIOIr 
u g ...
32 152
33 144
34 116
35 118
36 112
Table A#72: showing serum vitamin B_0 levels in
58 1relation to injections of Co vitamin in 
Case A*T. The patient was in haematological 
relapse on week 0 when an injection of vitamin 
B^ was given*
Each value for serum vitamin B^ is the 
mean of two estimationss all samples were 
assayed in the same hatch*
(101)
CASE A .T .
THEE
weeks
SERIM
VITAMIN Bno 12
uug/ml,
5 00
VITAMIN B 
INJECTION1 
___  ug
0 112 100 (54.4 ug retained)
1 360
2 302
3 260
4 200
5 185
6 157 50 (37*5 ug retained)
7 245
8 220
9 187
10 145
11 138
12 126
13 122 100 (49*5 ug retained)
14 345
15 305
16 252
17 237
18 230
19 225
20 179 1 x 100 (ll4*0 ug retained)
21 377
22 315
(102)
CASE A .T . (o o n td .)
TIME
weeks
SERUM 
VITAMIN B12
uug/ml.
58CO
VITAMIN B 9 
INJECTION
. ...  ug
23 290
25 192
26 153
27 159
29 liiB
30 148
31 130
Table A.73: showing serum vitamin B_0 levels in
58 1relation to injections of Co vitamin 
in case A.T. The patient had been treated and 
was in full haematological remission on week 0.
Each value for serum vitamin is the mean 
of two estimations: all samples were assayed 
in the same batch.
(103)
CASE I.W .
THE
weeks
SERUM 
VITAMIN B
12
----- uug/ml.
58co
VITAMIN B 9 
INJECTION 
ug
0 176 1000 (38I ug retained)
1 400
2 254
3 216
4 196
5 178
6 120
7 100 100 (49.5 ug retained)
8 264
9 208
10 188
11 138
12 108
Table A*74* showing serum vitamin B_5 levels in relation
f - O
to injections of Co vitamin Case I.W.
The patient had been treated and was in full 
haernatological remission on week 0*
Bach value for serum vitamin B^  Is the mean 
of two estimations: all samples were assayed in 
the same batch.
(104)
CASE I .W .
TIME
weeks
SERUM 
VITAMIN Bl2
uuff/ml.
58co
VITAMIN 3 
INJECT! N 
u g
0 137 100 (49*3 ug retained)
1 287
2 210
3 182
4 182
5 166
6 153
7 138
a 142 2 x 100 (ll8 *8 ug retained)
9 362
10 322
ii 257
12 2i|0
13 193
Ilf 168
15 I63
16 155
17 149
18 142
A*175s shoving serum vitamin levels in relation to 
injections of ^ C o  vitamin in Case III# The 
patient had been treated and was in full naernatological 
remission on week 0#
Each value for serum vitamin is the mean of 
two estimations: all samples were assayed in the 
same batch#
(105)
CASE J .A .
TIME
weeks
SERUM 
VITAMIR B12
uug/ml.
58co
VITAMIF B 
iNJEcrcoir
. ..  ug ______
0 66 12 x 1000 (4104 ug retained)
5 660
11 405
17 352
23 322
27 300
31 270
35 265
39 220
45 202
49 212
53 202
59 177
61 158
(Table A«76: showing serum vitamin B^g levels in 
relation to injections of ^8Co vitamin B12 in 
Case J.A. The patient was in haematological
relapse on week 0*
Each value for serum vitamin B g  is the 
mean of two estimations: all samples were assayed 
in the same hatch#
(106)
CASE C.D.
THE
weeks
SERUM 
VITMIF Bl2
uug/ml.
5 CO 
VITAMIN 3 
INJECTION 
ug
0 50 16 x 1140 (5727 ug retained)
13 255
18 203
25 184
31 195
32 191
33 177
36 156
40 164
44 122
49 127
50 134
Table A*77: showing serum vitamin 3-0 levels in
(-Q JmC,
relation to injections of Co vitamin in 
Case C.D* The patient was in haematological 
relapse on week 0.
Bach value for serum vitamin B ^  i0 niean 
of two estimations: all samples were assayed in 
the same hatch.
(107)
CASE J .F .
TIME
weeks
SERUM 
VITAMIN B12
uug/ml.
5 CO 
VITAMIN B p 
INJECTION1 
ug
0 52 9 x 100 (451 ug retained)
6 515
10 387
14 290
18 240
22 205
27 215
30 203
33 203
37 193
40 202
41 222
48 181
53 161
57 142
61 140
Table A,78: showing serum vitamin B10 levels ineg
relation to injections of 5 Co vitamin B ^  in 
Case J.F. The patient was in haematological 
relapse on week 0.
Each value for serum vitamin B ^  is the mean 
of two estimations: all samples were assayed in 
the same hatch*
(108)
CASE G.G.
TIME
weeks
SERUM 
VITAMIN Blg
uug/ml•
5 CO 
VITAMIN B p 
INJECTION1 
ug
0 ¥> 18 x 540 (2731 ug retained)
6 360
9 290
12 210
16 157
20 141
Table A.79i showing serum vitamin B.0 levels in
eft
relation to injections of Co vitamin B ^  in 
Case G*G. The patient was in haematological relapse 
on week 0.
Bach value for serum vitamin B ^  is the mean 
of two estimations: all samples were assayed in the 
same batch*
(109)
CASE M.McD.
TIME
weeks
SEBUM 
VITAMIN B12
uug/ml.
5 CO 
VITAMIN B_p 
INJECTION 
ug
0 40 15 x 10,000 (43,500 ug 
retained)
9 292
27 222
39 192
95 148
100 127
Table A.80: showing serum vitamin B.0 levels in
cO It
relation to injections of Co vitamin B ^  in 
Case M.McD* The patient was in haematological 
relapse on week 0*
Each value for serum vitamin B ^  is the 
mean of two estimations: all samples were 
assayed in the same batch*
(no)
CASE S.R .
TIME
weeks
SERUM 
VITAMIN B12
uug/ml•
58co
VITAMIN B,p 
INJECTION 
_____ ug
0 25 17 x 20,000 (83,300 ug 
retained)
9 765
19 405
25 327
42 290
48 265
52 257
57 194
61 180
64 237
69 260
74 290
77 217
83 149
Table A.8l: showing serum vitamin Bno levels in
eg I*-
relation to injections of 3 Co vitamin
in Case S*R. The patient was in haematological
relapse on week 0*
Each value for serum vitamin B ^  is the 
mean of two estimations: all samples were assayed 
in the same batch.
(Ill)
CASE J .S .
TIME
weeks
SERUM 
VITAMIN B 2
uug/ml.
58CO
VITAMIN B 9 
INJECTION1 
ug
0 50 18 x 1000 ug (5598 ug 
retained)
6 332
10 231
18 159
24 129
Table A.82: showing serum vitamin B_0 levels in
58relation to injections of Co vitamin
in Case J.S. The patient was in haematological
relapse on week 0#
Each value for serum vitamin B g  is ike 
mean of two estimations: all samples were 
assayed in the same hatch.
(112)
CASE
PREINJECTION
SERUM
VITAMIN
LEVEL
uug/ml.
DOSE
INJECTED
ug
DOSE
RETAINED
ug
DURATION
OF
EFFECT ABOVE 
140 uug/ml*
days
H*F. 102 100 58.0 17
n 111 1000 461 49
it 137 100 52.3 40
M.F* 105 50 32.4 30
J.G. 112 50 37.2 14
J *0*H* 126 100 56.9 27
it 123 1000 328 40
n 130 100 59.0 31
C.J* 118 100 78.0 35
D.J. 157 1000 900 42
t« 151 100 98.0 32
it 134 50 35.1 28
« 171 100 67.2 38
J.K* 129 50 43*9 17
M.McB. 114 100 65.9 39
it 125 1000 320 38
ti 109 100 58*5 35
I.HcC. 145 100 52.8 42
it 153 1000 337 70
J .McQ. 115 1000 485 59
E.P. 147 100 51.1 40
C.R. 148 100 80.2 29
it 144 100 52.0 26
ti 109 100 52,8 20
(113)
CASE
PRBIMJECTION 
SERUM 
VITAMIN B 
LEVEL 1 
uug/ml*
DOSE
INJECTED
ug
DOSE
RETAINED
ug
DURATION
OF
EFFECT ABOVE 
140 uug/ml* 
days
I.R. 144 1000 341 28
ti 106 100 78.8 20
M.R* 156 50 35.0 31
tt 106 50 35.0 16
J*S. 129 1000 161 51
tt 113 100 53.7 49
A*T* 80 1000 288 30
it 116 50 34.2 30
n 157 50 37.5 34
M.T. 147 100 85.O 24
it 87 100 89*5 15
ii 83 100 63.1 20
it 104 100 75.9 26
I.f. 137 100 49.3 49
tt 176 1000 381 39
tt 100 100 49*5
__________
28
- -..— . - -
Tahle A*83: showing details of results selected for
58analysis relating the amount of Co vitamin 
injected and retained after parenteral administration 
to the duration of effect*
(114)
CASE
PREINJECTION 
SERUM 
VITAMIN B 
LEVEL 1 
uug/ml*
LOSE
INJECTED
ug
DOSE
RETAINED
ug
DURATION
OP
EFFECT ABOVE 
140 uug/ml# 
days
J.G. 108 2 x 50 76.0 35
J.K. 86 ti 80*5 18
M.McB. 131 2 x 100 109.7 47
A.T. 179 ti 114.0 73
I.W* 142 tt 118 #8 70
Table A#84j showing details of results selected forcO
analysis relating the amount of Co vitamin 
injected and retained after two injections of 
^ C o  vitamin B ^  at 24 hour intervals to the duration 
of effect#
(115)
CASE
PBEINJECTION 
SERUM 
VITAMIN B p 
LEVEL i 
uug/ml.
BOSE
INJ3CTSB
ug
BOSE
JETAINED
ug
DURATION
OP
EFFECT ABOVE 
140 uug/ml. 
days
J.F. 52 9 x 100 45 427
H.P. 30 16 x 100 72 6 100
G.G. 40 18 x 540 2731 140
J.A* 66 12 x 1000 4104 >427
J.S. 50 18 x 1000 5598 152
C.B. 50 16 x 1140 5731 290
M .McD • 40 15 x 10,000 43500 679
S.B. 25 1? x 20,000 83300 >  581
58
Table A.85: shewing details of amounts of Co vitamin 
injected and retained and the duration of effect 
in eight patients given a series of injections in 
a short space of time. The results from Cases 
J.A. Sc S.R. were not included in the analysis as 
the serum vitamin level had not fallen to 
140 uug/ml by the end of the observation period*
(116)
TECHNICAL MATERIALS AMD METHODS
MICROBIOLOGICAL ASSAYS 
ISOTOPE MATERIALS AND METHODS 
OTHER TECHNICAL METHODS 
STATISTICAL METHODS
(1X7)
MICBOBIODOGICAD ASSAYS
METHOD
MEDIUM 
STOCK CULTURES 
PROCEDURE
COLLECTION AND PREPARATION OP SAMPLES 
RECOVERY EXPERIMENTS 
PREPARATION OE GLASSWARE
(118)
The technique used was modified from that 
described by Ross (1952), Hutner et al (1956) 
and Ross et al (1957) using Euglena gracilis 3 
strain as the test organism. The organism was 
supplied by Dr. G. I. M. Ross. Apart from the 
preparation and sterilisation of the medium 
which was carried out in the Departments of 
Biochemistry and Bacteriology, Western Infirmary, 
all work was done entirely by the author.
Medium
The medium used was that described by 
Hutner et al (1956). A large volume was made up: 
single strength medium was dispensed in 500 ml. 
aliquots in glass bottles sealed by a rubber 
bung and metal screw cap and double strength 
medium in 20 ml. aliquots in smaller glass bottles 
similarly sealed. After dispensing the solutions 
were sterilised by autoclaving, at 10 lbs. 
per square inch for 20 minutes.
Stock Cultures
Stock cultures of the organism were 
maintained in single strength basal medium 
containing 0.05$ tryptone and 30 - 40 uug
(119)
/■vitamin per ml. Stock cultures were 
subcultured after washing, every two weeks. 
Procedure
Phis differed slightly from that described 
by Ross (1952), Hutner et al (1956) and Ross 
et al (1957) the modifications used being 
employed to assist a single worker to deal with 
a large number of samples in a limited time.
The principal modification lay in the use of 
single strength medium throughout. Solutions for 
assay containing final concentrations of 0,
1.25, 2.5, 5, 10, 15, 25 and 50 uug vitamin 
B-^^/ml. were prepared by adding suitable volumes 
of standard solutions of vitamin in single 
strength medium to appropriate volumes of single 
strength medium to a total volume of 4 ml.
The standard solutions were made by adding 
commercially available vitamin B^2 to single 
strength medium, diluting as required to obtain 
final concentrations of 100 and 20 uug/ml.
The solutions for assay with final concentrations 
of 1.25, 2.5, 5.0 and 10.0 uug/ml. were made by 
adding 0.25, 0.5, 1.0 and 2.0 ml. of the
(120)
/20 uug/ml. stock solution to 3.75> 3-5i 3.0 
and 2.0 ml. single strength medium respectively 
and the solutions with final concentrations of 
10, 15, 25 and 50 uug/ml by adding 0.4, 0.6,
1.0 and 2.0 ml. of the 100 uug/ml stock solution 
to 3.6, 3.4, 2.0 and 1.0 ml. of single strength 
basal medium respectively.
Samples for assay were prepared by adding 
the appropriate volume of test solution to the 
appropriate volume of single strength medium 
dispensed by automatic burette to a total 
volume of 4 ml.. Information on the preparation 
of samples for assay is given elsewhere. The 
dilution of test sample in medium was 1.20, 1.40 
or 1.80 depending on the vitamin B^2 content. 
Dilutions of 1.20 and 1.40 were commonly used 
for serum and 1.40 for other samples..
All samples were assayed in aluminium capped 
6" x 5/8M Pyrex glass tubes in duplicate. 
Triplicate or quadruplicate estimations were 
not found to be superior to duplicate estimations 
and were therefore discontinued. After 
preparation all solutions were heated at 100°C
(121)
/in a water bath for 15 minutes. After cooling
the samples v/ere Inoculated and Incubated.
The inoculum was prepared from stock cultures 
which had been incubated for two weeks: they 
were washed three times with single strength 
medium and resuspended in a suitable volume of 
single strength medium before use. The 
incubation period was five, occasionally six, 
days in a perspex water bath illuminated from 
below by two 30 watt fluorescent strip lights.
A faint pink tint was found to assist growth 
and was achieved by adding a few drops of 
Edico'l supra-rose solution to the water in the 
bath. A few crystals of copper sulphate were 
also added to discourage the growth of moulds.
An even bath temperature of 29°C* was maintained 
by two 150 watt "Queensborough* aquarium heaters 
connected by a Sunvic type 102/4 relay to a 
mercury contact thermometer and by a "H&ndUab* 
stirrer. Headings were made in a Unicam SP 
300 UP colorimeter and the values for the unknown 
samples were calculated from a curve constructed 
from the values obtained for the st. * Is.
(122)
/Optical cells with a light path 2.5 aims, thick 
were used instead of the usual 10 mm. thick 
cells, allowing readings to he made without 
diluting the samples. The modifications, i.e. 
the use of single strength medium, the dispensing 
of medium by an automatic burette and the use of 
thin optical cells were all approved by 
Dr.' G-. I. M. Ross. When the modified method 
was tested against the original methods using 
Euglena gracilis 3 strain described by Hutner et 
al (1956) and Ross et al (1957) it gave the same 
results. An aliquot of a large volume of pooled 
serum was assayed in every batch. To ensure 
accuracy many samples were assayed in more than 
one assay batch as noted in the text.
Collection and preparation of samples
Treatment with cyanide or papain was never 
used and no preservatives were added to any sample. 
Serum: Blood was collected by clean venepuncture 
into 20 ml; sterile acid washed bottles and 
allowed to clot at room temperature. After 
centrifugation at 2000 — 3000 r.p.m. the 
serum was decanted into 5 ml. sterile acid
(123)
/washed bottles and stored at -20 C.
Urine: Collections were made directly into acid 
washed dark glass bottles via a large filter 
funnel to avoid contamination by faeces. No 
preservatives were used. The total volume 
was noted. Urine collected after an injection 
of vitamin was diluted at once and 
aliquots of the original and the diluted 
samples were stored in sterile, acid washed 
5 ml. or 20 ml. bottles at -20°C till 
assayed. Assays were performed as soon as 
possible after collection. As general rule 
urine samples collected after an injection 
of 1000 ug vitamin were diluted 1:1000 
by diluting 10 ml. urine with 990 ml. water 
and further diluting by adding 10 ml. of 
this solution to 90 ml. water. Similarly 
samples collected after injections of 
500 ug vitamin B^2 were usually diluted 
1.500 and samples collected after injections 
of 100 ug and 50 ug were usually diluted 
1.100 and 1.10 respectively.
(124)
Liver: The liver was removed at autopsy and
weighed after removal of the gall bladder.
A generous sample was taken, weighed and 
homogenised with distilled water in a 
Kenmix 155f homogenisor to a known volume. 
Aliquots of the homogenate were diluted 
serially and stored in sterile acid washed 
bottles at -20°C.
Artificial kidney bath fluid: Samples were
taken with an acid washed pipette and stored 
in sterile acid washed glass bottles at 
-20°C. till assayed.
Recovery experiments
The presence of inhibitors to the growth 
of Euglena gracilis in test samples was 
investigated on several occasions. The method 
employed was to set up in the same assay batch 
tubes containing:
(1) single strength b&sal medium only.
(2) single strength basal medium with the test
sample in a concentration of (usually) 1.40,
(3) single strength basal medium with vitamin
in a concentration of 2.5, 5.0, 10.0 and
(125)
/15.0 uug/ml.
(4) single strength basal medium with vitamin 
a concentration of 10 uug/ml and also 
the test sample in the same concentration as 
in (2), the total volume being 4 ml. in each tube 
Estimations were made in duplicate or triplicate. 
The solutions were heated as usual, cooled, 
inoculated with the standard inoculum and 
incubated for five days. The vitamin B,0 content 
of (2) and (4) was calculated as usual.
Inhibitors were assumed to be absent when the 
value of (4) - (2) = 10 uug/ml.t. 1 uug/ml.
Tissue homogenates, artificial kidney bath 
fluids and urines containing drugs or their 
end products were investigated by this method. 
Collections of urine were made for 24 hours, 
the patient taking the drug for at least 24 
hours before the collection period and continuing 
to take it during the collection period.
Usually the urines were not diluted prior to 
assay. The drugs taken were acetylsalicylic acid 
aluminium hydroxide, amylobarbitone sodium, 
butobarbitone, chlorothiazide, digitalis,
(126)
/ferrous sulphate, Imferon, insulin soluble and 
IZS, magnesium trisilicate, mersalyl, penicillin, 
phenindione, phenobarbitone sodium, probenecid, 
propantheline bromide, reserpine and tetracycline. 
Normal therapeutic doses were given. In many 
cases the author was the subject of the study.
No inhibitory effect on the growth of luglena 
gracilis was detected.
Preparation of glassware
All glassware used in assays or in the 
preparation or storage of samples for assay 
was cleaned by immersion in potassium 
dichromate sulphuric acid mixture for at least 
one hour, washing at least six times with 
vitamin free water and sterilising by dry 
heat or in an autoclave.
(127)
ISOTOPE MATERIALS AND METHODS
Co vitamin B ^
Source
Purity
Preparation and storage of stock solutions
Stability of stock solutions
Boses
Preparation of doses for injection
Isotope counting methods
Collection and preparation of samples 
Counting equipment 
Counting techniques
(128)
Source
All supplies of Co vitamin B ^  were obtained
from the Radiochemical Centre, Amersham. The 
5 5
Co containing vitamin was commonly used: on 
57occasions the Co containing vitamin was used,
58usually when Co vitamin was not available. 
Purity
The radiochemical purity of the products 
was always greater than SQfi as established by 
dilution analysis carried out at the 
Radiochemical Centre.
Preparation and storage of stock solutions
Until mid 1959 the isotopes were received 
in aqueous solution: after that date they were 
received freeze-dried in sealed glass ampoules. 
Soon after receipt stock solutions were made, 
containing 0.5 ug with a specific activity of 
0.5 uc in 5 ml. 0.9^ saline. These solutions 
were dispensed in acid washed, dark glass bottles 
stoppered with a rubber diaphragm and screw cap, 
autoclaved at 5 lbs. per square inch for 30 
minutes and stored in the dark at +- 4°C when 
not in use. Each bottle contained 80 to 100 ml.
(129)
/of the stock solution.
Stability of stock solutions
The vitamin content of each batch was 
determined by microbiological assay each week 
the batch was in use* Deterioration was never 
observed.
Doses
The doses of radioactivity given were kept 
as small as possible compatible with obtaining 
acceptably accurate results. The doses used 
are given in the text. As a general rule the 
doses of radioactivity given parenterally 
were 0.3 (50 ug), 0.2 uc (100-1000 ug),
0.2 or 0.1 uc (1000-30,000 ug). In many cases 
the radioactivity of a dose is actually over­
rated as no correction was made for decay e.g. 
a dose of 2.0 ml. of the stock solution which 
had a specific activity of 0.2 uc when freshly 
prepared was still regarded and listed as having 
a specific activity of 0.2 uc one month after 
receipt when the specific activity would have 
declined appreciably. This procedure was adopted 
for convenience and also served to ensure that
(130)
/the total amount of radioactivity given to each 
patient was well within the limits permitted 
by the Medical Research Council’s Advisory 
Panel on the Allocation of Radioactive isotopes 
for Clinical Use.
Preparation of doses for injection
Two methods of preparing solutions of
5bCo vitamin B^ for injection were used, in
both cases solutions were prepared by the author.
The first method, used for the ’matched’ series
reported in Chapter 1 was as follows. The
appropriate volumes of stock solution of 
58Co vitamin were added aseptically to
ampoules containing appropriate volumes of non
radioactive vitamin B-^ using tuberculin
syringes, a suitable number of ampoules being-
prepared at the beginning of each experiment.
The tuberculin syringes were calibrated by
weighing on an Oertling balance when empty and
when filled with distilled water and were found
to contain 1.00, 1 .0 8 and 1.14 ml. The
necessary corrections resulted in the apparently
58unusual choice of doses of Co vitamin B ^
(131)
/used in the studies reported in Chapter l,viz. 
54* 540, and 1140 ug. The second method, often 
used for other studies, was to draw up the 
desired volume of stock Co vitamin solution
into a 5 ml, syringe and then to draw up the 
desired volume of vitamin B-^ solution and mix 
the solution in the barrel of the syringe.
The volumes were measured from mark to mark 
in the barrel of the syringe. Some air was 
left in the syringe and injected after the 
solution to ensure that no solution remained 
in the nozzle of the syringe or needle.
Collection and preparation of samples
a )  Urine: Collections were made as described
previously. The total volume was noted 
and 450 ml. aliquots were taken into 
screw-capped, wide mouthed plastic 
bottles. If the total volume was less 
then 450 ml. as occurred when hourly 
collections of urine were made the 
volume was made up to 450 ml. with water.
(2) Bile: Collections were made into acid washed
dark glass bottles via a T-tube inserted
(132)
/into the common bile duct. The same 
procedure was followed as with urine 
samples.
(3) Faeces: Stools were collected into washed
stainless steel bed pans care being 
taken to avoid contamination with urine. 
Samples were transferred to waxed paper 
cartons and the collection homogenised 
to a known volume with water and a 
450 ml. aliquot of the hornogenate taken 
for counting.
(4) Liver: The liver was homogenised as described
previously and a 450 ml. aliquot of the 
undiluted hornogenate taken for counting.
(5) Other tissues: Were treated in the same way
as liver.
(6) Blood: 5 ml. aliquots of heparinised venous
blood haemolysed by the addition of 
saponin were pipetted into suitable 
glass tubes.
(7) Plasma: 5 ml. aliquots of plasma were taken
into suitable glass tubes after 
centrifugation of heparinised venous blood.
(133)
/It was established that adsorption of radioactivi 
from samples and standards onto the walls of 
plastic bottles or glass tubes did not occur. 
Counting equipment
Three different counters were used: the 
first to count the radioactivity in aliquots 
of urine, bile, faeces and tissue homogenates.
The second to count the radioactivity in aliquots 
of blood or plasma. The third for external 
counting of hepatic radioactivity,
(1) The radioactivity in 450 ml. aliquots of 
urine, bile, faeces or tissue homogenates 
contained in screw-capped, wide-mouthed, plastic 
bottles was measured by an end-on method in a 
suitably modified EKCO scintillation counter
N 550 with a thallium activated sodium iodide 
crystal 3.8l cm. diameter and 2.4 cm. deep 
shielded by three inches of lead and an EKCO 
automatic scaler type N 530 A. A standard 
containing 0.2 uc Co vitamin with 2000 ug 
vitamin as a carrier in 450 ml. water was used
(2) The radioactivity in 5 ml. aliquots of blood 
or plasma contained in glass test tubes was
(134)
/measured, with an EKCO type N 664 universal 
scintillation counter fitted with well type 
thallium activated sodium iodide crystal N 597 
shielded by four inches of lead and an EKCO 
automatic scaler type N 530 A. A standard 
containing 0.05 uc Co vitamin in 5 ml. water 
was used.
(3) The uptake of hepatic radioactivity was 
measured by an EKCO type N 599c scintillation 
counter fitted with a thallium activated 
sodium iodide crystal type N 566 A. A wide 
angle collimator was used. The scaler was an 
EKCO automatic type N 530 A.
Counting techniques
With the exception of a few samples all 
counting was done by the author in the 
Isotope laboratory, G-ardiner Institute, Western 
Infirmary. ?/hen 450 ml. volumes were being 
counted the background count was established 
over 300 seconds after a suitable time had been 
allowed for the equipment to "warm up". The 
background count rate over the period in which 
the studies reported here were done ranged from
(135)
/l.49 - 4.95 counts per second and was usually 
2*00 counts per second. The standard was then 
counted until at least 10,000 counts were 
recorded. Samples were generally counted for 
at least 300 seconds or until 5000 counts had 
bean recorded. In the experiments reported in 
Chapter 1 all samples in the 1140, 1000 and 
540 ug series were counted until 10,000 counts 
had been recorded giving a counting error of 
i 1$ and all samples in the 100 ug and 54 ug 
series were counted until 5000 counts had been 
recorded giving a counting error of - 2$.
The range of results obtained was typical of 
that obtained in other experiments and is shown 
overleaf.
(136)
Net Standard Net Sample 
counts/seeond counts/second
1140ug series 145*78-167.79 10.58-86.61
(matched)
lOOOug series 56.21-193.25 1.82-58.41
(mise.)
540ug series 147.89-176.76 15.09-60.53
(matched)
lOOug series 94.00-225.70 3.40-80.93
(misc.)
54ug series 175.94-195.94 2.02-67.05
(matched)
The net dose count was the same as the net 
standard count except in the 54 ug series 
where the net dose count ranged from 
263.86 - 293*91 counts per second.
When the gross counts per sample were less 
than twice the background the radioactivity 
in the sample was regarded as insignificant and 
a value of zero was recorded. Knowing the 
background and standard count rates the lowest 
detectable amount of radioactivity in a sample 
could be calculated. The coincidence of a large 
sample volume, a high backgruund count and a low 
standard count could, in theory, result in a 
recorded value of d/c when in fact the actual
(137)
/value was as much as 5$. This never occurred 
with urine samples and values recorded at 0fo 
dose excreted never represent true values of 
more than 1 f& dose excreted. With samples 
of bile and faeces (see Chapter 5) significant 
count rates were often not obtained and the 
only solution was to record the result as 
< x^ dose excreted as calculated above. In such 
cases it seemed wrong to adopt the alternative of 
increasing the dose of radioactivity in the hope 
of obtaining more accurate results*
The counting of 5 ml. samples of blood or 
plasma was conducted on similar lines. A 
background count was established over 300 
seconds, the standard count until 10,000 counts 
had been recorded and the sample count over at 
least 300 seconds.
The accumulation of hepatic radioactivity was 
measured by establishing the background count over 
the liver for 300 seconds and counting for periods 
of 100 seconds every 2 minutes or longer after
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/the injection of Co vitamin B M o  standard 
was used in this technique. The counter wasi 
placed over the anterolateral projection of the 
liver in contact with the skin and remained in 
position for the duration of the experiment.
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OTHER TECHNICAL METHODS
HAEMOGLOBIN ESTIMATION 
MARROW BIOPSY SMEARS 
DETERMINATION OE GASTRIC ACIDITY 
58CO VITAMIN B12 ABSORPTION TESTS 
SERUM IRON ESTIMATION 
EAECAL PAT ESTIMATION 
XYLOSE EXCRETION TESTS 
INTESTINAL BIOPSY 
ARTIFICIAL KIDNEY
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Haemoglobin
Estimations were made photoelectrically 
on venous blood using Sequestrene as an 
anticoagulant. Values are expressed as 
percentages, lOOjb = 14.8 g./lOO ml,. 
Estimations were made in the Haematology 
Departments, Western Infirmary and Vale of 
Leven Hospital.
Marrow biopsy smears
Sternal marrow biopsy was performed under 
local anaesthesia and preparations made 
by the method of Davidson et al (1943) 
and stained with May-Grunwald and Giemsa or 
with Leishmann. All blood and marrow smears 
were inspected by the author.
Gastric acidity
The presence or absence of gastric acid 
was established by the augmented histamine 
test (Kay 1953) in all patients p©senting 
after January 1956 the pH of the aspirate 
being determined with pH papers and usually 
checked by the author. Histamine fast 
achlorhydria was diagnosed if the pH did
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/not fall below 6.0. Prior to 1956 
various stimulants to acid secretion and 
various pH indicators were used.
Co vitamin absorption tests
The capacity to absorb orally administered 
Co vitamin was determined by the method 
of Schilling (1953) as modified by Adams 
& Seaton (1961) using an oral dose of 
0.5 ug 0.5 uc. The normal value was taken 
as>7*5f« dose excreted. Tests were carried 
out after the experiments reported in this 
thesis had ended and intervals of up to 
three years elapsed between the patient 
coming under observation and tests being- 
done. Tests with intrinsic factor were not 
carried out on patients who had received 
commercial preparations of vitamin B^and 
heterologous intrinsic factor until at 
least a year after such treatment had been 
stopped:when necessary tests with homologous 
intrinsic factor were done on such patients. 
Heterologous intrinsic factor was obtained 
from several drug firms and the dose varied
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/but was always considered to be optimal.
All tests were conducted and the samples 
counted by the author.
Serum iron
The serum iron concentration was estimated 
by the method of Hamsay (1957) in the 
Biochemistry Department, Western Infirmary. 
ffaecal fat
The amount of fat in the faeces was 
estimated by the Soxhlet method of Harrison 
(1^47). Three day collections on a ward 
diet were usually submitted for examination 
and the normal value was taken as 4 5.0 g./day 
or <25$ of the dried weight of the sample. 
Estimations were made in the Biochemistry 
Departments, Western Infirmary and Yale of 
Leven Hospital.
P-Xylose absorption
The amount of d-xylose excreted in the 
urine in the five hours after oral 
administration of 25.0 g was estimated by 
the method of Hoe & Hice (1948) in the 
Biochemistry Department, Western Infirmary.
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/The normal value was taken as }5.0 g. 
Gastric and intestinal biopsy
Samples of gastric or intestinal mucosa were 
obtained by an intestinal biopsy tube 
(Shiner 1956) or capsule (Crosby,& Kugler 
1957) passed under radiological control.
The samples were fixed within five minutes 
and were stained by haematoxylin and eosin. 
Artificial kidney
Details of the machine and operating 
instructions are given overleaf.
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D I S P O S A B L E  C O I L  K I D N E Y
The disposable coil kidney produced by Travenol Laboratories, Inc., is 
based on developmental work of Willem J. Kolff, M.D. of the Cleveland 
Clinic, Cleveland, Ohio. The principle by which the kidney operates and 
’ its clinical application has been reported by Kolff et al.1-2'® The kidney 
consists of perm anent equipm ent (container, tank  and pumps) and 
expendable equipm ent (coil dialyzing unit, arterial and venous sets).
DESCRIPTION
A schematic cross section of the coil is operation, blood flows through the cellulose
shown in Fig. 1. Two cellulose tubes (A) are tubing and dialyzing fluid is pumped up
enveloped in fiberglass screens (B). The coil through the screen,
is wrapped around a central cylinder. In
Ft« . 1
The complete circuit of dialyzing fluid and 
blood is shown in Fig. 2. (A) in Fig. 2 is a 
cross section of the dialyzing unit. Dialyzing 
fluid is pumped into the bottom of the per­
m anent container (B) and flows up through 
the screening and over the top of the con­
tainer to fall back into the  dialyzing fluid 
tank. Blood enters the cellulose tubing through 
the central cylinder, flows through the cellu­
lose coil and leaves through tubing a t the 
periphery.
The coil kidney is a twin kidney. I t has two 
lengths of cellulose tubing in parallel arrange­
ment; each approximately 10.75 m eters long.*
The dialyzing area is approxim ately 19,000 
sq. cm. Blood required for prim ing is approxi­
mately 1200 ml. At a flow rate  of 200-400 ml. of 
blood per m inute, the average am ount of urea 
removed in a dialysis of 5-6 hours’ duration  is 
greater than  70 gms. There 1s a wide range in 
urea clearance and th is is attribu tab le to the 
wide variance in  the in itial levels of p a tien t’s 
blood urea, body weight and blood flow. The
•The cellulose tubing has a wall thickness of 1/1000 
of an inch. When ljlng flat, It has a width of 4.5 cm.
am ount of urea clearance is 100-300 ml. per 
minute. Dialyzing fluid flow should be 3-5 
liters per m inute. The pum p is designed to 
produce this rate  of flow. The u ltra filtra te  is 
approxim ately 300 m l./hour (2-6 lbs. weight 
loss during dialysis). If the outflow pressure 
is increased to 250 mm. Hg., then  the loss is 
approxim ately 700 ml. per hour (6-8 lbs.).
P a tien t’s blood is pum ped from the radial 
artery  into two tubes of the  arterial set which 
are placed in  parallel in  the  blood pum p, see 
Fig. 2(E), so th a t a substantially  equal flow 
of blood is obtained in  each tube as it passes 
through the  coil.
Blood leaves the  coils th rough  tubes in  the 
periphery and flows th rough  two filter cham ­
bers of the  venous set (F ) , where air bubbles 
are trapped and blood flow can be observed. 
Blood passes th rough the  filter before it re­
tu rns to the p a tien t’s vein.
Dialyzing fluid is contained in a 100 liter 
tank  (C) beneath the  disposable un it. Tem ­
perature of the  fluid is m aintained a t 39°C. 
(102°F.) and 90% O, plus 10% CO, is bubbled 
into it continuously th rough  inlet (D).
1
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P erm anent equipm ent consists of:
1. Pum p for blood (Sigm am otor pum p, 
Model TL, available from  Travenol).
2. A 100 liter tan k  for dialyzing fluid. The 
tan k  is m ounted on wheels and  pro­
vided w ith :
a. A clear plastic cover and  lam p.
b. A p la tfo rm  for the  blood pum p.
c. A container for th e  coil dialyzing 
un it.
d. An opening in  th e  ta n k  th rough  
which 0 2 and  COa can  be adm itted  
in to  th e  dialyzing fluid.
e. A stan d  for hang ing  set and  blood 
bottle.
f. A cen tral panel w ith electrical con­
tro l sw itches and  ligh ts for the 
equipm ent g, h  and  i.
g. A utom atic tem pera tu re  r e g u la to r  
set a t 39°C. (102°F.) and  dial th e r­
m om eter.
h. D ialyzing fluid pum p w hich circu­
la tes fluid th ro u g h  th e  coil un it.
i. E xhaust pum p w ith  a ttach ed  hose 
w hich will d ra in  the  dialyzing tan k  
in  5 m inutes.
DIRECTIONS FOR
1. Remove Coil un it*  from  plastic bag 
and  fasten  in  place in  p erm anen t con­
ta in e r (B) w ith  th e  closed end of the  
p lastic core down. Blood inflow (ar­
te rial) tubes have clear vinyl plastic 
ends w ith  co tton  plugs. Outflow (ven­
ous) tubes are a ttac h ed  to  th e  peri­
phery  an d  te rm inate  in  connectors. 
Corresponding inflow and  outflow 
tubes from  one of th e  cellulose coils 
are  identified by a  yellow band.
2. C ut off p a r t  of p lastic  ends on Coil 
inflow tubes to  rem ove co tton  plug. 
Remove pro tecto rs from  plug-ins on 
arte ria l set and  in se rt in to  cu t ends 
of inflow tubes (G ).
CAUTION: Avoid k in ks  in  tub ing  be­
tw een the  arterial ca theter and the  
pu m p  tubes.
ASSEMBLING
3. C ut connecting tube on venous set in 
cen ter an d  in se rt plug-ins on outflow 
tubes of coil u n it  (H).
4. Clam p side arm s (L) on each filter 
cham ber.
5. H ang  filter cham bers in  u p rig h t posi­
tio n  (filter a t  bottom ) on s ta n d  using 
green p lastic r in g  (I).
6. P u t ta p  w ater in  the  100 lite r ta n k  (C) 
an d  circu late it  th ro u g h  the  screening 
of th e  coil u n it (A) for about 10 m in­
utes.
7. Remove ta p  w ater from  ta n k  an d  fill 
w ith  dialyzing fluid p repared  as fol­
lows.
8. S ta r t  flow of 90% Oa an d  10% C 0 2 in to  
tank .
•NOTE: Should the coll unit show evidence of 
having been water soaked prior to use, DO NOT USE.
PR EPA R A T IO N  O F  D IA LY ZIN G  FLUID
Dialyzing fluid of th e  following com position 
is effective. F lu id  of o the r electrolyte composi­
tion  m ay be used.
G m . p ar 
C o m p o n en t 10 0  L.
M illlo q u iv a le n ti  p a r  lltor 
N « + K + Ca + + M 0 + + C l“ HCOi “
NaCl1 5 7 0  = 9 7  — —  — 9 7 —
N aH C O , 3 0 0  = 3 6  — —  — — 36
KCI 4 0  = —  5 —  — 5 —
CaCI,* 28  = —  — 5 — 5 —
Mg Cl** 7 .5  = —  — —  1.5 1.5 —
Total 133 5 5 1.5 108.5 36
Invert Sugar (TRAVERT) 0 .4 % .4
Lactic acid to  adjust pH to app rox . 7 .4
To maintain the pH during dialysis, 9 0 %  0 2 with 1 0 %
CO j is bubb led  through fluid.
1. Dissolve NaCl, NaHCOs an d  KC1 in  a  sepa­
ra te  con tainer of h o t w ater.
2. Pour in to  dialyzing fluid ta n k  and  th e n  add 
one lite r of 40% TRAVERT (Invert S ugar).
3. F ill ta n k  w ith  w arm  ta p  w ater u n til 100 L. 
m ark  is reached. T em peratu re  should be 
39°C. (102°F.).
1When high serum sodium levels are present, 600 
Gm. NaCl (138 mEq. of Na+) is used In the first 
bath, to prevent a rapid shift in serum sodium con­
centration.
*15 or 30 Gm. KC1 (1.8 to 3.7 mEq. of K+) may be 
used, depending upon initial serum potassium levels.
‘When MgCl« • 6H jO is used, 15 Gm. is required to 
provide 1.5 mEq. per liter of Mg++ in the rinsing 
fluid.
‘40% Travert (Invert Sugar) available in 1000 ml. 
pour bottle from Travenol Laboratories, Inc.
2
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Fig. 2
4. Add lactic acid until pH is approx. 7.4.
5. CaCl2 and MgCl2 can now be added without 
formation of precipitate.
6. As a final check prior to testing the Kid­
ney, spin a test tube of dialyzing fluid with 
some blood. If hemolysis does not occur,
the solution is isotonic and satisfactory 
for use. However, if hemolysis occurs, the 
solution should be discarded.
If the patient has a serum potassium 
higher than  6 mEq./L., one-half the usual 
potassium concentration is used in dialyzing 
fluid. If patient is dehydrated, replacement
3
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with paren tera l fluid may be indicated be­
cause considerable u ltra filtra te  is removed per 
hour.
To replace fluid during  dialysis of p a tien t:
1. Keep blood pum p running .
2. D rain  dialyzing fluid from  tan k  w ith 
exhaust pum p.
3. Stop recirculating  pum p before all the 
fluid is ou t of the  ta n k  and  do not 
re s ta r t un til the  new batch  of dialyzing
TESTING
1. Switch on circu lating  pum p. Circulate 
dialyzing fluid th rough  screen of 
coil un it. Never test kidney before coil 
u n it is wet.
2. Place pum p tubes of arte i !al set in Sig- 
m am otor w ith plastic stops (J) just 
outside of pum p housing on inflow 
side of pum p. Care should be taken  to 
properly position the pum p tubes in 
the holes of the  pum p housing and 
th a t  the  tub ing  is no t pinched when 
it is closed.
3. The m ale Luer adap te r of s tan d ard  ad­
m in istra tion  sets m ay be plugged into 
the female Luer adap te r a t the  end of 
the  s id e  a rm  on the  a r t e r i a l  set 
(K ). A Y-type adm in istra tion  set w ith 
filter is recom m ended for connecting 
to  saline and blood bottles. Pum p a t 
least six liters of sterile saline solution 
th rough  th e  u n it using Sigm am otor 
p u m p . C A U T IO N : S t a r t  pum ping  
slowly. S top  S igm am otor before bot­
tles are em p ty  to avoid introducing air 
in to  the  system .
PREPARATION
Two un its  of fresh blood, preferably no t 
older th a n  24 hours, m ust be available on the 
day of dialysis. A dditional un its  no t older 
th a n  3 days should be on han d  in  case of 
emergency. These bloods m ust be cross­
m atched  w ith th e  p a tie n t’s blood and  w ith 
each other.
To prepare th e  p a tien t:
1. A ligh t breakfast is allowed if the p a­
tie n t desires, b u t should no t be forced.
2. Shave both arm s from  above elbow to 
below w rist and  both  lower legs to the 
ankle.
3. Surgical cut-down on th e  p a tie n t’s ves­
sels should be done about one hour 
prior to  connection so th a t  th e  wounds
fluid Is prepared and  in tank . If dialyz­
ing fluid is pum ped up th ro u g h  the 
Coil before the solution is m ade iso­
tonic by dilution, hemolysis will occur 
in the  cellulose tubes of the Coil.
IM PO RTANT: D ia ly z in g  flu id  m u st be p rep ared  
Im m ed ia tely  prior to d ia ly sis  s in ce  Ca an d  Mg p re­
c ip ita te  a t an  In creasin g  rate  up on s ta n d in g  a t body  
tem p era tu re . I f p rec ip ita tio n  occu rs, th e  so lu tio n  
w ill becom e clou d y . P r ec ip ita tio n  m ay a lso  occu r If 
th e  tem p era tu re  o f th e  w ater used  in  p rep a r in g  th e  
so lu tio n  is over 110°F.
KIDNEY
4. Remove trapped  air from pum p tubes 
of a rte ria l set by bending outflow ends 
of tubes upward.
5. Pum p 100 ml. of heparinized blood 
th rough  the un it. Follow th is w ith 
sterile saline to which 250 USP heparin  
un its per liter have been added. At th is 
point, dialyzing fluid m ust be isotonic 
to prevent hemolysis.
6. Leaks can be detected from  the ap­
pearance of blood in  the dialyzing 
fluid.
7. Observe flow in Alter cham bers (F) to 
be sure th a t flow is substan tia lly  equal 
th ro u g h  both coils of the  unit.
8. C alibrate blood pump* (E) w ith sterile 
saline by collecting outflow from  kid­
ney in to  g r a d u a t e .  A d j u s t  flow to 
about 5% above average desired rate. 
(Flow ra te  will g r a d u a l l y  decrease 
during  dialysis.)
•NO TE: U A -11A — M odel TL b lood pu m p m a y  be 
ca lib ra ted  prior to use. S ee  In stru c t io n s  for th e  
U A-11A pum p.
O F THE PATIENT
have opportun ity  to clot. If poor blood 
flow is an tic ipated  from  the  rad ia l 
a rte ry , it is advisable to in sert a ca the­
te r h igh in to  the  saphenous vein u n ­
til its tip  lies in  the  inferior vena cava.
4. B ring p a tien t to  artificial kidney and  
in se rt venous ca the ter. C atheters are 
filled w ith saline con tain ing  1000 USP 
h ep a rin  u n its  (approx. 10 mg.) per 100 
ml.
5. H eparinize p a tien t w ith 50 to  100 USP 
u n its  (approx. 0.5-1.0 mg.) per kilo­
gram  body weight.
6. In se rt a r te ria l ca the ter.
W hen both  ca the ters  are  in  place, the  a r t i­
ficial kidney is prim ed w ith blood.
A
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P R IM IN G  A N D  O PER A TIN G  KIDNEY
Approximately 2 un its  of blood are required 
to prim e th e  kidney. Additional un its  should 
be available should a fall in blood pressure 
occur afte r connecting the p a tien t to the ap­
paratus. As pointed out, these bloods should 
be cross-m atched w ith the  p a tie n t’s blood and  
w ith each other. Most patien ts  require more 
th a n  the  in itial 2 un its  of blood used to prim e 
the kidney to  prevent hypotension. Prepare to 
observe this fall w ith in  the first hour.
1. Add 1000 to 2000 USP heparin  un its  
(approx. 10-20 mg.) to each u n it of 
fresh blood.
2. Pum p blood in to  kidney th ro u g h  ad­
m in istra tion  set connected to side arm  
(K) on A rterial Set. F ill the  cellulose 
tubes and  venous set w ith blood. 
NOTE: I t  is advisable to create some 
additional pressure in  the outflow line 
to m ake cellulose tub ing  distend. This 
m ay be done by briefly holding the  ou t­
flow end of the  venous set 100 cm. 
above the  level of the  kidney.
3. S h u t off blood pum p (E). Clam p in­
flow line between side arm  and  blood 
pum p and  fill rem ainder of a rte ria l 
tub ing  w ith blood.
4. To establish blood level one to two 
inches above filter in  each cham ber, 
carefully release clam p on side arm s 
(L) to  bleed a ir out. W hen desired 
level is a tta ined , clam p securely. If
level is too high, a  syringe m ay be 
connected to  adap te r on side arm  afte r 
rem oving pro tector and  a ir forced in  
to reduce blood level. M edication may 
be added if desired by using a  syringe 
in  the  sam e m anner or preferably by 
in jection  in to  the  rubber sections on 
th e  inflow or outflow tubes of the coil 
un it.
5. W hen blood appears a t th e  outflow 
end of th e  un it, the  ca the ters  are a t­
tached  to  the  venous and  a rte ria l sets.
D ura tion  of tre a tm e n t is 5-7 hours, d in ing  
which tim e th e  p a tien t needs continuous ob­
servation.
1000 USP heparin  u n its  (approx. 10 mg.) 
are injected in to  the  inflow (arteria l) line 
approxim ately every hour du ring  the  first 
hours of dialysis. C lotting tim e on blood draw n 
from  the blood outflow line should be done 
hourly and  should be m ain ta ined  between 15 
to 20 m inutes (Lee-WTiite glass tube method. 
End point—first evidence of clo tting  in  tu b e ) . 
W hen clo tting  occurs w ith in  20 m inutes, 2000 
USP heparin  un its  are given to the  patien t.
No additional heparin  is given during  the 
la st two hours of dialysis as long as th e  clot­
ting  tim e is longer th a n  10 m inutes. WThen 
there is danger of occurrence of ac tua l bleed­
ing a t the  end of the  dialysis, 1 mg. p rotam ine 
sulfate, for each 100 USP heparin  u n its  used, 
is slowly given intravenously.
PRECAUTIONS
1. At a flow ra te  of 200-400 ml. of blood per 
min., a p a tien t m ay bleed to dea th  in  a few 
m inutes if a broken tube or loose connection is 
not noticed. O perator of the ap p ara tu s  should 
keep the  u n it  under observation a t all times. 
Careful check and  control of th e  p a tie n t’s 
blood pressure and  general condition should 
be m ade du ring  th e  period of dialysis.
2. In  p a tien ts  w ith low blood pressure or 
sm all arteries, the  a rte ria l wall m ay be sucked 
in to  the opening of the  ca the ter, a  vacuum  
created an d  a ir sucked in  th ro u g h  punctu re  
holes in  th e  tubes. Therefore, an  open buret 
or inverted blood bottle w ith  a ir  ven t is pro­
vided on th e  side arm  of th e  a rte ria l set. Vac­
uum  m ay be broken by infusing a sm all 
am ount of blood. If  a rte ria l flow is sm all, it
m ay be necessary to han g  th e  bu ret or blood 
bottle a t  a certain  level and  ad ju st th e  blood 
pum p so th a t  th is level stays constan t and  no 
vacuum  is produced. W hen blood flow is 
abundan t, the  buret or blood bottle should 
be clam ped off.
3. Perforation  of a vein w ith the  outflow 
ca the ter m ay cause enorm ous hem atom as. 
The re tu rn  vein should be checked carefully 
during  the  first m inutes of operation.
4. If th e  lower p a r t  of th e  saphenous vein 
is used for blood re tu rn , resistance m ay be so 
h igh th a t  h igh  back pressure builds up  in  the  
kidney. This also m ay occur if adhesive tape 
or position of th e  arm  obstructs th e  re tu rn  
flow. These difficulties can  be recognized by 
observing th e  pressure in  th e  filter cham bers.
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5. Em pty containers of electrolytes should 
be kep t as proof for correct com position of the 
dialyzing fluid.
6. T em perature of th e  dialyzing fluid m ust 
be w atched carefully a t all tim es.
7. Blood levels in  th e  filter cham bers m ust 
be m ain ta ined  th ro u g h o u t the  dialysis.
8. Carefully position th e  pum p tubes of 
the  a rte ria l set in  th e  proper openings m ak­
ing sure th a t  they  are no t p inched by the 
housing of the  S igm am otor pum p.
9. The lam p should be placed no closer to 
th e  p lastic cover th a n  8 inches.
10. C ondensation on the  p lastic cover can 
be reduced by application  of silicone to the  
inside surface by m eans of com mercially avail­
able silicone im pregnated  cloths.
11. D ialyzing fluid m ust be isotonic before 
s ta rtin g  c ircu lating  pum p to prevent hem ­
olysis of blood in  th e  cellulose tubes.
12. H eating  elem ent in  ta n k  m u st be off 
w hen it is no t com pletely covered w ith solu­
tion.
EQUIPM ENT
All of th e  item s below are available th ro u g h  TRAVENOL LABORA­
TORIES, INC.—MORTON GROVE, ILLINOIS.
EXPENDABLE EQUIPMENT
CATALOG 
LIST NO.
U200 DISPOSABLE COIL KIDNEY (COMPLETE)
This Unit Consists of Three Elements
U200A COIL DIALYZING UNIT 
U200B INLET (ARTERIAL) SET 
U200C OUTLET (VENOUS) SET
U510 TAPERED CATHETERS FR 14 TO FR  5— 12/BOX
NONEXPENDABLE EQUIPMENT
CATALOG 
LIST NO.
UA-10 100 LITER DIALYZING PUMP-TANK UNIT— 60 CYCLE
FUA-10 100 LITER DIALYZING PUMP-TANK UNIT—50 CYCLE 
UA-11A SIGMAMOTOR BLOOD PUMP, MODEL T I^ -6 0  CYCLE 
FUA-11A SIGMAMOTOR BLOOD PUMP, MODEL T I ^ 5 0  CYCLE
FOR DIALYZING FLUID
CATALOG 
LIST NO.
TG114 1000 ML. 40% TRAVERT (INVERT SUGAR) SOLUTION IN
POUR BOTTLE
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STATISTICAL METHODS
SYMBOLS 
t TEST 
ANALYSIS OP VARIANCE 
REGRESSION EQUATION 
C01PPICIENT OP CORRELATION 
COMPARISON OP REGRESSION COEPPICIENTS 
CONFIDENCE LIMITS
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The statistical techniques used were all 
standard methods and only a brief description 
is necessary. Frequent reference was made to 
works by Bernstein and Weatherall (1952),
Fisher and Yates (1957) and Fisher (1958) and 
considerable guidance and tuition was given by 
Dr. R. A. Robb, Mitchell Lecturer in Statistics, 
University of Glasgow. All calculations however, 
were made by the author using a Facit calculating 
machine and the author accepts responsibility 
for the choice of methods, calculations and 
interpretation of results.
The following symbols were used: 
x and y = when two values of the same sort were 
studied.
x, x^, x^ = when three values of the same sort 
were studied.
Y = the value of y corresponding to a given 
value of x obtained from the regression 
equation relating y to x.
S(x) r the sum of all the values of x.
S(X) = the sum of S(x)+ Six^ + S l x ^ ..........
/S(x2) = the sum of all the values of (x2).
(Sx)2 r the square of S(x).
n — the number of observations.
B = the sum of n + nn .... ....... .1 2
(x)= the arithmetic mean of S(x).
(xy) = the product of x and y.
S(xy) « the sum of all the values of (xy).
S(x) S(y) = the product of S(x) and S(y).
V = degrees of freedom 
r = coefficient of correlation, 
sd = standard deviation, 
se =- standard error.
t = a statistic calculated from the mean and 
the standard error.
F = a statistic calculated as the ratio of two 
estimates of variance.
P -- the probability of a complex event occurring.
(153)
t TEST
The t test was used to test whether the 
means of two samples x and y differed 
significantly.
The standard deviation of all values was 
calculated from the equation
„ S(x - x)2-i_S(y - y)2 
(sd)2 = ----------------------
(nx+ n y ' 2)
and the standard error of the difference between 
means from the equation
(se)2 = (sd)2. (| + |  )
x y
The value of t was then found from the equation
( *  -  y )
t = se
Where t was equal or greater than tQ the
means were significantly different at the 5%
level of significance and where t was equal or
greater than tQ the means were significantly
different at the 1% level of significance. The
values for tQ and tQ were obtained from
the table of the t distribution with (n 4-n - 2)x y
degrees of freedom.
(154)
AHALYSIS OF VARIANCE
This technique was used to test whether 
the means of say three samples differed 
significantly. The following values were 
calculated:
(1) The total sum of squares for three samples
A = S(x2)+S(x 12) +  S(x 22) - (SX)2
N
(2) The sum of squares between groups (B):
B = (Sx)2+  (Sx 1)2+(3 x 2)2 - (SX)2
N
(3) The residual sum of squares was calculated 
by subtracting B from A and also independently 
from the equation:
S(x - x)24-S(x1 - x1)2-v-S(x2 - x2)2
(4) The degrees of freedom between groups (V-^ )
V1 = No. of groups - 1.
(5) The total degrees of freedom ( :
V3 = (N - 1)
(6) The residual degrees of freedom (V^)
(155)
The values were then analysed as follows:
Source
of
Variation
Degrees
of
Freedom
Sum
of
Squares
Variance
Mean
Square
F
Between
Groups h
B B/V, = C
C/D
Besidual V2 A - B A-B/Vg = D
TOTAL
V3
A
The probability of a difference between the
means was found by comparing F with the values
of Fq and in the tables the degrees
of freedom V^ and V^ corresponding to the greater
and lesser mean square respectively.
The probability of a difference between
(xx) and (Xg) say was found by a t-test, t being
found by dividing the difference of the means
by the standard error which was obtained by
taking the square root of the product of the
1 1 \
residual mean square (D) and lr **" r )•
(156)
REGRESSION EQUATIONS 
fhe linear regression of one variate j on 
another variate x was calculated from the 
equation:
Y = y +  b (x - x)
5 U  - x)• (y - y)
where h =
S(x - x)2
■i o Y ^ Y (s(x - *)-(y - y)) = (S(x - x)-(y - y)) i.e. X = y + x (-----------  ^.x (---------  ---- )
( S(x - x) ) ( S(x - x) )
(157)
C O E FFIC IE N T O f COKBELATION
The coefficient of correlation (r) was 
calculated from the equation:
„ S(x - x) (y - y) S(x - x) ly - y)
_   • __________________
S(x - x)2 S(y - y)2
S(x - x) (y - y) being calculated from S(x), 
S(y), S(xy) and n thus:
S(x - x) (y - y) = (s(xy) -|S(x)S(y)
' n
—  9 2and S(x - x) being calculated from S(x) and
n thus:
Six - x)2 = S(x2) - (Sx)2
n
and S(y - y) similarly.  ^ ^
(158)
COMPARISON OI1 REGRESSION COEFFICIENTS
The. method of testing whether two regression 
coefficients differed significantly was as follows. 
The following values were calculated for each group
The standard error (se) of the difference of 
the regression coefficients was then obtained from 
the equation:
The value of t was then found by dividing 
the difference of the regression coefficients by 
the standard error. The regression coefficients 
were not significantly different from each other 
at the level of significance if the value of t 
was less than tQ as found in the table of the 
t-distribution.
S(x - x ) 2
V = (n- - 2)
+• -------1— j?)
S(x1 - xx) )
1
(159)
CALCULATION Off 95ft CONFIDENCE LIMITS
The 95^ > confidence limits were calculated
by multiplying the standard error of the
regression line at various values of x by
t« r^- obtained from the table of the t distribution O.Op
for (n - 2) degrees of freedom. The standard 
error was obtained from the equation.
(in - 1 ) 2Cl - r )) separately.( ------
((n - 2) )
(160)
CASE EEPOBTS
(161)
The reports are listed in alphabetical 
order. Particular attention is paid to diagnostic 
investigations. The age given is the age on 
admission to hospital unless otherwise stated. 
Abbreviations have been used freely, e.g. W.I.G. 
for Western Infirmary, Glasgow, V.L.H. for Vale 
of Leven Hospital, Alexandria, HEA for histamine 
fast achlorhydria as judged by the augmented 
histamine test (Kay 1953), IE for intrinsic factor 
and so on. Achlorhydria implies absence of gastric 
acid as demonstrated by methods other than the 
augmented histamine test. The investigations in 
some cases were not as complete as were desired 
for a variety of reasons and the diagnosis given 
for each case is based on the available evidence.
(162)
Case F.A. female, aged 58. Admitted W.I.G. May 
1956. Macrocytic anaemia, Hb. 41$.
Megaloblastic erythropoiesis. HFA. Treated 
with parenteral vitamin B^^. Reticulocytes 
12$ on 5th day. Schilling test 5.4$: with 
IF 24.5$.
Diagnosis: pernicious anaemia.
Case J.A. male aged 59. Admitted W.I.G. September
1958. Macrocytic anaemia, Hb. 26$.
Megaloblastic erythropoiesis. HFA. Serum 
30 uug/ml. Serum iron 140 ug/100 ml. Treated 
with 1 pint blood transfusion and parenteral
jr  Q
Co vitamin Serum iron 5 ug/100 ml on
2nd day: reticulocytes 33$ on 6th day. Barium
meal and follow through normal. Schilling
test 0$: with IF 12.0$.
Diagnosis: pernicious anaemia.
Case C.B. male aged 65. Admitted W.I.G. August
1958. Dietary history poor. Macrocytic
anaemia, Hb. 34$. Megaloblastic erythropoiesis.
HFA. Serum B-^ 59 uug/ml. Treated with 
58parenteral Co vitamin B^* Reticulocytes 
12$ on 7th day. Barium meal and follow through 
normal. Xylose excretion 5.8 g. Faecal fat
(163)
/4.0 g/day ( 3 x 3  day collection). Schilling 
tests - 1 3.8%, 19.5#, 20.9#, 1 3.6#, 10.4# 
and 12.5#.
Diagnosis: dietary vitamin deficiency.
Case B.C. female aged 65. Admitted W.I.G.
November I9 6 0. Macrocytic anaemia, Hb. 44#.
Megaloblastic erythropoiesis. HFA. Serum B^^
40 uug/ml. Serum iron 110 ug/100 ml.
58Treated with parenteral Co vitamin 
Serum iron 25 ug/100 ml on 3rd day: reticulocyte 
19# on 7th day. Schilling test 0#: with IP 
9.4#.
Diagnosis: pernicious anaemia.
Case E.C. female aged 61. Admitted V.L.H.
February 1959. Macrocytic anaemia, Hb. 38#.
Megaloblastic erythropoiesis. HFA. Serum
®12 ^  uug/ml. Treated with parenteral 
58Co vitamin B^* Reticulocytes 25# on 6th 
day. Schilling test 3#: with IP 12#.
Diagnosis: pernicious anaemia.
Case E.V.C. female aged 59. Admitted V.L.H.
December 1958. Macrocytic anaemia, Hb. 32#. 
Megaloblastic erythropoiesis. HPA. Serum
(164)
/ B12 25 uug/ml. Treated with parenteral 
vitamin B.^. Reticulocytes 20# on 7th day. 
Schilling test 0#:with IP 13#.
Diagnosis: pernicious anaemia.
Case H.C. female aged 57. Admitted W.I.G.
1951. Macrocytic anaemia, Hb. 40#.
Megaloblastic erythropoiesis. Achlorhydria. 
Treated with parenteral vitamin B.^. 
Reticulocytes 40# on 5th day. Later given 
oral B ^  and IP but failed to maintain normal 
serum levels and parenteral vitamin B ^  
recommenced 1958. Schilling test 4.4#: 
with IP 9*5#.
Diagnosis: pernicious anaemia.
Case I.C. female aged 70. Admitted W.I.G.,
October 1958. Macrocytic anaemia, Hb. 53#.
Megaloblastic erythropoiesis. HPA. Serum
B12 ^  uug/ml. Serum iron 115 ug/100 ml.
58Treated with parenteral Co vitamin B^.
Serum iron 10 ug/100 ml on 2nd day: Reticulocyte 
12# on 3rd day. Schilling test 0#: with IP 
26.5#.
Diagnosis: pernicious anaemia 
Case J.C. male aged 77. Admitted V.L.H. March
(165)
/1959. Macrocytic anaemia, Ht>. 41 
Megaloblastic erythropoiesis. HPA, Serum
®12 ^  Treated with parenteral
5bCo vitamin B-j_2 * Heticulocytes 16% on
5th day. Schilling test 1.3%: with IP 11.1%.
Diagnosis: pernicious anaemia.
Case M.C. female aged 65. Admitted W.I.G.
April 1959. Macrocytic anaemia, Hb. 56%.
Megaloblastic erythropoiesis. HPA. Serum
B12 74 uug/ml. Serum iron 9b ug/100 ml.
58
Treated with parenteral Co vitamin 
Serum iron 45 ug/100 ml on 3rd day. 
Reticulocytes 17% on 6th day. Schilling 
test 0%: with IP 10%.
Diagnosis: pernicious anaemia.
Case T.C. male aged 22. Admitted W.I.G. after 
a haematemesis 1954. Partial gastrectomy. 
Recurrences of bleeding 1955, 1957, 1958. 
Laparotomy 195b - angiomatous lesion in 
gastric remnant - total gastrectomy. Serum 
fell to 140 uug/ml 14 months after 
operation and parenteral vitamin B ^  begun. 
Schilling test 0%: with IP 8%.
Diagnosis: IP deficiency following total
(166)
/gastrectomy.
Case C.D. male aged 55. Admitted W.I.G# March
1959. Macrocytic anaemia, Hb. 33%.
Megaloblastic erythropoiesis. HPA. Serum
1*12 ^  uus/ml* Serum iron 35 ug/100 ml.
58Treated with parenteral Co vitamin B^*
Serum iron 5 ug/100 ml on 2nd day: reticulocytes 
35% on 5th day. Barium meal and follow 
through normal. Paecal fat 8 .8 g./day (3 day 
collection). Repeated Schilling tests <. 5%: 
with IP <5%: after tetracycline 11.7%.
Diagnosis: loop syndrome.,
Case J.D. male aged 59. Admitted W.I.G. January
1960. Macrocytic anaemia, Hb. 41%.
Megaloblastic erythropoiesis. HPA. Serum
B^2 45 uug/ml. Serum iron 160 ug/100 ml.
58Treated with parenteral Co vitamin B^*
Serum iron 15 ug/100 ml on 2nd day: 
reticulocytes 26% on 7th day. Schilling 
test 2.8%: with IP 23*4%.
Diagnosis: pernicious anaemia.
Case A.I. female aged 31, when diagnosed as having 
pernicious anaemia 1940. Treated with 
parenteral liver extract and later with
(167)
/vitamin until 1957. Developed
Addison*s disease 1959 and treated with salt
DOCA and later with Cortisone. Anaemia
recurred and readmitted W.I.G-. February I960.
Macrocytic anaemia, Hb. 50%. Megaloblastic
erythropoiesis. HFA. Serum vitamin
120 uug/ml. Serum iron 5 ug/100 ml. Treated
5bwith parenteral Go vitamin B^. Beficulocytes
6$ on 5th day: Faecal fat 2 g./day (3 day
collection). Schilling test 0%: with IF 15%.
Diagnosis: pernicious anaemia. Addison*s disease
Case H.F. female aged 55. Admitted W.I.G. February
1959. Macrocytic anaemia, Hb. 42%. Megaloblast
erythropoiesis. HFA. Serum B ^  30 uug/ml.
Serum iron 150 ug/100 ml. Treated with 
5bparenteral Go vitamin B^. Serum iron 
45 ug/1 0 0 ml on 1st day: reticulocytes 21% 
on 5th day. Schilling test 0.7%: with IF 
11.0%.
Diagnosis: pernicious anaemia.
Case J.F. female aged 72. Admitted W.I.G.
January 1959. Macrocytic anaemia, Hb. 3b%. 
Megaloblastic erythropoiesis. HFA. Serum
(168)
/Big 52 uug/ml. Treated with parenteral 
5 5
Go vitamin Reticulocytes 23% on
5th day. Schilling test 4.2%: with IF 16.1%.
Diagnosis: pernicious anaemia.
Case M.F. female aged 6 6. Admitted W.I.G.
1959. Macrocytic anaemia, Hh. 54%.
Megaloblastic erythropoiesis. Achlorhydria.
Treated with parenteral vitamin B ^  an(^
later with oral vitamin B ^  and IF. Failed
to maintain normal serum B^^ levels and
parenteral vitamin B ^  recommenced 1958.
Schilling test 0%: with IF 8%.
Diagnosis: pernicious anaemia.
Case G.G. male aged 60. Admitted W.I.G. August
1959. Macrocytic anaemia, Hb. 60%.
Megaloblastic erythropoiesis. HFA. Serum
B^^ 40 uug/ml. Serum iron 225 ug/100 ml.
58Treated with parenteral Co vitamin B-^. 
Serum iron 160 ug/100 ml. on 2nd day. 
Reticulocytes 15% on 5th day. Schilling test 
0%: with IF 8.7%.
Diagnosis: pernicious anaemia.
Case J.G. female aged 76. Admitted W.I.G. April
(169)
/1956. Macrocytic anaemia, lib. 47$. 
Megaloblastic erythropoiesis, HFA. Serum 
I*i2 26 uug/ml. Treated with parenteral vitamin 
B ^ * Reticulocytes 13$ on 6th day. Schilling 
test 1.0$: with IF 15$.
Diagnosis: pernicious anaemia.
Case J.G.G. male aged 45. High partial gastrectomy 
for carcinoma of stomach May 1951. Readmitted 
W.I.G. October 1959. Macrocytic anaemia,
Hb. 35$. Megaloblastic erythropoiesis.
Serum vitamin 36 uug/ml. Treated with
38parenteral " Co vitamin £^2 * Reticulocytes 
34$ on 5th day.
Diagnosis: presumed IF deficiency following 
high partial gastrectomy.
Case J.Q.G. male aged 60. Admitted W.I.G.
August 1956. Macrocytic anaemia, Hb. 73$* 
Megaloblastic erythropoiesis. HFA. Serum 
B12 45 uug/ml. Treated with parenteral 
vitamin • Reticulocytes 14$ on 7th day. 
Barium meal and follow through normal.
Schilling test 1.5$: with IF 14.5$.
Diagnosis: pernicious anaemia.
(170)
Case J.S.G. male aged 73* Brother of Case J.O.G.
Admitted W.I.G* March 1961. Macrocytic anaemia, 
Hb. 68%. Megaloblastic erythropoiesis. HPA. 
Serum vitamin 40 uug/ml. Serum iron
130 ug/100 ml. Treated with parenteral 
vitamin B  ^ zinc tannic acid complex.
Serum iron on 2nd day 23 ug/100 ml: rise 
in peripheral blooad to normal. Schilling 
test 0$: with IP 22.7%.
Diagnosis: pernicious anaemia.
Case M.G. female aged 66. Admitted V.L.H.
April 1956. Macrocytic anaemia, Hb. 38%. 
Megaloblastic erythropoiesis. HPA. Serum 
vitamin <. 50 uug/ml. Treated with 
parenteral vitamin B^. Rise in peripheral 
blood to normal. Schilling test 0%: with IP 
11.4%.
Diagnosis: pernicious anaemia.
Case A.H. male aged 4 8. Admitted W.I.G.
September 1959. History of treatment of 
anaemia by liver injections 1929.
Macrocytic anaemia, Hb. 42%. Megaloblastic
erythropoiesis. Pree gastric acid. Serum
(171)
/vitamin 25 uug/ml. Serum iron 165 ug/100
58Treated with parenteral Co vitamin B^.
Reticulocytes 12# on 5th day. Faecal fat
6 g/day (3 day collection). Barium meal
and follow through normal. Schilling tests
6.5#: with IF 1.9# and 1.5#*
Diagnosis: malabsorptive disease.
Case J.H. female aged 6 6. Admitted W.I.G. June
1959- Macrocytic anaemia, Hb. 26#.
Megaloblastic erythropoiesis. HFA. Serum
B12 73 uug/ml. S erum iron 250 ug/1 0 0 ml.
58Treated with parenteral Co vitamin B
12
Serum iron 55 ug/100 ml. on 2nd day: 
Reticulocytes 65# on 6th day. Schilling test 
0#: with IF 14*7#.
Diagnosis: pernicious anaemia.
Case J.Q.H. male aged 67. Admitted W.I.G. 
September 1956. Macrocytic anaemia, Hb.
49#. Megaloblastic erythropoiesis. HFA.
Serum < 50 uug/ml. Treated with parenteral 
vitamin B^. Reticulocytes 12# on 5th day. 
Barium meal and follow through normal. 
Schilling test 1#: with IF 16.8#.
Diagnosis: pernicious anaemia.
(172)
Case T.H. male aged 45. Admitted W.I.G. June
1955. Total gastrectomy with splenectomy, 
partial pancreatectomy and oesophago- 
jejeunal anastomosis for carcinoma of stomach 
June 1957 - Hb. 87#. Macrocytic film. 
Megaloblastic erythropoiesis. Serum B ^
100 uug/ml. Schilling test 0#: with IF 12.3# 
Diagnosis: intrinsic factor deficiency 
following total gastrectomy.
Case C.J. female aged 53. Admitted W.I.G. March
1956. Macrocytic anaemia, Hb. 57#. 
Megaloblastic erythropoiesis. Diagnex test 
meal showed gastric acid. Faecal fat
2 g./day (4 day collection). Treated with
parenteral vitamin B.^ and oral folic acid
and discharged on oral folic acid only.
Readmitted November 1959. Macrocytic anaemia
Hb. 56#. Megaloblastic marrow. Serum B-^
5845 uug/ml. Treated with parenteral Co 
vitamin B-^. Schilling test 0#: with IF 
34.1#. Later developed thrombocytopenia. 
Readmitted after a haematernesis October I960.
At laparotomy a malignant gastric polyp was
(173)
/found, and partial gastrectomy performed as
well as splenectomy. Gastric mucosa
atrophic: jejeunal mucosa normal.
Diagnosis: pernicious anaemia.
Case D.J. male aged 6 8, on coming under observation
in 1957 v/hile being treated with oral B ^
and IP. Diagnosis of pernicious anaemia
previously established on macrocytic anaemia,
megaloblastic erythropoiesis and achlorhydria.
Pailed to maintain normal serum level
on oral therapy and parenteral therapy
instituted. Schilling test 1.9$: with IP 10.0%.
Diagnosis: pernicious anaemia.
Case J.J. male aged 40. Admitted W.I.G. August
1959. Macrocytic anaemia, Hb. 54$.
Megaloblastic erythropoiesis. HPA. Serum
*^12 ^  So:]?™ iron 120 ug/1 0 0 ml.
58
Treated with parenteral Co vitamin B^ .2*
Serum iron 60 ug/100 ml on 2nd day: 
reticulobytes 10$ on 6th day. Schilling test 
0$: with IP 10.3$.
Diagnosis: pernicious anaemia.
(174)
/Case S.J. female aged 47. Vegetarian since
childhood. Admitted W.I.G. September 1959*
Macrocytic anaemia, Hb. 42$. Megaloblastic
erythropoiesis. HFA. Serum 3 ^  25 uug/ml.
Serum iron 172 ug/100 ml. Treated with 
58parenteral Co vitamin B^. Serum iron 
57 ug/1 0 0  ml on 2nd day: reticulocytes 26$ 
on 4th day. Schilling tests 22$, 10.7$,
1 3.1$, 1 4.0$, 2.7$, 9.4$, 14.9$, 15.3$.
Xylose excretion 1.6, 3*9 g. Faecal fat 
3 ~ 4 g./day (3 day collections). Banum 
meal and follow through normal. Gastric 
biopsy normal. Jejeunal biopsy atrophic. 
Diagnosis: vitamin B ^  deficiency probably 
due to deficient dietary intake in a patient 
with evidence of rnalabsorptive disease.
Case A.K. 1 male aged 56. Transferred W.I.G. 
with anuria and uraemia due to paralytic 
ileus following removal of gangrenous appendix. 
Dialysed with fall in blood urea from 596 mg.$ 
to 290 mg.$. Clearance of injected vitamin 
^12 5 th and 6th hours of dialysis.
Died suddenly shortly after dialysis.
(175)
/Case A.K. 2 female aged 30. Transferred W.I.G. 
with anuria and uraemia following intra­
abdominal haemorrhage after Caesarean section. 
Dialysed with fall in blood urea from 380 mg.$ 
to 156 mg.$. Clearance of injected vitamin 
Bf2 studied in 5th and 6th hours of dialysis. 
Spontaneous diuresis with complete recovery.
Case A.K. 3 female aged 41. Transferred W.I.G, 
with anuria and uraemia. Brief history of 
pyrexia and oedema of legs. Dialysed on 
four occasions in next 30 days. Clearance 
of injected vitamin B ^  studied during 
first dialysis. Benal biopsy showed 
appearances suggestive of chronic nephritis. 
Died in uraemic coma 47 days after admission. 
Diagnosis of chronic nephritis confirmed at 
autopsy.
Case A.K. 4 female aged 52. Admitted W.I.G. 
with polyarthritis, skin rash, oedema of 
all tissues, anuria, uraemia and later 
delirium and coma. Dialysed with fall in 
blood urea from 420 mg.$ to- lBO mg.$.
Eventual recovery.
Case A.K. 5 female aged 43* Known mental
(176)
/defective. Admitted to neurosurgical unit 
for investigation of signs suggestive 
intracranial space occupying lesion.
Cortical atroxjhy diagnosed on ventriculography. 
Became comatose and oliguric and found to 
have hyperglycaemia and uraemia. Transferred 
to W.I.G. Hyperglycaemia controlled by 
insulin but blood urea rose. Dialysed with 
fall in urea 520 mg.$ to 120 mg.$. Clearance 
of injected B ^  studied in 5th and 6th 
hours of diaTLysis. Died of pneumonia 13 days 
later.
Case A.K. 6 female a.ged 30. Known case of
pulmonary tuberculosis with non functioning 
left kidney. Transferred to W.I.G. with 
anuria and uraemia. Dialysed with fall in 
urea 392 mg.$ to 170 mg.$. Clearance of 
injected vitamin B-^ studied in 4th and 5th 
hours of dialysis. Spontaneous diuresis and 
recovery.
Case H.K. female aged 62. Admitted W.I.G.
March 1959. Macrocytic anaemia, Hb. 60$. 
Megaloblastic erythropoiesis. HFA. Serum
(177)
/vitamin B 50 uug/ml. Treated with
58
parenteral Go vitamin Reticulocytes
15$ on 6th day. Barium meal and follow 
through normal. Schilling test 4*0$: 
with IP 16.0$.
Diagnosis: pernicious anaemia.
Case J.K. male aged 6 8. Admitted V.L.H.
November 1958. Macrocytic anaemia, Hb. 31$.
Megaloblastic erythropoiesis. HPA. Serum
B12 36 uug/ml. Treated with parenteral 
58
Co vitamin B^g. Reticulocytes 36$ on 
4th day. Schilling test 0$: with IP 15$. 
Diagnosis: pernicious anaemia.
Case J.L. male aged 50. Admitted W.I.G. July
1956. Macrocytic anaemia, Hb. 33$.
Megaloblastic erythropoiesis. HPA. Treated
with parenteral vitamin B^. Reticulocytes 
11$ on 5th day. Barium meal and follow 
through normal. Schilling test 3$s with 
IP 10.6$.
Diagnosis: pernicious anaemia.
CASE W.L. male aged 7 8. Admitted V.L.H.
April 1958. Macrocytic anaemia, Hb. 38$.
(178)
/Megaloblastic erythropoiesis. HPA. Serum
25 uug/ml. Treated with parenteral
vitamin B^ .2* Rise peripheral blood values
to normal. Readmitted after cerebrovascular
accident one year later and died in hospital
Gastric mucosa atrophic at post mortem.
Diagnosis: pernicious anaemia
Case J.A.M. female aged 80. Admitted W.I.G.
May 1959. Macrocytic anaemia, Hb. 43$.
Megaloblastic erythropoiesis. HPA. Serum
B12 120 uug/ml. Serum iron 150 ug/100 ml.
58Treated with parenteral Co vitamin B^* 
Serum iron 105 ug/100 ml on 2nd day. 
Reticulocytes 15$ on 6th day. Schilling test 
16$: with IP 6$. Barium meal and follow 
through - hiatus hernia. Paecal fat 25$ of 
drie d spe cimen•
Diagnosis: malabsorptive disease.
Case J.O.M. female aged 6 8. Admitted W.I.G.
February I960. Macrocytic anaemia, Hb. 51$.
Megaloblastic erythropoiesis. HPA. Serum
B12 42 uug/ml. Serum iron 135 ug/100 ml.
58Treated with parenteral Co vitamin B.^*
(179)
/Serum iron 10 ug/100 ml on 2nd day. 
Reticulocytes 10$, on 6th day. Schilling 
test 1.6$: with IF 17.2$.
Diagnosis: pernicious anaemia.
Case E.McB. female aged 51. Admitted V.L.H.
May 195b. Macrocytic anaemia, Hb. 36$. 
Megaloblastic erythropoiesis. HFA.
Serum B ^  37 uug/ml. Treated with parenteral 
' Co vitamin B^^. Reticulocytes 18$ on 5th 
day. Barium meal and follow through normal. 
Schilling test 1.5$: with IF 13.7$.
Diagnosis: pernicious anaemia.
Case M.McB. female aged 56. Admitted V.L.H. 
August 1956. Macrocytic anaemia, Hb. 39$. 
Megaloblastic erythropoiesis. HFA.
Treated with parenteral vitamin B^^• Rise 
in peripheral blood values to normal. 
Schilling test 1.5$: with IF 12.1$.
Diagnosis: pernicious anaemia.
Case D.McC. male aged 52. Admitted W.I.G.
Juice 1959. Macrocytic anaemia, Hb. 74$. 
Megaloblastic erythropoiesis. HFA. Serum 
®12 ^  uug/ml. Serum iron 165 ug/100 ml.
(180)
/Treated with parenteral 5^Co vitamin B12.
Serum iron 45 ug/100 ml. on 2nd day:
reticulocytes 17# on 5th day.
Diagnosis: pernicious anaemia.
Case I.McC. female aged 67. Admitted W.I.G.
November 1956. Macrocytic anaemia, Hb. 41#.
Megaloblastic erythropoiesis. HPA.
Gastroscopy atrophic mucosa. Serum B^2
30 uug/ml. Treated with parenteral vitamin
^12* Reticulocytes 30# on 5th day.
Schilling test 1#: with IP 17.2##
Diagnosis: pernicious anaemia.
Case J.McQ. male aged 6 3. Admitted W.I.G.,
December I960. Macrocytic anaemia, Hb. 35#.
Megaloblastic erythropoiesis. HPA.
Serum B^2 68 uug/ml. Serum iron 114 ug/100 ml.
58Treated with parenteral Co vitamin B^g.
Serum iron 23 ug/100 ml on 2nd day. 
Reticulocytes 19# on 7th day. Schilling 
test 6#: with IP 20.5#.
Diagnosis: pernicious anaemia.
Case K.McD. female aged 47. Admitted W.I.G.
June 1959. Macrocytic anaemia, Hb. 37#.
(181)
/Megaloblastic erythropoiesis. HPA.
Serum B ^  50 uug/ml. Serum iron 115 ug/100 ml.
58Treated with parenteral Co vitamin
Serum iron 70 ug/100 ml on 2nd day:
reticulocytes 19% on 6th day. Barium meal
and follow through normal.
Diagnosis: pernicious anaemia.
Case M.McD. female aged 69. Admitted W.I.G.
April 195b. Macrocytic anaemia, Hh. 33$.
Megaloblastic erythropoiesis. HPA. Serum
^12 ^  uu&/ml* Serum iron 175 ug /100 ml.
58
Treated with parenteral Co vitamin 
Serum iron 17 ug/100 ml on 4th day: 
reticulocytes 26$* on 6th day.
Diagnosis: pernicious anaemia.
Case J.McP. female aged 68. Admitted W.I.G.
April 1958. Macrocytic anaemia, Hb. 60%. 
Megaloblastic erythropoiesis. HPA. Serum 
B-j^ 2 H O  uug/ml. Treated with parenteral 
vitamin Reticulocytes 12% on 6th
day. Barium meal and-follow through normal. 
Schilling test 1%: with IP 17.2%.
Diagnosis: pernicious anaemia.
(182)
/Case H.McGr. male aged 40. Admitted W.I.G.
September 1959* Macrocytic anaemia, Hb*
45%. Megaloblastic erythropoiesis, HFA.
Serum < 25 uug/ml. Serum iron 250 ug/100 ml.
58Treated with parenteral Go vitamin ^.12
Serum iron 75 ug/100 ml.on 2nd day:
reticulocytes 16% on 5th day. Barium meal
and follow through normal. Schilling test
3.8%: with IF 18.4%
Diagnosis: pernicious anaemia.
Case J.McG. male aged 67. Laparotomy November
I960 - intestinal diverticulosis. Admitted
W.I.G. December I960. Macrocytic anaemia,
Hb. 54%. Megaloblastic erythropoiesis.
Free gastric acid. Serum B ^  32 uug/ml.
Serum iron 30 ug/100 ml. Treated with 
58parenteral Co vitamin B^. Reticulocytes 
6% on 5th day. Faecal fat 9 g./day (3 day 
collection). Xylose excretion 4.7 g. Barium 
meal and follow through - diverticulosis 
of small bov/el. Barium anema normal.
Jejeunal biopsy normal. Schilling test 4%. 
Diagnosis: loop syndrome - small intestinal
(183)
/diverticulosis.
Case T.McG. male aged 65* Admitted W.I.G.
September 1956. Macrocytic anaemia, Hb* 33$.
Megaloblastic erythropoiesis. HPA.
Serum 51 uug/ml. Treated by one pint
blood transfusion and parenteral vitamin B^2•
Reticulocytes 19$ on 6th day. Schilling
test 2.1$: with IP 16.4$.
Diagnosis: pernicious anaemia.
Case C.McI. female aged 63* Admitted W.I.G.
January 195b. Macrocytic anaemia, Hb. 52$#
Megaloblastic erythropoiesis. HPA.
Gastroscopy - atrophic mucosa. Serum B-^
5840 uug/ml. Treated with parenteral Co 
vitamin B12* Reticulocytes 30$ on 5th day. 
Barium meal and follow through normal.
Died of cerebrovascular accident ten months 
later. Gastric mucosa atrophic at post mortem. 
Diagnosis: pernicious anaemia.
Case N.McL. male aged 47* Admitted W.I.G. 1944 
with corrosive gastritis subsequent to 
drinking solder flux. Total gastrectomy 
with oesophagojejeunal anastomosis,
(184)
/October 1944. Readmitted June 1950 with 
macrocytic anaemia, Hb. 32$ and megaloblastic 
erythropoiesis. Treated with parenteral 
vitamin and oral folic acid with complete
response. Later defaulted. Readmitted June 
1957 - macrocytic anaemia, Hb. 41$*
Megaloblastic erythropoiesis. Serum B^2 
< 60 uug/ml. Treated with parenteral vitamin 
B^. Rise in peripheral blood values to 
normal. Schilling test 0.3$: with IP 19$. 
Diagnosis: IP deficiency following total 
gastrectomy.
Case J.McM. male aged 58. Admitted W.I.G. May 1955.
Total gastrectomy for carcinoma of stomach.
Readmitted September 1959 - macrocytic anaemia,
Hb. 51$. Megaloblastic erythropoiesis. Serum
58Big 68 uug/ml. Treated with parenteral Co 
vitamin B^. Rise in peripheral blood values 
to normal. Schilling test 4$: with IP 15.4$. 
Diagnosis: intrinsic factor deficiency following 
total gastrectomy.
Case J.McQ. male aged 54. Admitted W.I.G.
1949* Partial gastrectomy for duodenal ulcer. 
Admitted V.L.H. August 1959. Macrocytic
(185)
/anaemia, Hb. 56fc. Megaloblastic
erythropoiesis. HFA. Serum B12 <. 25 uug/ml.
5btreated with parenteral Co vitamin 
Reticulocytes 20$ on 6th day. Schilling 
test 3*0$: with IF 14$.
Diagnosis: intrinsic factor deficiency 
following partial gastrectomy.
Case P.P. female aged 71. Admitted W.I.G.
February 1956. Macrocytic anaemia, Hb. 47$. 
Megaloblastic erythropoiesis. HFA. Treated 
with parenteral vitamin B-^. Reticulocytes 
11$, on 6th day. Schilling test 0$: with 
IF 11$.
Diagnosis: pernicious anaemia.
Case M.P. female aged 4b. Admitted V.L.H. May 1958. 
Macrocytic anaemia, Hb. 72$. Megalohlastic
erythropoiesis. HFA. Serum 3 ^  60 uug/ml.
58Treated with parenteral Co vitamin B^.
Rise in peripheral blood values to normal. 
Schilling test 1.6$: with IF 13.1$.
Diagnosis: pernicious anaemia.
Case C.R. female aged 69. Admitted W.I.G. August
1959. Macrocytic anaemia, Hb. 39$.
(186)
/Megaloblastic erythropoiesis. HFA. Serum
Bi2 <25 uug/ml. Serum iron 138 ug/100 ml.
58Treated with parenteral Co vitamin B^2*
Serum iron 0 ug/100 ml on 3rd day: reticulocytes 
30$ on 5th day. Barium meal and follow 
through normal. Schilling test 0$: with 
IF 14.4$.
Diagnosis: pernicious anaemia.
Case I.R. female aged 71. Admitted W.I.G.,
September 1956. Macrocytic anaemia, Hb.
44$. Megaloblastic erythropoiesis. HFA.
Treated with parenteral vitamin B^2.
Reticulocytes 14$ on 6th day. Barium meal
and follow through normal. Schilling test
0$: with IF 18.2$.
Diagnosis: pernicious anaemia.
Case M.R. female aged 53. Admitted W.I.G.
May 1958. Macrocytic anaemia, Hb. 19$.
Megaloblastic erythropoiesis. HFA. Serum
Big 62 uug/ml. Treated with one pint blood
58transfusion and parenteral Co vitamin B^2. 
Reticulocytes 20$ on 5th day. Schilling 
test 5.6$: with IF 13*2>b.
Diagnosis: pernicious anaemia.
(187)
Case S .R. male aged 70. Admitted W.I.G. June
1958. Macrocytic anaemia, Hb. 39$.
Megaloblastic erythropoiesis. HFA. Serum
25 uug/ml. Serum iron 125 ug/100 ml.
58Treated with parenteral Go vitamin 
Serum iron 0 ug/100 ml on 3rd day: reticulocytes 
30$ on 5th day. Barium meal and follow 
through normal. Schilling test 0$: with 
IF 14.4$.
Diagnosis: pernicious anaemia.
Case W.R. male aged 51* Admitted W.I.G. 1946.
Partial gastrectomy for duodenal ulcer.
Readmitted September 1959. Microcytic
anaemia, Hb. 60$. M.C.H.C. 25*7$.
Normoblastic erythropoiesis. Serum iron
87 ug/100 ml. Iron binding capacity 410 ug/
100 ml. Serum B ^  172 uug/ml. Given parenteral 
58Co vitamin B-^ prior to iron therapy. 
Diagnosis: iron deficiency following partial 
gastrectomy.
Case A.S. female aged 67. Admitted W.I.G. 1952. 
Macrocytic anaemia, Hb. 42$. Megaloblastic 
erythropoiesis. Achlorhydria. Treated with
(188)
/parenteral vitamin with full response.
Barium meal normal. Schilling test 2.8$: 
with IF 15*5$.
Diagnosis: pernicious anaemia.
Case J.S. female aged 51. Admitted V.L.H.
April 1959. Macrocytic anaemia, Hb. 58$. 
Megaloblastic erythropoiesis. HFA.
Serum B ^  50 uug/ml. Treated with parenteral
r Q
Co vitamin B-^. Reticulocytes 30$ on 
5th day. Barium meal and follow through 
normal. Schilling test 0$: with IF 12$. 
Diagnosis: pernicious anaemia.
Case M.S. female aged 68. Admitted V.L.H.
October 1959. Macrocytic anaemia, Hb. 44$. 
Megaloblastic erythropoiesis. HFA. Serum 
Big 42 uug/ml. Treated with parenteral 
•^Co vitamin B^. Reticulocytes 22$ on 
5th day. Died suddenly in acute cardiac 
failure on 12th day. P.M. - myocardial 
infarct: oedematous lungs: gastric mucosal 
atrophy.
Diagnosis: pernicious anaemia.
Case M.J.S. female aged 67. Admitted W.I.G.
February 1961. Microcytic ana.em.ia, Hb.44$,
(189)
/M.C.H.C. 23$• Normoblastic erythropoiesis. 
Serum iron 20 ug/100 ml. Serum B-^ 390 uug/ml. 
Given vitamin B-^ zinc tannic acid complex 
parenterally prior to iron therapy. Barium 
meal - duodenal diverticulum. Barium enema 
normal.
Diagnosis: iron deficiency anaemia (? cause).
Case S.S. male aged 54. Admitted W.I.G. April
1958. Macrocytic anaemia, Hb. 37$.
Megaloblastic erythropoiesis. HFA. Serum
B12 ^  uug/ml. Treated with parenteral 
58Co vitamin B^. Beticulocytes 16$ on
5th day. Schilling test 1.3$s with IB 15.7$.
Diagnosis: pernicious anaemia.
Case A.T. female aged 6 4. Investigated at OPD
V.L.H. 1958. Macrocytic anaemia, Hb. 79$.
Megaloblastic erythropoiesis. HFA. Serum
B ^  60 uug/ml. Treated with parenteral vitamin
Bn  ^with full response. Barium meal and 12
follow through normal. Schilling test 0$: 
with IF 22$
Diagnosis: pernicious anaemia.
(190)
Case J.T. female aged 61. Admitted W.I.G.
January 1961. Macrocytic anaemia, Hb. 50$. 
Megaloblastic erythropoiesis. HFA. Serum 
Bi2<25 uug/ml. Serum iron 90 ug/100 ml. 
Treated with parenteral vitamin B-^ zinc 
tannic acid complex. Serum iron on 3rd day 
35 ug/100 ml: reticulocytes 23$ on 5th day. 
Diagnosis: pernicious anaemia.
Case J.O.T. male aged 50. Investigated at OPD 
W.I.G. December I960. Macrocytic anaemia,
Hb. 35$. Megaloblastic erythropoiesis. HFA. 
Serum B-^ 62 uug/ml. Treated with parenteral 
*^Co vitamin B^^• Beticulocytes 1S$ on 
5th day. Schilling test 0$: with IF 13*9$. 
Diagnosis: pernicious anaemia.
Case M.T. female aged 59. Admitted V.L.H.
October 1958. Macrocytic anaemia, Hb. 56$. 
Megaloblastic erythropoiesis. HFA. Serum 
Bf2 50 uug/ml. Treated with parenteral 
^ C o  vitamin B-^reticulocytes 17$ on 
5th day. Schilling test 3.7$: with IF 12.5$ 
Diagnosis: pernicious anaemia.
(191)
Case R.T. male aged 78. Admitted W.I.G.
March 1958. Macrocytic anaemia, Hb. 31$. 
Megaloblastic erythropoiesis. HFA. Serum 
1*12 34 uug/ml. Serum iron 125 ug/100 ml.
Treated with parenteral vitamin B
12
Serum iron on 4th day 60 ug/100 mis reticulocyt 
28% on 5th day. Schilling test 0.7%: with 
IF 12.7%
Diagnosis: pernicious anaemia.
Case I . W . female aged 41. Admitted W.I.G.
August 1956. Macrocytic anaemia, Hb. 42%.. 
Megaloblastic erythropoiesis. HFA.
Treated with parenteral vitamin with 
full response. Schilling test 0%: with IF 
18.6%.
Diagnosis: pernicious anaemia.
Case M.W. female aged 77. Admitted W.I.G.
April 1955. Macrocytic anaemia.
Megaloblastic erythropoiesis. Achlorhydria. 
Treated with parenteral vitamin 
Discontinued maintenance treatment.
Readmitted April 1959. Macrocytic anaemia,
Hb. 72%. Megaloblastic erythropoiesis.
(192)
/HFA* Serum 30 uug/ml. Seram iron
172 ug/100 ml. Treated with parenteral 
58Co vitamin ^• Serum iron 52 ug/100 ml 
on 2nd day: reticulocytes on 4th day. 
Schilling test 0$.
Diagnosis: pernicious anaemia.
(193)
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